<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002203.pub3" GROUP_ID="CF" ID="604900012714485554" MERGED_FROM="" MODIFIED="2012-09-12 10:16:22 +0100" MODIFIED_BY="Nikki Jahnke" REVIEW_NO="0034" REVMAN_SUB_VERSION="5.1.7" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2012-09-12 09:53:06 +0100" MODIFIED_BY="Nikki Jahnke">
<TITLE>Macrolide antibiotics for cystic fibrosis</TITLE>
<CONTACT>
<PERSON ID="11809" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Kevin</FIRST_NAME>
<MIDDLE_INITIALS>W</MIDDLE_INITIALS>
<LAST_NAME>Southern</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Lecturer</POSITION>
<EMAIL_1>kwsouth@liv.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Child Health</DEPARTMENT>
<ORGANISATION>University of Liverpool</ORGANISATION>
<ADDRESS_1>Alder Hey Children's NHS Foundation Trust</ADDRESS_1>
<ADDRESS_2>Eaton Road</ADDRESS_2>
<CITY>Liverpool</CITY>
<ZIP>L12 2AP</ZIP>
<REGION>Merseyside</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 151 252 5693</PHONE_1>
<PHONE_2/>
<FAX_1>+44 151 252 5456</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2012-09-12 09:53:06 +0100" MODIFIED_BY="Nikki Jahnke">
<PERSON ID="11809" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Kevin</FIRST_NAME>
<MIDDLE_INITIALS>W</MIDDLE_INITIALS>
<LAST_NAME>Southern</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Lecturer</POSITION>
<EMAIL_1>kwsouth@liv.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Child Health</DEPARTMENT>
<ORGANISATION>University of Liverpool</ORGANISATION>
<ADDRESS_1>Alder Hey Children's NHS Foundation Trust</ADDRESS_1>
<ADDRESS_2>Eaton Road</ADDRESS_2>
<CITY>Liverpool</CITY>
<ZIP>L12 2AP</ZIP>
<REGION>Merseyside</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 151 252 5693</PHONE_1>
<PHONE_2/>
<FAX_1>+44 151 252 5456</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11593" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Pierre</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Barker</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Vice President</POSITION>
<EMAIL_1>Pbarker@ihi.org</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Institute for Healthcare Improvement</ORGANISATION>
<ADDRESS_1>20 University Road, 7th Floor</ADDRESS_1>
<ADDRESS_2/>
<CITY>Cambridge</CITY>
<ZIP>MA 02138</ZIP>
<REGION>Massachusetts</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11636" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Arturo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Solis-Moya</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>artuso@gmail.com</EMAIL_1>
<EMAIL_2>arturosolismoya@me.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Servicio de Neumología</DEPARTMENT>
<ORGANISATION>Hospital Nacional de Niños</ORGANISATION>
<ADDRESS_1>Caja Costarricense del Seguro Social</ADDRESS_1>
<ADDRESS_2>PO Box 220 - 1017</ADDRESS_2>
<CITY>San José</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CR">Costa Rica</COUNTRY>
<PHONE_1>+ 506 2255 1838</PHONE_1>
<PHONE_2/>
<FAX_1>+506 2223 9316</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="70565921624935462193100412115824" ROLE="AUTHOR">
<PREFIX>Miss</PREFIX>
<FIRST_NAME>Latifa</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Patel</LAST_NAME>
<SUFFIX/>
<POSITION>Honorary Research Fellow</POSITION>
<EMAIL_1>latifa.b.patel@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Child Health</DEPARTMENT>
<ORGANISATION>University of Liverpool</ORGANISATION>
<ADDRESS_1>Alder Hey Children's Foundation Trust</ADDRESS_1>
<ADDRESS_2>Eaton Road</ADDRESS_2>
<CITY>Liverpool</CITY>
<ZIP>L12 2AP</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2012-09-11 14:52:32 +0100" MODIFIED_BY="Nikki Jahnke">
<UP_TO_DATE>
<DATE DAY="29" MONTH="2" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="28" MONTH="2" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="2" MONTH="9" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="12" YEAR="2011"/>
</DATES>
<WHATS_NEW MODIFIED="2012-09-11 14:47:27 +0100" MODIFIED_BY="Nikki Jahnke">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-09-11 14:47:27 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="11" MONTH="9" YEAR="2012"/>
<DESCRIPTION>
<P>A search of the Group's Cystic Fibrosis Trials Register identified five new additional references to a study already included in the review (<LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>). There was some additional information identified on serum inflammatory markers, but we have only been able to include a narrative description of this so far. Data were skewed and presented as log-transformed data; we are awaiting the non-transformed data from the authors.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-09-11 14:47:22 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="11" MONTH="9" YEAR="2012"/>
<DESCRIPTION>
<P>Some additional narrative information has been added about serum inflammatory markers; however, the conclusions of the review remain the same.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-02-29 09:42:29 +0000" MODIFIED_BY="Nikki Jahnke">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2012-02-29 09:42:29 +0000" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="20" MONTH="10" YEAR="2011"/>
<DESCRIPTION>
<P>Due to an editorial error this review should have been flagged as a new citation due to the inclusion of large amounts of new data leading to a change in conclusions. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-02-29 09:42:26 +0000" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="9" MONTH="2" YEAR="2011"/>
<DESCRIPTION>
<P>A search of the Group's Cystic Fibrosis Trials Register identified 18 new references.</P>
<P>Five new references were to three new studies which have been included (<LINK REF="STD-Kabra-2010" TYPE="STUDY">Kabra 2010</LINK>; <LINK REF="STD-O_x0027_Connor-2009" TYPE="STUDY">O'Connor 2009</LINK>; <LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>).</P>
<P>Four new references were to one study previously listed as ongoing which has now been included (<LINK REF="STD-McCormack-2007" TYPE="STUDY">McCormack 2007</LINK>).</P>
<P>Two new references were to a study previously listed as 'Awaiting classification' (<LINK REF="STD-Steinkamp-2007" TYPE="STUDY">Steinkamp 2007</LINK>). This study has now been included.</P>
<P>Two studies (with no new references found) previously listed as 'Awaiting classification' have now been included (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>; <LINK REF="STD-Rotschild-2005" TYPE="STUDY">Rotschild 2005</LINK>).</P>
<P>Four new references to two new studies have been excluded (<LINK REF="STD-Aaron-2005" TYPE="STUDY">Aaron 2005</LINK>; <LINK REF="STD-Shmarina-2004" TYPE="STUDY">Shmarina 2004</LINK>).</P>
<P>We found one new additional reference to a study previously listed under 'Awaiting classification'; the study has now been excluded (<LINK REF="STD-Rubin-2003" TYPE="STUDY">Rubin 2003</LINK>).</P>
<P>Seven studies previously listed as 'Awaiting classification' have now been excluded (<LINK REF="STD-Anstead-2001" TYPE="STUDY">Anstead 2001</LINK>; <LINK REF="STD-Beringer-2005" TYPE="STUDY">Beringer 2005</LINK>; <LINK REF="STD-Dionyssopoulou-2005" TYPE="STUDY">Dionyssopoulou 2005</LINK>; <LINK REF="STD-Dogru-2004" TYPE="STUDY">Dogru 2004</LINK>; <LINK REF="STD-Frederiksen-2001" TYPE="STUDY">Frederiksen 2001</LINK>; <LINK REF="STD-Kessaris-2003" TYPE="STUDY">Kessaris 2003</LINK>; <LINK REF="STD-Sriram-2003" TYPE="STUDY">Sriram 2003</LINK>).</P>
<P>One study which was previously included has now been removed from the review as it is an open label pharmacokinetic study (<LINK REF="STD-Cipolli-2001" TYPE="STUDY">Cipolli 2001</LINK>). This has had no bearing on the overall conclusions.</P>
<P>Two new studies have been listed as 'Awaiting classification' (<LINK REF="STD-Elmasry-2010" TYPE="STUDY">Elmasry 2010</LINK>; <LINK REF="STD-Pukhalsky-2001" TYPE="STUDY">Pukhalsky 2001</LINK>).</P>
<P>A new plain language summary has been drafted in line with current guidance from The Cochrane Collaboration.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-12-11 14:52:48 +0000" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="12" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-10-27 15:04:14 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="13" MONTH="2" YEAR="2006"/>
<DESCRIPTION>
<P>After a search of the Group's Cystic Fibrosis Register, a total of nine studies have been added to the review: one to the list of excluded studies (Jensen 2005); five to studies awaiting assessment (Beringer 2005; Clement 2005; Dionyssopoulou 2005; Dogru 2004; Kessaris 2003); and three to the list of ongoing studies (AZ003; AZ004; Rubin 2003).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="17" MONTH="2" YEAR="2004"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-04-09 13:49:52 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="17" MONTH="2" YEAR="2004"/>
<DESCRIPTION>
<P>Following a recent search of the Group's Trials Register (January 2004), Cipolli 2001 has been added to the 'Included studies', but no data were available for inclusion in MetaView. Also, this update contains recently published data from the largest RCT examining azithromycin versus placebo for CF chest disease (Saiman 2003), which has improved the impact of this review and has altered the conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-04-09 13:44:14 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="18" MONTH="11" YEAR="2003"/>
<DESCRIPTION>
<P>Following publication the Saiman 2003 reference has been moved from 'Ongoing studies' to 'Studies awaiting assessment'. The review will be updated fully in 2004.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-04-09 13:43:22 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="20" MONTH="5" YEAR="2003"/>
<DESCRIPTION>
<P>After a search of Group's Trials Register (March 2003), the following studies have been added to the section 'Included studies': Equi 2002; Wolter 2003.<BR/>Frederiksen 2001 has been added to the section 'Studies awaiting assessment'. We have requested data from the primary authors of this study in order to incorporate them into a later update.<BR/>The following studies have been added to the section "Excluded studies": Ordonez 2001; Pukhalsky 2001.<BR/>The following study has been added to the 'Ongoing studies' section: McCormack 2003.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-04-09 13:40:34 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="25" MONTH="1" YEAR="2001"/>
<DESCRIPTION>
<P>After a search of Group's Trials Register two references by Baumann 2000 were identified and excluded as they were not RCTs.<BR/>The descriptions of Ongoing studies were added to. New data from these ongoing studies will be incorporated when they become available and if they meet the inclusion criterion.<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-09-12 10:11:24 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2011-02-03 09:42:02 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2010-11-24 12:23:24 +0000" MODIFIED_BY="Nikki Jahnke">Treatment with macrolide antibiotics for people with cystic fibrosis and chronic chest infection</TITLE>
<SUMMARY_BODY MODIFIED="2011-02-03 09:42:02 +0000" MODIFIED_BY="[Empty name]">
<P>People with cystic fibrosis suffer from chest infections, often caused by the bacteria <I>Pseudomonas aeruginosa.</I> This bacteria is resistant to nearly all antibiotics that can be taken by mouth. Macrolide antibiotics, e.g. azithromycin, have no direct killing effect on <I>Pseudomonas aeruginosa</I>, but they may reduce the activity of these bacteria. We have included ten randomised controlled trials with a total of 959 participants in this review. Eight of these trials compared azithromycin (a macrolide antibiotic) to placebo and two compared different doses of azithromycin. Four trials in children and adults (549 participants) showed significant improvements in lung function after treatment with azithromycin compared to placebo at six months; although data from later time points are not so clear. Patients treated with azithromycin were about twice as likely to be free of pulmonary exacerbation; needed fewer oral antibiotics and had fewer instances of <I>Staphylococcus aureus</I> in cultures from their lungs and airways. Adverse events were not common and not obviously associated with azithromycin, although there was an increase in resistance to macrolides. Most studies used a three times a week dosing schedule. Taking a high weekly dose was linked to an increase in mild gastrointestinal adverse events. Further multicentre studies are needed to look at the long-term effects of this antibiotic treatment, especially for infants diagnosed through newborn screening.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-02-29 10:02:23 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2011-02-15 19:40:54 +0000" MODIFIED_BY="[Empty name]">
<P>Macrolide antibiotics may have a modifying role in diseases which involve airway infection and inflammation, like cystic fibrosis.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-02-03 09:36:52 +0000" MODIFIED_BY="[Empty name]">
<P>To test the hypotheses that, in people with cystic fibrosis, macrolide antibiotics:<BR/>1. improve clinical status compared to placebo or another antibiotic;<BR/>2. do not have unacceptable adverse effects.<BR/>If benefit was demonstrated, we aimed to assess the optimal type, dose and duration of macrolide therapy.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-02-29 10:02:23 +0000" MODIFIED_BY="Nikki Jahnke">
<P>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches, handsearching relevant journals and abstract books of conference proceedings.</P>
<P>We contacted investigators known to work in the field, previous authors and pharmaceutical companies manufacturing macrolide antibiotics for unpublished or follow-up data (May 2010).</P>
<P>Latest search of the Group's Cystic Fibrosis Trials Register: 29 February 2012.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-02-07 11:52:17 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Randomised controlled trials of macrolide antibiotics compared to: placebo; another class of antibiotic; another macrolide antibiotic; or the same macrolide antibiotic at a different dose.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-02-03 09:37:33 +0000" MODIFIED_BY="[Empty name]">
<P>Two authors independently extracted data and assessed risk of bias. Seven groups were contacted and provided additional data which were incorporated into the review.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-02-16 11:13:33 +0000" MODIFIED_BY="[Empty name]">
<P>Ten of 31 studies identified were included (959 patients). Five studies with a low risk of bias examined azithromycin versus placebo and demonstrated consistent improvement in forced expiratory volume in one second over six months (mean difference at six months 3.97% (95% confidence interval 1.74% to 6.19%; n = 549, from four studies)). Patients treated with azithromycin were approximately twice as likely to be free of pulmonary exacerbation at six months, odds ratio 1.96 (95% confidence interval 1.15 to 3.33). With respect to secondary outcomes, there was a significant reduction in need for oral antibiotics and greater weight gain in those taking azithromycin. Adverse events were uncommon and not obviously associated with azithromycin, although a once-weekly high dose regimen was associated with more frequent gastrointestinal adverse events. Treatment with azithromycin was associated with reduced identification of <I>Staphylococcus aureus</I> on respiratory culture, but also a significant increase in macrolide resistance.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-02-07 11:53:57 +0000" MODIFIED_BY="Nikki Jahnke">
<P>This review provides evidence of improved respiratory function after six months of azithromycin. Data beyond six months were less clear, although reduction in pulmonary exacerbation was sustained. Treatment appeared safe over a six-month period; however, emergence of macrolide resistance was a concern. A multi-centre trial examining long-term effects of this antibiotic treatment is needed, especially for infants recognised through newborn screening.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-09-12 10:11:24 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2011-02-03 09:47:01 +0000" MODIFIED_BY="[Empty name]">
<P>This review examines the use of macrolide antibiotics for the treatment of cystic fibrosis (CF) chest infection.</P>
<CONDITION MODIFIED="2011-02-03 09:46:04 +0000" MODIFIED_BY="[Empty name]">
<P>Cystic fibrosis (CF) is caused by mutation of the cystic fibrosis transmembrane conductance regulator (CFTR) gene (<LINK REF="REF-Riordan-1989" TYPE="REFERENCE">Riordan 1989</LINK>) and is the most common life-shortening inherited disease in the Caucasian population, with reducing prevalence in Hispanic, African and South East Asian populations, respectively. The CFTR protein has an important role in the transport of salt and water across the surface of epithelia (<LINK REF="REF-Boucher-1999" TYPE="REFERENCE">Boucher 1999</LINK>). In CF, abnormal CFTR function affects a number of organs in the body; however, involvement of the airway has the most dramatic impact on quality of life and survival. The defect in CF salt transport results in abnormal airway secretions, which leads to chronic airway infection and inflammation (<LINK REF="REF-Matsui-1998" TYPE="REFERENCE">Matsui 1998</LINK>). Chronic bacterial infection in the airway is associated with an intense inflammatory process, which causes lung damage and further infection, eventually leading to respiratory failure.</P>
<P>Characteristic organisms associated with lower airway infection in people with CF are, most notably, <I>Staphylococcus aureus </I>(<I>S. aureus</I>) in the early course of the disease and <I>Pseudomonas aeruginosa</I> (<I>P. aeruginosa</I>) at a later stage (<LINK REF="REF-Hutchison-1999" TYPE="REFERENCE">Hutchison 1999</LINK>). Chronic airway infection with <I>P. aeruginosa</I> in CF is characterised by the production of alginate which provides the bacteria with a protective mucoid coat. This biofilm may have an important role in the chronic airway infection that characterises CF. This is an unusual chronic airway condition as acute inflammatory cells (neutrophils) are the predominant mediators of the process.</P>
<P>Treatment of chronic <I>P.aeruginosa</I> infection in CF airways is challenging because of the limited number of antibiotics with direct killing activity. Quinolones, such as ciprofloxacin, are the only oral antibiotics available with direct killing activity against <I>P. aeruginosa</I>. Other classes of anti-pseudomonal antibiotics need to be given intravenously or aerosolised into the lungs. Increasing resistance of <I>P. aeruginosa </I>to antibiotics is a significant challenge in the management of chronic airway infection in people with CF.</P>
</CONDITION>
<INTERVENTION MODIFIED="2011-02-03 09:47:01 +0000" MODIFIED_BY="[Empty name]">
<P>Macrolides are an orally available class of antibiotics that are often prescribed to treat community-acquired pneumonia and skin infections. They have a broad spectrum of action against gram-positive bacteria and some gram-negative bacteria. The oldest and most widely used macrolide (in the United Kingdom) is erythromycin. Newer antibiotics in this class include clarithromycin, roxithromycin and azithromycin (this is quite a distinct molecule, called an azalide). Macrolides work by inhibiting protein synthesis in bacteria, but they can also impact on human cellular functions; care has to be taken when macrolides are prescribed alongside certain other drugs such as statins, theophyliines and the oral contraceptive pill. They have no direct killing activity against <I>P. aeruginosa</I>. </P>
</INTERVENTION>
<THEORY MODIFIED="2010-11-24 13:49:28 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Although macrolide antibiotics have direct killing properties against a number of characteristic CF pathogens, in particular <I>S. aureus</I> and <I>Haemophilus influenzae </I>(<I>H. influenzae</I>), it is the potential for these agents to have indirect actions against <I>P. aeruginosa</I> and possibly other anti-inflammatory actions that has generated the most interest in this class of antibiotic.</P>
<P>In Japan, macrolides have been widely used since 1982 as a treatment for diffuse panbronchiolitis, a rare inflammatory lung condition affecting older Japanese people (<LINK REF="REF-Hoiby-1994" TYPE="REFERENCE">Hoiby 1994</LINK>). Infection with <I>P. aeruginosa</I> in these people is associated with a poor outcome. There is some evidence (including one randomised controlled trial) that, even at low doses, the long-term use of macrolides has a beneficial effect on survival for people with this condition (<LINK REF="REF-Kobayashi-1993" TYPE="REFERENCE">Kobayashi 1993</LINK>). This has been attributed to a reduction in factors (called virulence factors) that increase the activity of <I>P. aeruginosa</I>. These virulence factors, such as the production of the mucoid biofilm, may be important for the pathogenicity of <I>P. aeruginosa</I> in diffuse panbronchiolitis and CF. Laboratory studies also suggest that macrolides may have anti-inflammatory properties (<LINK REF="REF-Labro-1998" TYPE="REFERENCE">Labro 1998</LINK>; <LINK REF="REF-Anderson-1996" TYPE="REFERENCE">Anderson 1996</LINK>; <LINK REF="REF-Yanagihara-1997" TYPE="REFERENCE">Yanagihara 1997</LINK>).</P>
<P>Azithromycin is reported to show the most significant activity against the virulence factors of <I>P. aeruginosa</I> (<LINK REF="REF-Ichimiya-1996" TYPE="REFERENCE">Ichimiya 1996</LINK>; <LINK REF="REF-Mizukane-1994" TYPE="REFERENCE">Mizukane 1994</LINK>; <LINK REF="REF-Molinari-1993" TYPE="REFERENCE">Molinari 1993</LINK>; <LINK REF="REF-Retsema-1987" TYPE="REFERENCE">Retsema 1987</LINK>). The pharmacokinetics of azithromycin (an azalide) are fairly unique with considerable intracellular uptake and slow excretion (through the liver). The high tissue concentrations and long half-life of azithromycin means that infrequent dosing schedules (for example, three times a week) are possible, making it an attractive oral therapy for people with CF (<LINK REF="REF-Ball-1991" TYPE="REFERENCE">Ball 1991</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2010-12-09 10:53:18 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Macrolide antibiotics are well-tolerated and relatively inexpensive; however, their increasingly widespread use has resulted in the emergence of resistant bacteria (in particular macrolide-resistant <I>S. aureus</I>) (<LINK REF="REF-Hansen-2009" TYPE="REFERENCE">Hansen 2009</LINK>; <LINK REF="REF-Phaff-2006" TYPE="REFERENCE">Phaff 2006</LINK>; <LINK REF="REF-Tramper_x002d_Stranders-2007" TYPE="REFERENCE">Tramper-Stranders 2007</LINK>). It is critical therefore that the efficacy and safety of macrolide therapy for CF are examined in a systematic manner.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-01-25 13:51:45 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>To test the hypothesis that, in people with CF, macrolide antibiotics improve clinical status compared to placebo or another antibiotic</LI>
<LI>and do not have unacceptable adverse effects.</LI>
</OL>
<P>If benefit was demonstrated, we aimed to assess the optimal type, dose and duration of macrolide therapy</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-09-11 14:48:32 +0100" MODIFIED_BY="Nikki Jahnke">
<SELECTION_CRITERIA MODIFIED="2012-09-11 14:48:18 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2011-02-03 09:49:57 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs), published or unpublished. Quasi-randomised (e.g. alternate allocation and stratification) controlled trials were included if there were no significant baseline differences between intervention and control groups. Cross-over trials were included if there was evidence of a sufficient washout period. If the washout period was shorter than three months and if baseline characteristics were not significantly different for intervention and control groups, then data from the first arm were used.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-06-05 12:28:25 +0100" MODIFIED_BY="[Empty name]">
<P>Participants fulfilled criteria for a diagnosis of CF. If two disease-causing genetic mutations were not recognised, participants were required to have a positive sweat test and clinical features consistent with CF.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-10-27 15:24:13 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Short-term or long-term (greater than 12 months) use of a macrolide antibiotic compared to controls who receive placebo, another antibiotic class, another macrolide or the same macrolide at a different dose.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-09-11 14:48:18 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-09-11 14:47:52 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Lung function (absolute and per cent predicted values for age, height and gender)</LI>
<OL>
<LI>forced expiratory volume in one second (FEV<SUB>1</SUB>)</LI>
<LI>forced vital capacity (FVC)</LI>
<LI>non-routine tests (e.g., thoracic gas volume (TGV), airway conductance (Gaw) and lung clearance index (LCI))</LI>
</OL>
<LI>Pulmonary exacerbation (protocol defined or physician determined)</LI>
<OL>
<LI>number of patients free of exacerbation</LI>
<LI>time to first exacerbation</LI>
</OL>
<LI>Survival</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2012-09-11 14:48:18 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Adverse effects</LI>
<OL>
<LI>mild (defined as transient and treatment continued)</LI>
<LI>moderate (generally treatment discontinued)</LI>
<LI>severe (life threatening or seriously debilitating)</LI>
</OL>
<LI>Number of days in hospital</LI>
<LI>Acquisition or eradication of <I>P. aeruginosa</I> infection</LI>
<LI>Acquisition or eradication of other significant CF pathogen</LI>
<OL>
<LI>
<I>S. aureus</I> (including MRSA)</LI>
<LI>
<I>H. influenzae</I>
</LI>
<LI>Other significant pathogens</LI>
</OL>
<LI>Additional treatment required (courses or days of treatment)</LI>
<OL>
<LI>oral antibiotics</LI>
<LI>intravenous antibiotics</LI>
<LI>oral steroids</LI>
<LI>any other medical CF therapy</LI>
</OL>
<LI>Development of allergic bronchopulmonary aspergillosis (ABPA)</LI>
<LI>Nutritional markers (for example, weight and body mass index (BMI))</LI>
<LI>Liver disease (as defined by any new clinical, radiographic or biochemical evidence of CF-related liver disease)</LI>
<LI>Quality of life (QoL) (as measured by a valid disease-specific QoL tool)</LI>
<LI>Changes in treatment burden (as measured by a disease-specific tool)</LI>
<LI>Changes in inflammatory markers</LI>
<OL>
<LI>broncho-alveolar lavage (BAL) samples</LI>
<LI>serum samples</LI>
</OL>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-09-11 14:48:32 +0100" MODIFIED_BY="Nikki Jahnke">
<ELECTRONIC_SEARCHES MODIFIED="2012-09-11 14:48:32 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Relevant studies were identified from the Group's Cystic Fibrosis Trials Register using the term: macrolide.</P>
<P>The Cystic Fibrosis Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of <I>The Cochrane Library</I>), quarterly searches of MEDLINE, a search of EMBASE to 1995 and the prospective handsearching of two journals - <I>Pediatric Pulmonology </I>and the <I>Journal of Cystic Fibrosis</I>. Unpublished work is identified by searching through the abstract books of three major cystic fibrosis conferences: the International Cystic Fibrosis Conference; the European Cystic Fibrosis Conference and the North American Cystic Fibrosis Conference. For full details of all searching activities for the register, please see the relevant sections of the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/CF/frame.html">Cystic Fibrosis and Genetic Disorders Group Module</A>.</P>
<P>Date of the most recent search of the Group's CF Trials Register: 29 February 2012.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2011-01-26 18:03:18 +0000" MODIFIED_BY="[Empty name]">
<P>Principal investigators, known to work in the field were contacted for unpublished or follow-up data. Pharmaceutical companies, that manufacture macrolide antibiotics, were also approached (last contacted May 2010).</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-02-03 09:58:57 +0000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<STUDY_SELECTION MODIFIED="2011-02-03 09:52:00 +0000" MODIFIED_BY="[Empty name]">
<P>Three authors (KWS, PMB and LP (2011 update)) independently selected studies to be included in the review. They resolved any disagreement through discussion with arbitration from the fourth author (AS).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-02-03 09:53:09 +0000" MODIFIED_BY="[Empty name]">
<P>Three authors (KWS, PMB and LP (2011 update)) independently extracted data from included studies. For the 2011 update, they entered all data onto data extraction sheets; KWS entered data into the review software (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>).</P>
<P>The authors considered outcomes to be short term if they were measured at the end of a treatment period, unless the treatment period was for more than 12 months. They also considered outcomes to be long term if there were more than three months between the end of the treatment and the measure. The authors did not consider long-term outcome measures for cross-over studies.</P>
<P>The authors grouped outcome data into those measured at one, two, three, four, six and twelve months (annually thereafter). They also included outcome data recorded at other time periods.</P>
<P>Study groups sometimes reported the same outcome measure differently. For example, need for additional oral antibiotics could be presented as a dichotomous outcome (number of patients who received additional oral antibiotics) or as a continuous outcome (number of courses or number of days). In these cases, the review authors contacted the primary investigators to request further data for the meta-analysis. One of the primary outcomes was relative change in per cent predicted FEV<SUB>1</SUB> from the baseline (calculated as (baseline minus post-intervention) divided by baseline multiplied by 100). If per cent predicted FEV<SUB>1</SUB> was calculated as absolute change, the authors contacted the primary investigators for further data to include in the meta-analysis.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-02-03 09:54:52 +0000" MODIFIED_BY="[Empty name]">
<P>KWS, PB and LP (2011 update) independently assessed the risk of bias for each included study using the Cochrane risk of bias tool (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). In particular, the authors examined the process of randomisation (allocation and generation), the degree of blinding in the study, whether outcome data were complete (the description of participants lost to follow-up and those excluded from the study), selective outcome reporting and any other potential sources of bias. The authors recorded these factors on a risk of bias table for each study. Risk of bias was assessed as high, low or uncertain.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2011-02-01 17:02:10 +0000" MODIFIED_BY="Nikki Jahnke">
<P>For binary outcome measures the authors calculated a pooled estimate of the treatment effect for each outcome across studies using the pooled odds ratio (OR) and 95% confidence intervals (CIs) as a treatment effect estimate. </P>
<P>For continuous outcomes, they recorded either mean change from baseline for each group or mean post-treatment or intervention values and standard deviation (SD) for each group (standard errors were converted to SDs). The authors calculated a pooled estimate of treatment effect by calculating the mean difference (MD) and 95% CIs.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2011-02-03 09:56:12 +0000" MODIFIED_BY="[Empty name]">
<P>When outcomes were presented in different forms, the authors have reported both and have approached primary investigators in order to obtain a single outcome. The review authors have reported results at (for continuous data) or after (for dichotomous data) set time periods of the interventions. In this way they have been able to examine for changes over time and for heterogeneity. For adverse events they have combined all data regardless of time period of the study.</P>
<P>The review authors considered data from cross-over studies for this review; although this study design may not be ideal for a condition when the intervention could potentially have a long-standing impact on disease progression. If a washout period is not available, they have considered data from the first arm of the study as for a parallel design study, providing there was no significant differences in the baseline characteristics of both groups. They have included data for dichotomous outcomes (such as adverse events and number of patients free from pulmonary exacerbation) as a direct comparison of the two arms, although this undervalues the power of the cross-over design (<LINK REF="REF-Curtin-2002a" TYPE="REFERENCE">Curtin 2002a</LINK>; <LINK REF="REF-Curtin-2002b" TYPE="REFERENCE">Curtin 2002b</LINK>; <LINK REF="REF-Curtin-2002c" TYPE="REFERENCE">Curtin 2002c</LINK>).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2011-02-03 09:56:36 +0000" MODIFIED_BY="[Empty name]">
<P>In order to allow an intention-to-treat analysis, the review authors sought data on the number of participants with each outcome event, by allocated treated group, irrespective of compliance and whether or not the participant was later thought to be ineligible or otherwise excluded from treatment or follow-up. If any data were missing or unclear, we contacted the primary investigators for clarification. For one study, the primary outcome was reported at various time points, but only in a figure (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>). Subsequent individual patient data (IPD) provided by the authors did not contain data from all time points, so these were calculated by measuring the figure (using a formula to convert the CI to SD).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-02-03 09:57:58 +0000" MODIFIED_BY="[Empty name]">
<P>The review authors examined heterogeneity through visual examination of the combined data presented in the Forest plots. Heterogeneity was also assessed by considering the I<SUP>2</SUP> statistic together with chi-squared (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). They assessed any analysis with an I<SUP>2</SUP> value above 40% for evidence of heterogeneity with higher values more supportive of significant heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2011-02-03 09:58:20 +0000" MODIFIED_BY="[Empty name]">
<P>Where possible the review authors compared outcomes described in the protocol with those reported in the papers. If protocols were not available, they wrote to the primary investigators requesting the protocol; and if that was not available, they compared the outcomes listed in the 'Methods' section of the full paper to the 'Results' section. If the published papers reported negative findings either only partially or not at all, the review authors have approached the primary investigators for those data.</P>
<P>We have assessed the studies for publication bias (often characterised by presentation at a conference with no subsequent peer-reviewed publication).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-02-03 09:58:32 +0000" MODIFIED_BY="[Empty name]">
<P>The review authors employed a fixed-effect model to analyse data from studies that were not considered heterogeneous. When significant heterogeneity was present (I<SUP>2</SUP> greater than 40%), the authors used a random-effects model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2010-11-23 15:31:49 +0000" MODIFIED_BY="[Empty name]">
<P>When considering the possible mechanism of action of macrolide antibiotics, subgroup analysis may be appropriate, particularly when considering patients with and without chronic airway infection (most commonly with <I>P. aeruginosa</I>). A number of authors have reported data independently for these groups, although this is hampered by a clear and consistent definition of chronic airway infection. We are currently undertaking subgroup analysis to examine confounding factors, such as age and chronic airway infection.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2011-02-03 09:58:57 +0000" MODIFIED_BY="[Empty name]">
<P>The review authors have examined the impact of bias on the results, by including and excluding studies with concerns over study design from the combined analysis.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-09-12 10:11:24 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-09-11 14:44:54 +0100" MODIFIED_BY="Nikki Jahnke">
<P>The majority of included studies have examined the intervention of azithromycin versus placebo using a parallel study design and some studies have looked at different dosing regimens. Studies examining other macrolides, mostly clarithromycin, have been incompletely reported (<I>see</I> <LINK TAG="EXCLUDED_STUDIES_DESCR" TYPE="SECTION">Excluded studies</LINK>). Overall study quality has been good, with complete and thorough reporting (<I>see</I> <LINK TAG="INCLUDED_STUDIES_DESCR" TYPE="SECTION">Included studies</LINK> and <LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK>).</P>
<SEARCH_RESULTS MODIFIED="2012-09-11 14:44:54 +0100" MODIFIED_BY="Nikki Jahnke">
<P>A total of 58 publications (abstracts, papers and one thesis) were identified, representing 31 separate studies. In some cases further unpublished data were provided by authors<I>.</I> Only trials examining azithromycin have been published in peer-reviewed journals. Of the 31 studies identified, 10 have been included and 19 excluded; two studies are awaiting classification (<LINK REF="STD-Elmasry-2010" TYPE="STUDY">Elmasry 2010</LINK>; <LINK REF="STD-Pukhalsky-2008" TYPE="STUDY">Pukhalsky 2008</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2011-02-03 11:42:15 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Trial Design</HEADING>
<P>The ten included studies examined azithromycin as an intervention for CF (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Two were cross-over studies (<LINK REF="STD-Equi-2002" TYPE="STUDY">Equi 2002</LINK>; <LINK REF="STD-O_x0027_Connor-2009" TYPE="STUDY">O'Connor 2009</LINK>) and the rest were of parallel design (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>; <LINK REF="STD-Kabra-2010" TYPE="STUDY">Kabra 2010</LINK>; <LINK REF="STD-McCormack-2007" TYPE="STUDY">McCormack 2007</LINK>; <LINK REF="STD-Rotschild-2005" TYPE="STUDY">Rotschild 2005</LINK>; <LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>; <LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>; <LINK REF="STD-Steinkamp-2007" TYPE="STUDY">Steinkamp 2007</LINK>; <LINK REF="STD-Wolter-2002" TYPE="STUDY">Wolter 2002</LINK>). Duration of the intervention ranged from 2 to 12 months (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>The included studies enrolled people with a confirmed diagnosis of CF. Four studies enrolled children over six years of age (<LINK REF="STD-Equi-2002" TYPE="STUDY">Equi 2002</LINK>; <LINK REF="STD-Kabra-2010" TYPE="STUDY">Kabra 2010</LINK>; <LINK REF="STD-O_x0027_Connor-2009" TYPE="STUDY">O'Connor 2009</LINK>; <LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>), one study enrolled adults (<LINK REF="STD-Wolter-2002" TYPE="STUDY">Wolter 2002</LINK>) and the remaining five studies enrolled both adults and children (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). In some studies, <I>P. aeruginosa</I> airway infection (presence (<LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>) or absence (<LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>)) was an important entry criteria. The number of participants ranged from 17 to 260. In total, 959 children and adults with CF have been included in these studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>Azithromycin was the intervention in all included studies. In eight studies this was compared to placebo. One study compared high-dose and low-dose regimens (<LINK REF="STD-Kabra-2010" TYPE="STUDY">Kabra 2010</LINK>). Another study compared a once-weekly with a daily dosing regimen (<LINK REF="STD-McCormack-2007" TYPE="STUDY">McCormack 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>The primary outcome measure in all the trials was a change in FEV<SUB>1</SUB> over the course of the study (either relative or absolute change). All studies examined for and reported adverse effects. A number of studies have measured and reported pulmonary exacerbations (either total number during study or time to exacerbation). The reporting of this outcome was variable (time to exacerbation, number of exacerbations etc.).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2011-02-10 10:39:47 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Twenty studies were excluded. Seven studies examined azithromycin in an open or retrospective manner (<LINK REF="STD-Anstead-1999" TYPE="STUDY">Anstead 1999</LINK>; <LINK REF="STD-Anstead-2001" TYPE="STUDY">Anstead 2001</LINK>; <LINK REF="STD-Baumann-2000" TYPE="STUDY">Baumann 2000</LINK>; <LINK REF="STD-Jaffe-1998" TYPE="STUDY">Jaffe 1998</LINK>; <LINK REF="STD-Jensen-2005" TYPE="STUDY">Jensen 2005</LINK>; <LINK REF="STD-Pirzada-1999" TYPE="STUDY">Pirzada 1999</LINK>; <LINK REF="STD-Rubin-2003" TYPE="STUDY">Rubin 2003</LINK>). Two studies have provided some important information on the pharmacokinetics of azithromycin in CF (<LINK REF="STD-Beringer-2005" TYPE="STUDY">Beringer 2005</LINK>; <LINK REF="STD-Cipolli-2001" TYPE="STUDY">Cipolli 2001</LINK>). In our first review, we included the Cipolli study; however, in the reassessment for this review the authors felt it was not appropriate to include either of these pharmacokinetic studies, given the open label nature.</P>
<P>Six studies examined clarithromycin in an open manner (<LINK REF="STD-Dogru-2004" TYPE="STUDY">Dogru 2004</LINK>; <LINK REF="STD-Frederiksen-2001" TYPE="STUDY">Frederiksen 2001</LINK>; <LINK REF="STD-Kessaris-2003" TYPE="STUDY">Kessaris 2003</LINK>; <LINK REF="STD-Ordonez-2001" TYPE="STUDY">Ordonez 2001</LINK>; <LINK REF="STD-Pukhalsky-2001" TYPE="STUDY">Pukhalsky 2001</LINK>; <LINK REF="STD-Sriram-2003" TYPE="STUDY">Sriram 2003</LINK>), and one study compared azithromycin and clarithromycin also in an open manner (<LINK REF="STD-Radionovitch-2005" TYPE="STUDY">Radionovitch 2005</LINK>). These studies have not been fully reported and have all been presented in abstract form. The number of participants was small and we were not able to adequately assess study design from the abstract reports and subsequent correspondence. Two groups provided protocols that suggested adequate randomisation, but individual patient data provided was not presented in a manner that permitted analysis (<LINK REF="STD-Frederiksen-2001" TYPE="STUDY">Frederiksen 2001</LINK>; <LINK REF="STD-Sriram-2003" TYPE="STUDY">Sriram 2003</LINK>).</P>
<P>One study compared clarithromycin to nimesulide<B> </B>not to placebo, another antibiotic class, another macrolide or the same macrolide at a different dose (<LINK REF="STD-Shmarina-2004" TYPE="STUDY">Shmarina 2004</LINK>).</P>
<P>One study examined roxithromycin. This was presented in abstract form and not with sufficient detail to assess the study design and outcomes (<LINK REF="STD-Dionyssopoulou-2005" TYPE="STUDY">Dionyssopoulou 2005</LINK>).</P>
<P>One study did not examine macrolides as an intervention <I>per se</I>, rather the use of multiple antibiotic sensitivity testing (<LINK REF="STD-Aaron-2005" TYPE="STUDY">Aaron 2005</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-02-03 11:49:43 +0000" MODIFIED_BY="[Empty name]">
<P>In four of the ten included studies, there was no apparent risk of bias (<LINK REF="STD-Equi-2002" TYPE="STUDY">Equi 2002</LINK>; <LINK REF="STD-McCormack-2007" TYPE="STUDY">McCormack 2007</LINK>; <LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>; <LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>). For two studies there were minor concerns over reporting and baseline characteristics (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>; <LINK REF="STD-Wolter-2002" TYPE="STUDY">Wolter 2002</LINK>). These six studies enrolled the majority of patients included in this review (836 of 959 total patients). In four studies there were significant concerns over the risk of bias (<LINK REF="STD-Kabra-2010" TYPE="STUDY">Kabra 2010</LINK>; <LINK REF="STD-O_x0027_Connor-2009" TYPE="STUDY">O'Connor 2009</LINK>; <LINK REF="STD-Rotschild-2005" TYPE="STUDY">Rotschild 2005</LINK>; <LINK REF="STD-Steinkamp-2007" TYPE="STUDY">Steinkamp 2007</LINK>) (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
<ALLOCATION MODIFIED="2011-02-03 11:46:22 +0000" MODIFIED_BY="[Empty name]">
<P>For the majority of studies, the generation and concealment of allocation was undertaken in a correct and rigorous manner leading to a low risk of bias (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). In some studies, this was not clear in the trial reports, but subsequent correspondence has clarified the situation. Two studies caused concern (<LINK REF="STD-Kabra-2010" TYPE="STUDY">Kabra 2010</LINK>; <LINK REF="STD-O_x0027_Connor-2009" TYPE="STUDY">O'Connor 2009</LINK>). Details of allocation were unclear in the Indian study and we judged this to have an unclear risk of bias (<LINK REF="STD-Kabra-2010" TYPE="STUDY">Kabra 2010</LINK>). In the Northern Irish study, the placebo and active interventions were different colour capsules, permitting some conjecture by the participants and investigators as to the active and placebo arms and we judged this study to have a risk of bias (<LINK REF="STD-O_x0027_Connor-2009" TYPE="STUDY">O'Connor 2009</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2011-02-03 11:46:38 +0000" MODIFIED_BY="[Empty name]">
<P>Aside from the Northern Irish study, which we judged to have a high risk of bias from blinding (<LINK REF="STD-O_x0027_Connor-2009" TYPE="STUDY">O'Connor 2009</LINK>), the interventions were identical in the placebo-controlled studies. Investigators, clinicians and participants were blinded adequately leading to a low risk of bias.</P>
<P>For the studies examining different dosing regimens, in the Indian study (<LINK REF="STD-Kabra-2010" TYPE="STUDY">Kabra 2010</LINK>), it was not clear if treatment allocation was blinded (high or low dose) and so this needs to be considered an unclear risk of bias. The second Australian study comparing two dosing regimens was adequately blinded and had a low risk of bias (<LINK REF="STD-McCormack-2007" TYPE="STUDY">McCormack 2007</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2011-01-25 15:37:11 +0000" MODIFIED_BY="[Empty name]">
<P>For the French study, the primary outcome was reported at various time points, but only in a figure (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>). Subsequent IPD provided by the authors did not contain data from all time points, so these were calculated by measuring the figure (using a formula to convert the CI to SD). These were the only data beyond six months available for this review from placebo-controlled trials. Overall outcome data were well reported leading to a low risk of bias. </P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2011-02-03 11:47:22 +0000" MODIFIED_BY="[Empty name]">
<P>Protocols were not available for the included studies, but overall there was a good level of reporting of outcomes and aggregate data were included in this review. On some occasions, data were not fully reported. We contacted all authors and have subsequently been able to obtain most data, sometimes in the form of individual patient data (IPD). Overall, there were no major issues with selective reporting (low risk of bias), although again two studies were assessed as having a high risk of bias (<LINK REF="STD-Kabra-2010" TYPE="STUDY">Kabra 2010</LINK>; <LINK REF="STD-Rotschild-2005" TYPE="STUDY">Rotschild 2005</LINK>). In one study, data were only reported for eight weeks although were collected for longer on some participants (<LINK REF="REF-Steinkamp-2010" TYPE="REFERENCE">Steinkamp 2010</LINK>). Six studies measured QoL and the reporting of these results was incomplete with a lack of negative data (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>; <LINK REF="STD-McCormack-2007" TYPE="STUDY">McCormack 2007</LINK>; <LINK REF="STD-O_x0027_Connor-2009" TYPE="STUDY">O'Connor 2009</LINK>; <LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>; <LINK REF="STD-Steinkamp-2007" TYPE="STUDY">Steinkamp 2007</LINK>; <LINK REF="STD-Wolter-2002" TYPE="STUDY">Wolter 2002</LINK>). One author has consequently provided a full aggregate data set (<LINK REF="STD-Steinkamp-2007" TYPE="STUDY">Steinkamp 2007</LINK>). Similarly, nutritional outcomes were reported as summary outcomes, rather than complete data sets (<LINK REF="STD-Wolter-2002" TYPE="STUDY">Wolter 2002</LINK>; <LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>; <LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>; <LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2011-02-03 11:49:43 +0000" MODIFIED_BY="[Empty name]">
<P>Two studies employed a cross-over design, which may not be the ideal design for an intervention that potentially could have a significant impact on longer-term disease progression (<LINK REF="STD-Equi-2002" TYPE="STUDY">Equi 2002</LINK>; <LINK REF="STD-O_x0027_Connor-2009" TYPE="STUDY">O'Connor 2009</LINK>). However, both studies employed two-month washout periods and there did not appear to be any carry-over effects. Data have been included in the meta-analysis from the first arm of the Equi study, as the baseline characteristics of both groups were similar, although we appreciate this loses some of the power of the cross-over design (<LINK REF="STD-Equi-2002" TYPE="STUDY">Equi 2002</LINK>). Other concerns over potential bias from the O'Connor study precluded inclusion of these data (see above) and data from individual arms were not provided (<LINK REF="STD-O_x0027_Connor-2009" TYPE="STUDY">O'Connor 2009</LINK>).</P>
<P>There was a potential source of bias in the Wolter study, which reported different baseline characteristics of the two treatment groups, with the placebo group having significantly more males with better respiratory function and nutritional status (<LINK REF="STD-Wolter-2002" TYPE="STUDY">Wolter 2002</LINK>). The investigators adjusted for the differences between sex, BMI and FEV<SUB>1 </SUB>in the analysis of their data.</P>
<P>Only studies examining azithromycin have been published in peer-reviewed journals. Studies examining clarithromycin and roxithromyicn have only been presented at conference and published in abstract form. All these studies were reported as "negative" and this lack of publication in a peer-reviewed journal represents positive publication bias.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-09-12 10:11:24 +0100" MODIFIED_BY="[Empty name]">
<P>This review has identified six studies with a low risk of bias (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). These studies enrolled 836 of the total 959 recruited patients. Data from the four studies with methodological concerns have not had any significant impact on the overall conclusions from the meta-analysis of efficacy outcomes, although numbers were too small for a formal sensitivity analysis (<LINK REF="STD-O_x0027_Connor-2009" TYPE="STUDY">O'Connor 2009</LINK>; <LINK REF="STD-Kabra-2010" TYPE="STUDY">Kabra 2010</LINK>; <LINK REF="STD-Rotschild-2005" TYPE="STUDY">Rotschild 2005</LINK>; <LINK REF="STD-Steinkamp-2007" TYPE="STUDY">Steinkamp 2007</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Lung function</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">a. FEV<SUB>1</SUB>
</HEADING>
<P>The first three studies examining azithromycin versus placebo reported a significant difference in favour of azithromycin with respect to their primary outcome measure, change in FEV<SUB>1</SUB> from baseline (<LINK REF="STD-Equi-2002" TYPE="STUDY">Equi 2002</LINK>; <LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>; <LINK REF="STD-Wolter-2002" TYPE="STUDY">Wolter 2002</LINK>). The meta-analysis of these trials in an earlier version of this review supported this finding, particularly with respect to data at six months (azithromycin (n = 104) versus placebo (n = 114); MD 5.82% (95% CI 2.45% to 9.20%)) (<LINK REF="REF-Southern-2004" TYPE="REFERENCE">Southern 2004</LINK>).</P>
<P>Subsequent studies have not reported a difference in this outcome, including two studies with sizeable recruitment comparing azithromycin to placebo (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>; <LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>). The French study recruited adults and children (n = 82), both with and without chronic <I>P. aeruginosa</I> airway infection, over a twelve-month period (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>). The North American study was over six months and recruited 260 children aged 6 to 18 years without chronic <I>P. aeruginosa</I> airway infection (<LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>).</P>
<P>When data from these two studies were included in the most recent meta-analysis, the improvement in FEV<SUB>1</SUB> remained consistent at six months (azithromycin (n = 269) versus placebo (n = 280); MD 3.97% (95% CI 1.74% to 6.19%) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). The validity of this result was supported by the lack of heterogeneity as demonstrated by the I<SUP>2</SUP> value and the funnel plot (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<P>Studies have examined this outcome at different time points; however, the overall pattern of the meta-analysis was consistent before six months, again supporting the validity of this as a true finding (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). The French study provides data beyond six months and demonstrates no difference in this outcome at 8, 10 and 12 months (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). From the graph it can be seen that this represents a gradual reduction in the difference in FEV<SUB>1</SUB> over this time period (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<P>One smaller study with 38 participants reported absolute change in FEV<SUB>1</SUB> and did not demonstrate a difference between azithromycin and placebo after two months (<LINK REF="STD-Steinkamp-2007" TYPE="STUDY">Steinkamp 2007</LINK>) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>A large Australian study with 208 participants compared daily versus weekly dosing regimens and showed clinical equivalence with respect to the relative change in FEV<SUB>1</SUB> (<LINK REF="STD-McCormack-2007" TYPE="STUDY">McCormack 2007</LINK>) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
<P>In contrast to the first North American study, which recruited older patients with chronic <I>Pseudomonas aeruginosa</I> airway infection (<LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>), the second North American study did not demonstrate a difference in relative change in FEV<SUB>1</SUB> between the azithromycin and placebo groups (<LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>). Other studies enrolled patients with and without pseudomonas infection. Further analysis with individual patient data is required to examine the impact of <I>P. aeruginosa</I> infection on outcomes, particularly FEV<SUB>1</SUB>; however, the consistent pattern of response in favour of azithromycin seen in the meta-analysis suggests that this is not a significant confounding factor (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">b. FVC</HEADING>
<P>The results for relative change in FVC track those of FEV<SUB>1</SUB> and demonstrate significance differences at two and six months, MD 5.42 (95% CI 1.79 to 9.05) and MD 4.57% (95% CI 1.71 to 7.42) respectively. The confidence intervals are wider for this outcome, reflecting the variability of this outcome measure (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">c. Non-routine tests</HEADING>
<P>Non-routine tests such as TGV, Gaw and LCI were not reported in any of the included studies.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Respiratory exacerbations</HEADING>
<P>Respiratory exacerbations (either protocol defined or physician determined) were recorded in a number of ways (including time to exacerbation and total number). With data from five studies, it was possible to calculate the number of patients free of exacerbation at reported time points (<LINK REF="STD-Equi-2002" TYPE="STUDY">Equi 2002</LINK>; <LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>; <LINK REF="STD-Rotschild-2005" TYPE="STUDY">Rotschild 2005</LINK>; <LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>; <LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>). A meta-analysis of these data demonstrated that patients on azithromycin are more likely to be free of exacerbation at all time points reported (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). At six months, data were available from 609 patients and demonstrated an OR in favour of azithromycin; OR 1.96 (95% CI 1.15 to 3.33). Both the French and North American studies report in favour of azithromycin with respect to being free of exacerbation, in contrast to the negative result for the primary outcome in those studies, relative change in FEV<SUB>1 </SUB>(<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>; <LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>). The French study reported in favour of azithromycin at 12 months for being free of exacerbation; OR 10.77 (95% CI 2.26 to 51.34) (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
<P>The Australian study comparing daily to weekly dosing demonstrated significantly more days to first respiratory exacerbation in the weekly dose group, MD 17.30 days (95% CI 4.32 days to 30.28 days) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). However, this analysis is not consistent with the authors report, which suggests the difference is not significant (P = 0.17). The authors have been contacted for clarification.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Survival</HEADING>
<P>There were no deaths reported in any of the included studies.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Adverse effects</HEADING>
<P>The included studies have recruited 959 children and adults, of whom 632 received azithromycin as described in the additional tables (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). This provides a useful data set for assessing safety. All studies report standard clinical and laboratory monitoring for adverse events, including liver function tests. Hearing was assessed in the English study (<LINK REF="STD-Equi-2002" TYPE="STUDY">Equi 2002</LINK>) and in 11 out of 23 centres recruiting for the first North American study (<LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>). Overall, adverse events were not reported more frequently in the azithromycin group compared to placebo (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">a. Mild</HEADING>
<P>We defined mild adverse events as transient and which did not necessitate discontinuation of treatment. In the first North American study, treatment with azithromycin was associated with a significant increased risk of nausea, diarrhoea and wheeze (<LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>). In the second North American study of children without <I>P. aeruginosa</I> infection, these findings were not replicated (<LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>); although children receiving azithromycin had a decreased risk of cough, OR 0.39 (95% CI 0.23 to 0.64) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
<P>Although data from individual trials were not significantly different combined data from three studies (North American and French studies) suggest that patients treated with azithromycin were less likely to have a fever, OR 0.65 (95% CI 0.43 to 0.97) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
<P>In the second Australian study comparing weekly to daily dosing regimens, patients taking azithromycin weekly were more likely to have gastrointestinal adverse events (27 out of 105 versus 9 out of 103; P &lt; 0.02, OR 3.62 (95% CI 1.61 to 8.14)) (<LINK REF="STD-McCormack-2007" TYPE="STUDY">McCormack 2007</LINK>) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).<I> </I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">b. Moderate</HEADING>
<P>We defined moderate adverse events as those which generally resulted in treatment being discontinued or which resulted in hospitalisation. In studies comparing azithromycin versus placebo, study withdrawals were rare and did not increase in the azithromycin group. In the first Australian study, one patient receiving azithromycin discontinued treatment following an urticarial reaction (<LINK REF="STD-Wolter-2002" TYPE="STUDY">Wolter 2002</LINK>). In the French study, one patient treated with azithromycin developed ABPA and was withdrawn (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>).</P>
<P>In the second Australian study, 12 out of 105 of the weekly treatment arm discontinued treatment compared to 5 out of 103 from the daily regimen (<LINK REF="STD-McCormack-2007" TYPE="STUDY">McCormack 2007</LINK>) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">c. Severe</HEADING>
<P>We defined severe adverse events as those which are life-threatening or seriously debilitating. There were no serious adverse events reported in the included studies.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Number of days in hospital</HEADING>
<P>Only three studies reported on this outcome (<LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>; <LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>; <LINK REF="STD-Wolter-2002" TYPE="STUDY">Wolter 2002</LINK>). The first North American study reports a significant reduced risk of hospitalisation with azithromycin, 29 out of 98 patients on placebo versus 14 out of 87 who received azithromycin, OR 0.46 (95% CI 0.22 to 0.94) (<LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>), but this was not found in the second study on children (<LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>). When these data were combined there was no significant difference between the azithromycin and placebo groups (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
<P>The first Australian study did not demonstrate a significant reduction in hospital inpatient days over three months (placebo median 5.2 days (range 0 days to 36 days), azithromycin median 2.1 days (range 0 days to 15 days), P = 0.056) (<LINK REF="STD-Wolter-2002" TYPE="STUDY">Wolter 2002</LINK>).</P>
<P>The second Australian study did not demonstrate a difference between weekly and daily dosing with respect for need for hospitalisation and number of hospital days (<LINK REF="STD-McCormack-2007" TYPE="STUDY">McCormack 2007</LINK>) (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>; <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Acquisition or eradication of <I>P. aeruginosa</I> infection</HEADING>
<P>The North American and French studies reported acquisition of <I>P. aeruginosa</I>, but the number of events were very low (no new growths in the French study) (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>; <LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>; <LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). In the first North American study, three participants in the azithromycin group (one multi-resistant) and five in the placebo group had newly detected<I> P. aeruginosa </I>at the end of the study (<LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Acquisition or eradication of other significant CF pathogens</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">a. <I>S. aureus</I> (including MRSA)</HEADING>
<P>In the four studies reporting acquisition of <I>S. aureus,</I> treatment with azithromycin was associated with a reduced risk of <I>S. aureus </I>acquisition, OR 0.25 (95% CI 0.12 to 0.51) (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>; <LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>; <LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>; <LINK REF="STD-Steinkamp-2007" TYPE="STUDY">Steinkamp 2007</LINK>) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
<P>Two of these studies also looked at the number of patients with <I>S. aureus</I> who had eradication of this bacteria at the end of the study (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>; <LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>). Treatment with azithromycin was not associated with increased eradication (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
<P>The second North American study reported an increased risk of acquiring macrolide-resistant <I>S. aureus</I> for those patients on azithromycin, OR 5.01 (95% CI 2.14 to 11.71) (<LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>) (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P>
<P>The second Australian study reported a number of patients acquiring azithromycin resistant <I>S. aureus</I> (2 out of 105 weekly patients and 3 out of 103 daily patients) (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>).</P>
<P>There was no evidence of increased risk of acquiring MRSA at either 6 or 12 months following treatment with azithromycin compared to placebo (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">b. <I>H. influenzae</I>
</HEADING>
<P>There was no difference between placebo and azithromycin in the studies that reported this outcome at 6 months (<LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>) or at 12 months (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>) (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>). The second North American study reported acquisition of macrolide-resistant <I>H. influenzae</I> in 10 patients in the azithromycin group compared to 1 in the placebo group, OR 10.09 (95% CI 1.27 to 80.09) (<LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>) (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">c. Other significant pathogens</HEADING>
<P>There was no evidence of emergence of gram-negative bacteria or other significant CF pathogens. Five studies reported that culture for non-tuberculous mycobacterium (NTM) was undertaken on sputum samples and there was no evidence of emergence of this bacteria in azithromycin-treated patients (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>; <LINK REF="STD-Equi-2002" TYPE="STUDY">Equi 2002</LINK>; <LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>; <LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>; <LINK REF="STD-Wolter-2002" TYPE="STUDY">Wolter 2002</LINK>). The first North American study was the only trial that recognised treatment-emergent NTM in 4 out of 92 patients on placebo versus 1 out of 84 on azithromycin (<LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>) (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>). In the second North American study, NTM was cultured on screening for one patient, who was subsequently discontinued from study drug (placebo) but included in the analysis (<LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Additional treatment required (courses or days of treatment)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">a. oral antibiotics</HEADING>
<P>This outcome was reported as need for extra oral antibiotics by three studies (<LINK REF="STD-Equi-2002" TYPE="STUDY">Equi 2002</LINK>; <LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>; <LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>). Treatment with azithromycin was associated with a significant reduced risk, OR 0.28 (95% CI 0.19 to 0.42) (<LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>). The French study confirmed this finding over 12 months with a reduction in both the number of courses, MD -1.70 (95% CI -1.90 to -1.50), and days of treatment, MD -12.00 (95% CI -17.63 to -6.37) (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>) (<LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>; <LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">b. intravenous antibiotics</HEADING>
<P>Three studies reported need for intravenous antibiotic treatment and did not demonstrate a difference between azithromycin or placebo (<LINK REF="STD-Equi-2002" TYPE="STUDY">Equi 2002</LINK>; <LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>; <LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>) (<LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>).</P>
<P>The first Australian study reported significant reductions in the number of courses of intravenous antibiotic treatment (mean number of courses with azithromycin 0.4 (range zero to two courses) versus mean number of courses with placebo 1.1 (range zero to seven courses), P &lt; 0.016) and number of days of intravenous antibiotic treatment (mean number of days with azithromycin 2.0 (range 0 to 14 days) versus mean number of days with placebo 7.1 (range 0 to 44 days)) (<LINK REF="STD-Wolter-2002" TYPE="STUDY">Wolter 2002</LINK>).</P>
<P>The French study reported a reduction in both the number of courses, MD -0.80 (95% CI -0.94 to -0.66), and days of intravenous antibiotics, MD -12.00 (95% CI -13.96 to -10.04) over 12 months (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>) (<LINK REF="CMP-001.19" TYPE="ANALYSIS">Analysis 1.19</LINK>; <LINK REF="CMP-001.20" TYPE="ANALYSIS">Analysis 1.20</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">c. oral steroids</HEADING>
<P>This outcome was not reported in any of the included studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">d. any other CF therapy</HEADING>
<P>This outcome was not reported in any of the included studies.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Development of ABPA</HEADING>
<P>The first North American study reported an increase incidence of wheeze in the azithromycin group but no other evidence of ABPA (<LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>). One patient treated with azithromycin in the French study was diagnosed with ABPA and withdrawn from the study (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>) (<LINK REF="CMP-001.21" TYPE="ANALYSIS">Analysis 1.21</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7. Nutritional markers</HEADING>
<P>Overall, the reporting of nutritional parameters was limited. The French study reported change in BMI z score after 12 months (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>). There was no difference between patients treated with azithromycin and placebo (<LINK REF="CMP-001.22" TYPE="ANALYSIS">Analysis 1.22</LINK>).</P>
<P>Full aggregate data from other groups were not available; however, summary findings were reported in some cases.</P>
<P>The first Australian study reported no significant change in BMI (<LINK REF="STD-Wolter-2002" TYPE="STUDY">Wolter 2002</LINK>). Both of the North American studies, which recruited a total of 445 children and adults, reported more weight gain in patients receiving azithromycin (<LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>; <LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>). In the first study, the MD was 0.7 kg (95% CI 0.1 kg to 1.4 kg) (P = 0.02) (<LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>). In the second paediatric study, the MD was 0.58 kg (95% CI 0.14 kg to 1.02 kg) (P = 0.01) (<LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>). When combined, these data demonstrated a significant weight gain in the patients treated with azithromycin, MD 0.62 kg (95% CI 0.26 to 0.98) (<LINK REF="CMP-001.23" TYPE="ANALYSIS">Analysis 1.23</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">8. Liver disease</HEADING>
<P>There were no reports of significant liver involvement from any study.</P>
<P>Transient increases in liver transaminases were reported in some studies, but infrequently and not at an increased risk in patients treated with azithromycin (<LINK REF="STD-Equi-2002" TYPE="STUDY">Equi 2002</LINK>; <LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">9. QoL</HEADING>
<P>Six studies undertook questionnaire assessment of QoL (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>; <LINK REF="STD-McCormack-2007" TYPE="STUDY">McCormack 2007</LINK>; <LINK REF="STD-O_x0027_Connor-2009" TYPE="STUDY">O'Connor 2009</LINK>; <LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>; <LINK REF="STD-Steinkamp-2007" TYPE="STUDY">Steinkamp 2007</LINK>; <LINK REF="STD-Wolter-2002" TYPE="STUDY">Wolter 2002</LINK>). One used the Chronic Respiratory Disease Questionnaire, which is not validated in CF (<LINK REF="STD-Wolter-2002" TYPE="STUDY">Wolter 2002</LINK>). The others used language appropriate versions of the Cystic Fibrosis Questionnaire (CFQ).</P>
<P>The first North American study reported no difference between groups in the change in total QoL score (<LINK REF="CMP-001.23" TYPE="ANALYSIS">Analysis 1.23</LINK>), an improvement from baseline in the 'physical functioning' component in the azithromycin group, MD 2.70 (95% CI 0.09 to 5.31) (P = 0.05) (<LINK REF="CMP-001.25" TYPE="ANALYSIS">Analysis 1.25</LINK>), and no difference in other aspects of the questionnaire, including psychosocial functioning and body image (<LINK REF="CMP-001.26" TYPE="ANALYSIS">Analysis 1.26</LINK>; <LINK REF="CMP-001.27" TYPE="ANALYSIS">Analysis 1.27</LINK>) (<LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>). In the German study, significant improvement was described in three domains in azithromycin-treated patients compared to placebo after two months: respiratory symptoms, MD 15.40 (95% CI 2.16 to 28.64); eating disorder, MD 13.70 (95% CI 0.79 to 26.61); and problems with body weight, MD 35.20 (95% CI 14.82 to 55.58) (<LINK REF="STD-Steinkamp-2007" TYPE="STUDY">Steinkamp 2007</LINK>) (<LINK REF="CMP-001.28" TYPE="ANALYSIS">Analysis 1.28</LINK>; <LINK REF="CMP-001.29" TYPE="ANALYSIS">Analysis 1.29</LINK>; <LINK REF="CMP-001.30" TYPE="ANALYSIS">Analysis 1.30</LINK>), but not in the domain of body image (<LINK REF="CMP-001.26" TYPE="ANALYSIS">Analysis 1.26</LINK>). The French study reported no significant difference in any domain at 12 months (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>). The Northern Irish study reported significant improvement in two domains (vitality and physical functioning) comparing the azithromycin arm to the placebo arm of the cross-over study (<LINK REF="STD-O_x0027_Connor-2009" TYPE="STUDY">O'Connor 2009</LINK>). In the second Australian study comparing weekly and daily regimens, there was a significant improvement in the physical domain in the weekly group (+8.2 points, P = 0.02) and parents of patients aged less than 14 years reported higher scores for the health domain in the daily group (<LINK REF="STD-McCormack-2007" TYPE="STUDY">McCormack 2007</LINK>).</P>
<P>One study used a non-validated visual analogue scale for well-being (<LINK REF="STD-Equi-2002" TYPE="STUDY">Equi 2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">10. Changes in treatment burden</HEADING>
<P>This outcome was not reported in the included studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">11. Changes in inflammatory markers</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">a. BAL or sputum</HEADING>
<P>There were no differences in IL8 or neutrophil elastase in the first North American study (<LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">b. Blood</HEADING>
<P>The first Australian study reported that treatment with azithromycin had a significant effect on the time trend of the inflammatory marker C-reactive protein (CRP) (P &lt; 0.001) (<LINK REF="STD-Wolter-2002" TYPE="STUDY">Wolter 2002</LINK>). Median values for CRP were stated to have fallen in the azithromycin group but to have remained stable in the placebo group (<LINK REF="STD-Wolter-2002" TYPE="STUDY">Wolter 2002</LINK>). The second Australian study demonstrated a greater fall in CRP (though not clinically relevant) in the daily compared to the weekly treatment group at one, three and six months (<LINK REF="STD-McCormack-2007" TYPE="STUDY">McCormack 2007</LINK>) (<LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>).</P>
<P>In the German study patients were randomised following a two-week course of intravenous antibiotics (<LINK REF="STD-Steinkamp-2007" TYPE="STUDY">Steinkamp 2007</LINK>). Over the eight-week study period, CRP increased in both treatment arms; while this is not significantly more in the placebo group in our analysis (<LINK REF="CMP-001.31" TYPE="ANALYSIS">Analysis 1.31</LINK>), this was reported as a significant difference in favour of azithromycin in the original published paper.</P>
<P>The Israeli study examined antibodies against bactericidal or permeability-increasing protein (BPI-ANCA) and found no difference following treatment with placebo or azithromycin (<LINK REF="STD-Rotschild-2005" TYPE="STUDY">Rotschild 2005</LINK>).</P>
<P>The second North American study measured serum inflammatory markers at baseline, day 28 and day 168 of the study (<LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>). They report small but significant reductions in serum myeloperoxidase, absolute neutrophil count and CRP in children treated with azithromycin at day 28, but not at day 168 (<LINK REF="REF-Ratjen-2012" TYPE="REFERENCE">Ratjen 2012</LINK>). Due to the skewed distribution of the inflammatory markers, logarithmically transformed values were presented in the paper; for this reason these data have not been included in this review. We have contacted the authors and are awaiting non-transformed data from them.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-10-20 11:37:51 +0100" MODIFIED_BY="[Empty name]">
<P>A number of studies have examined azithromycin as a treatment for CF and analysis of combined data from these studies can guide the use of this intervention. For other macrolide antibiotics data were not so useful. Clarithromycin, in particular, has been the intervention investigated in a number of underpowered or aborted studies, which have been reported only in abstract form. Despite provision of some IPD, it has not been possible to adequately assess and meta-analyse these studies.</P>
<P>In contrast, study design and reporting has been good in six out of ten selected studies of azithromycin (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Five of these studies examined placebo versus azithromycin (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>; <LINK REF="STD-Equi-2002" TYPE="STUDY">Equi 2002</LINK>; <LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>; <LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>; <LINK REF="STD-Wolter-2002" TYPE="STUDY">Wolter 2002</LINK>) and one compared two dosing regimens (<LINK REF="STD-McCormack-2007" TYPE="STUDY">McCormack 2007</LINK>). Despite some variation in study design and the length of intervention, meta-analysis of data has been possible.</P>
<SUMMARY_OF_RESULTS MODIFIED="2011-10-20 11:37:51 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment with azithromycin for six months resulted in a consistent improvement in respiratory function (relative change in FEV<SUB>1</SUB>) compared to placebo (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). This improvement is small but of clinical significance in a condition that reports minimal reduction in respiratory function over time in stable patients. Two large studies published since the last update of this review did not report a significant difference in their primary outcome measure, relative change in FEV<SUB>1</SUB> (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>; <LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>). The baseline characteristics of these studies suggest that the patients had better respiratory condition than those enrolled in previous studies and this may have been a factor when considering the lack of improvement in the primary outcome. However, when aggregate data from these studies were included in the meta-analysis, the difference between interventions remained significant in favour of azithromycin (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). The magnitude of difference (4%) was less than that reported in our first meta-analysis (5.3%), but the confidence intervals were narrower reflecting the increased number of participants included (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). Homogeneity of the data up to six months further supports the validity of this finding (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). After six months, data were limited to one study (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>) and demonstrated a drift towards equivalence between placebo and azithromycin (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
<P>Patients treated with azithromycin for six months were approximately twice as likely to be free of respiratory exacerbation compared to placebo and, in contrast to relative change in FEV<SUB>1</SUB>, this difference remained consistent beyond six months in the French study (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). When examining respiratory exacerbation data from individual trials, it is evident that there is a degree of heterogeneity (in contrast to FEV<SUB>1</SUB> data). This is well illustrated in the funnel plot (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). Therefore caution needs to be exercised in the assessment of these results and further trials are required to confirm these findings. In an improving population, it may be that outcomes such as exacerbation have an increasing role in determining efficacy, it is important therefore that these outcomes are assessed and analysed in a robust and consistent manner. For this review a degree of manipulation of the available data was required in order to include all data in the meta-analysis.</P>
<P>Treatment with azithromycin was associated with a significant reduction in the need for additional oral antibiotic treatment (<LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>). The data were less conclusive with respect to a reduction in the need for intravenous antibiotic treatment (<LINK REF="CMP-001.19" TYPE="ANALYSIS">Analysis 1.19</LINK>). Two studies reported significantly fewer courses and days on intravenous antibiotics (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>; <LINK REF="STD-Wolter-2002" TYPE="STUDY">Wolter 2002</LINK>); however, combined data from the three studies that reported this as a dichotomous outcome did not support this finding (<LINK REF="STD-Equi-2002" TYPE="STUDY">Equi 2002</LINK>; <LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>; <LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>) (<LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>).</P>
<P>Reduction in treatment and fewer respiratory exacerbations are outcomes that have a direct positive impact on patients. It is disappointing therefore that the only patient-reported outcome, QoL, did not demonstrate any clear patterns with respect to azithromycin treatment (<LINK TAG="INTERVENTION_EFFECTS" TYPE="SECTION">Effects of interventions</LINK>, secondary outcome 9).</P>
<P>Other pragmatic outcomes, such as need for hospitalisation and eradication of <I>P. aeruginosa</I> have less consistent or negative results.</P>
<P>Over 600 children and adults have received azithromycin under the controlled environment of these clinical trials. Whilst an RCT is not the ideal mechanism to determine long-term safety, we can take some confidence from the small number of adverse events reported in these studies (<LINK TAG="INTERVENTION_EFFECTS" TYPE="SECTION">Effects of interventions</LINK>, secondary outcome 1). Initial concerns raised in the first North American study (<LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>) were not reproduced in the second study on children (<LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>) or in the French study (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>) (<LINK TAG="INTERVENTION_EFFECTS" TYPE="SECTION">Effects of interventions</LINK>, secondary outcome 1). In the second Australian study patients receiving the higher weekly dose of azithromycin had significantly more gastrointestinal adverse events compared to those on the daily regimen (<LINK REF="STD-McCormack-2007" TYPE="STUDY">McCormack 2007</LINK>) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>). Given the similar efficacy of these regimens, this represents a significant disadvantage of weekly dosing.</P>
<P>Microbiological data may give us some insight into the mechanism of action of azithromycin. Combined data from four studies, demonstrated that patients treated with azithromycin were less likely to have <I>S. aureus</I> identified on the respiratory cultures during the study (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). Significant eradication of this bacteria was not demonstrated (<LINK TAG="INTERVENTION_EFFECTS" TYPE="SECTION">Effects of interventions</LINK>, secondary outcome 4a). The second North American study demonstrated a significant increase in macrolide resistance in patients treated with azithromycin (<LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>), which is consistent with other epidemiological studies that have highlighted the swift emergence of macrolide resistance in clinics that have prescribed azithromycin for all their patients (<LINK REF="REF-Hansen-2009" TYPE="REFERENCE">Hansen 2009</LINK>; <LINK REF="REF-Phaff-2006" TYPE="REFERENCE">Phaff 2006</LINK>; <LINK REF="REF-Tramper_x002d_Stranders-2007" TYPE="REFERENCE">Tramper-Stranders 2007</LINK>). The impact of this increase in macrolide resistance on efficacy is not clear. There was no evidence of emergence of other resistant bacteria during azithromycin treatment, such as NTM and <I>Burkholderia cepacia</I> complex.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2011-02-03 12:11:35 +0000" MODIFIED_BY="[Empty name]">
<P>The combined data from these studies can provide us with confidence concerning the impact of azithromycin on respiratory function and other more pragmatic outcomes, such as need for oral antibiotics and risk of respiratory exacerbation. The studies have enrolled a broad range of patients over the age of six years, with and without chronic <I>P. aeruginosa </I>airway infection. To date, 959 children and adults have been enrolled in RCTs examining azithromycin for CF, of whom 632 have received azithromycin. No children below the age of six years have been recruited to these studies. This reflects the use of respiratory function as a primary outcome measure in all the studies and the difficulty in assessing this outcome in young children and infants. It is not possible, therefore, to comment on the applicability of this intervention in this younger age group. This is particularly pertinent following the expansion of newborn screening for CF and discrepancy in the advice regarding the need for long-term antibiotic prophylaxis in these infants (<LINK REF="REF-Smyth-2003" TYPE="REFERENCE">Smyth 2003</LINK>). </P>
<P>The second confounding variable that needs to be considered is chronic infection of the airways with <I>P. aeruginosa</I>. The North American studies enrolled patients with chronic <I>P. aeruginosa </I>infection (<LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>) and without (<LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>). Others have enrolled both populations. The second North American study did not demonstrate a significant improvement in the primary outcome of relative change in FEV<SUB>1</SUB>; however, when these data were included in the meta-analysis they did not change the overall result after six months and were consistent with other study results. In the French study sub-group analysis of patients with and without chronic <I>P. aeruginosa</I> infection did not alter the overall results, although data at six months were not presented.</P>
<P>The French study is the only one to examine outcomes beyond six months (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>) and further data are required to determine the impact of azithromycin on long-term outcomes.</P>
<P>Overall there is not sufficient evidence to advocate azithromycin therapy in any particular subgroup of patients (for example, children over six years of age or patients with chronic pseudomonas airway infection)</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2011-02-03 12:11:41 +0000" MODIFIED_BY="[Empty name]">
<P>This review has identified six studies with a low risk of bias (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). These studies enrolled 836 of the total 959 recruited patients. Data from the four studies with methodological concerns have not had any significant impact on the overall conclusions from the meta-analysis of efficacy outcomes, although numbers were too small for a formal sensitivity analysis (<LINK REF="STD-O_x0027_Connor-2009" TYPE="STUDY">O'Connor 2009</LINK>; <LINK REF="STD-Kabra-2010" TYPE="STUDY">Kabra 2010</LINK>; <LINK REF="STD-Rotschild-2005" TYPE="STUDY">Rotschild 2005</LINK>; <LINK REF="STD-Steinkamp-2007" TYPE="STUDY">Steinkamp 2007</LINK>). These studies have contributed to the overall safety data by reporting adverse events.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2011-01-27 16:29:26 +0000" MODIFIED_BY="[Empty name]">
<P>The mean and SD of the difference in relative change in FEV<SUB>1</SUB> was estimated at time points other than 12 months in the French study by measurements from a figure in the final publication (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>). Our previous experience with data from the Equi study suggests this is a valid technique, as subsequent IPD provided by those authors confirmed the accuracy of the process. The data from the French study represented the only results of this outcome measure beyond six months and we felt it important to include these data.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2011-02-03 12:13:05 +0000" MODIFIED_BY="[Empty name]">
<P>A previous meta-analysis by Florescu examined azithromycin for CF (<LINK REF="REF-Florescu-2009" TYPE="REFERENCE">Florescu 2009</LINK>) and included data from four studies (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>; <LINK REF="STD-Equi-2002" TYPE="STUDY">Equi 2002</LINK>; <LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>; <LINK REF="STD-Wolter-2002" TYPE="STUDY">Wolter 2002</LINK>). Only data from the first arm of the English cross-over study were included (<LINK REF="STD-Equi-2002" TYPE="STUDY">Equi 2002</LINK>). The authors demonstrated a significant increase in FEV<SUB>1</SUB> with azithromycin compared to placebo, MD 3.53% (95% CI 0.0 to 7.1%) (P = 0.05). They reported significant heterogeneity, which is improved when data from patients chronically infected with <I>P. aeruginosa</I> were analysed separately. Whilst we have demonstrated a similar small but significant improvement in relative change in FEV<SUB>1</SUB>, we do not agree with the conclusion that heterogeneity relates to <I>P. aeruginosa</I> infection. The reasons for this are:</P>
<OL>
<LI>we have included data from all time points reported in the French study (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>);</LI>
<LI>we do not feel it is appropriate to combine data from 6 and 12 months (we have reported data from each time point separately); and</LI>
<LI>we have included data from the most recent North American study (and other smaller studies).</LI>
</OL>
<P>With these factors, our data were more homogeneous and the impact of chronic <I>P. aeruginosa</I> infection was not apparent.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-02-03 12:16:27 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2011-02-03 12:15:28 +0000" MODIFIED_BY="[Empty name]">
<P>From the efficacy data presented in this review, there may be an argument that all adults and children over six years of age with CF should be offered therapy with azithromycin. Azithromycin therapy is associated with a small but consistent improvement in respiratory function at six months and appears to have a good safety profile<I>.</I> The three-times a week dosing regimen used by most studies represents a minimal treatment burden for patients and azithromycin is relatively inexpensive.</P>
<P>The evidence for treatment efficacy beyond six months is limited. One trial examined outcomes beyond six months and did not demonstrate a significant improvement in relative change in FEV<SUB>1</SUB>; however, other more pragmatic outcomes (need for oral antibiotics and remaining free of respiratory exacerbation) were in favour of azithromycin.</P>
<P>A wider concern may relate to the emergence of macrolide resistance reported in the most recent study and the reports from other epidemiological studies of the emergence of macrolide resistance in clinics prescribing azithromycin for all their patients. Early reports suggest that this phenomenon does not have a negative impact on clinical well-being; however, it is a concern. If the mechanism of action of azithromycin relates to its anti-staphylococcal activity, then there may be agents with better potency and a narrower spectrum of action against <I>S. aureus</I> that are more appropriate to employ.</P>
<P>Two recent studies enrolled patients without chronic <I>P. aeruginosa</I> airway infection (<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>; <LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>). The fact that neither study demonstrated a statistically significant change in their primary outcome measure (relative change in FEV<SUB>1</SUB>) supports the argument that azithromycin therapy is not appropriate in this patient group. However, when data from these studies were incorporated into our meta-analysis, they were consistent with previous studies and strengthened the finding of a small but significant improvement in FEV<SUB>1</SUB> after six months. We will continue to explore the impact of chronic <I>Pseudomonas</I> infection in an IPD analysis, but at present we do not feel there is sufficient evidence to preclude the use of azithromycin in this group of patients.</P>
<P>In view of the lack of long-term data and concerns over the emergence of macrolide-resistant strains of <I>S. aureus, </I>NTM and other bacteria, we do not feel that the current evidence is strong enough to support azithromycin therapy for all patients with CF. Given the consistent finding of a short-term improvement in FEV<SUB>1</SUB> in stable patients, there may be an argument for use in patients with poor respiratory condition despite maximal therapy or patients who have problems adhering to therapies (given the relatively infrequent dosing regimen). However, the intervention has not been formally evaluated in either of these circumstances.</P>
<P>A three-times a week dose of 500 mg (250 mg if weight less than 40 kg) has been employed in the North American studies and the French study, which together enrolled 547 patients (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). All these studies have contributed to the positive efficacy data reported in this review and the drug appeared to be well-tolerated with this dosing regimen. A larger once-a-week dose was associated with significantly more gastrointestinal side effects, which probably precludes it as a dosing strategy for a long-term therapy.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-02-03 12:16:27 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>There is an urgent need for a multi-centre RCT examining long-term antibiotic treatment for infants recognised through newborn screening. The findings of this review suggest that azithromycin should be considered as an intervention for such a trial; although given the relative lack of potency of azithromycin versus <I>S. aureus</I>, a comparison with another agent would be appropriate. The expansion of newborn screening and the international discrepancy in consensus statements highlights the need for a trial with pragmatic outcomes that are of relevance to families. The design and implementation of a trial that provides relevant long-term data and reassurance over safety will be challenging.</LI>
<LI>Clinics that currently employ azithromycin therapy should continue to monitor for and report adverse events, in particular relating to theoretical concerns over liver function and hearing. The emergence of macrolide resistance should also be recorded.</LI>
<LI>Data are required on the long-term efficacy of azithromycin, but in the current climate it seems unlikely that such studies will be organised.</LI>
<LI>Further studies are needed examining the dosing schedule (for example, a lower weekly dose).</LI>
</OL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-02-15 22:09:25 +0000" MODIFIED_BY="[Empty name]">
<P>The authors would like to thank members of all the study teams for their help and support and for providing extra data, in particular Lisa Saiman, Scott Bell, Mark Rosenthal, Preston Campbell III, Joe McCormack, Annick Clement, Sophie Ravilly, Gratiana Steinkamp and Bernadette O'Connor. We would also like to thank the referees for their useful comments and suggestions. Support from Nikki Jahnke in the Cystic Fibrosis and Genetic Disorders Cochrane Group has been crucial and greatly appreciated. Thanks also to Natalie Yates and Tracey Remmington for their invaluable continuing support with the Cochrane process; and Ashley Jones and Kerry Dwan for important statistical advice. Dr Southern would like to acknowledge the support of his clinical colleagues David Heaf, Jonathan Couriel, Paul McNamara and Elinor Burrows, which permitted him dedicated time to concentrate on the latest update.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-02-15 22:10:28 +0000" MODIFIED_BY="[Empty name]">
<P>KWS conceived and drafted the review, assessed studies, extracted data and wrote the first and subsequent drafts.<BR/>LP assessed studies, extracted data and commented on the review.</P>
<P>AS contributed to the content and commented on the review.<BR/>PMB contributed to the content and commented on the review.<BR/>
<BR/>KWS acts as guarantor of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2010-11-24 14:31:46 +0000" MODIFIED_BY="Nikki Jahnke">
<P>For this review we revisited all the studies taking into account new guidance on determining risk of bias. We have extracted data again and demonstrated that this was consistent with our first review. Data extraction sheets are now available for review.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2008-12-15 10:09:17 +0000" MODIFIED_BY="Nikki Jahnke">
<P>A 'Comment and Criticism' entitled: 'Inclusion of trials and conclusions drawn' (and the response from the reviewers) was attached to this review on Issue 2, 2004. This now appears as an appendix to this review (Feedback 1).</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-09-11 14:51:22 +0100" MODIFIED_BY="Nikki Jahnke">
<STUDIES MODIFIED="2012-09-11 14:51:22 +0100" MODIFIED_BY="Nikki Jahnke">
<INCLUDED_STUDIES MODIFIED="2012-09-11 14:34:24 +0100" MODIFIED_BY="Nikki Jahnke">
<STUDY DATA_SOURCE="MIX" ID="STD-Clement-2006" MODIFIED="2011-02-03 09:57:15 +0000" MODIFIED_BY="[Empty name]" NAME="Clement 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-08-12 12:14:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clement A, Tamalet A, Le Roux E, Ravilly S, Jais JP</AU>
<TI>Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2005</YR>
<VL>4</VL>
<NO>Suppl1</NO>
<PG>S68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-11 15:40:12 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Clement A, Tamalet A,Le Roux E, Ravilly S, Fauroux B, Jais JP</AU>
<TI>Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial</TI>
<SO>Thorax</SO>
<YR>2006</YR>
<VL>61</VL>
<NO>10</NO>
<PG>1643-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-08-12 12:14:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clement A, Tamalet A,Leroux E, Ravilly S, Jais J</AU>
<TI>Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2005</YR>
<VL>40</VL>
<NO>Suppl 28</NO>
<PG>285</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Equi-2002" MODIFIED="2011-02-03 12:12:26 +0000" MODIFIED_BY="[Empty name]" NAME="Equi 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Equi A, Balfour-Lynn IM, Bush A, Rosenthal M</AU>
<TI>Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<NO>9338</NO>
<PG>978-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Equi A, Bush A, Alton EW, Balfour-Lynn I, Rosenthal M</AU>
<TI>A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2001</YR>
<VL>Suppl 22</VL>
<PG>307</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Equi A//Bush A//Balfour-Lynn IM. A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis [abstract]. Thorax 2002;(Suppl III):iii38.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Equi A, Bush A, Balfour-Lynn IM.</AU>
<TI>A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis [abstract]</TI>
<SO>Thorax</SO>
<YR>2002</YR>
<VL>Suppl 3</VL>
<PG>iii38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kabra-2010" MODIFIED="2011-02-03 11:45:42 +0000" MODIFIED_BY="[Empty name]" NAME="Kabra 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-10-28 15:47:34 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kabra SK, Pawaiya R, Lodha R, Kapil A, Kabra M, Vani AS, et al</AU>
<TI>Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2010</YR>
<VL>9</VL>
<NO>1</NO>
<PG>17-23</PG>
<IDENTIFIERS MODIFIED="2010-10-28 15:47:02 +0100" MODIFIED_BY="Nikki Jahnke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCormack-2007" MODIFIED="2010-10-28 15:47:50 +0100" MODIFIED_BY="Nikki Jahnke" NAME="McCormack 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-08-12 12:17:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Bell S, Serisier D, Wainwright C, Bowler S, Senini S, Walmsley K, et al</AU>
<TI>6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis [abstract]</TI>
<SO>Respirology</SO>
<YR>2006</YR>
<VL>11</VL>
<NO>Suppl 2</NO>
<PG>A58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-08-12 12:17:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Bell S, Serisier D, Wainwright C, Bowler S, Senini S, Walmsley K, et al</AU>
<TI>Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis [abstract]</TI>
<SO>Respirology</SO>
<YR>2006</YR>
<VL>11</VL>
<NO>Suppl 2</NO>
<PG>A11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-10-28 15:47:50 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McCormack J, Bell S, Senini S, Walmsley K, Patel K, Wainwright C, et al</AU>
<TI>Daily versus weekly azithromycin in cystic fibrosis patients</TI>
<SO>European Respiratory Journal</SO>
<YR>2007</YR>
<VL>30</VL>
<NO>3</NO>
<PG>487-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-03-16 16:23:33 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="OTHER">
<AU>Senini S, McCormack J</AU>
<TI>A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis</TI>
<SO>Australian New Zealand Clinical Trials Registry (www.anzctr.org.au) (accessed 04 March 2010)</SO>
<YR>2005</YR>
<IDENTIFIERS MODIFIED="2010-03-16 16:23:33 +0000" MODIFIED_BY="Nikki Jahnke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-O_x0027_Connor-2009" MODIFIED="2011-02-03 12:41:01 +0000" MODIFIED_BY="[Empty name]" NAME="O'Connor 2009" YEAR="2008">
<REFERENCE MODIFIED="2010-04-27 14:50:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Connor BS, Reid AL, Steen HJ, Shields MD, Elborn JS</AU>
<TI>Use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2008</YR>
<VL>7</VL>
<NO>Suppl 2</NO>
<PG>S25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-02-03 12:41:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="BOOK">
<AU>O'Connor BS</AU>
<SO>The use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa</SO>
<YR>2009</YR>
<PB>Faculty of Medicine and Health Sciences, The Queen's University</PB>
<CY>Belfast, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rotschild-2005" MODIFIED="2010-04-27 14:28:15 +0100" MODIFIED_BY="[Empty name]" NAME="Rotschild 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-04-27 14:28:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rotschild M, Elias N, Berkowitz D, Pollak S, Shinawi M, Beck R, Bentur L</AU>
<TI>Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin</TI>
<SO>Clinical and Experimental Medicine</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>2</NO>
<PG>80-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Saiman-2003" MODIFIED="2011-02-03 12:41:33 +0000" MODIFIED_BY="[Empty name]" NAME="Saiman 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Nguyen D, Mayor-Hamblett N, Marshall BC, Saiman L, Burns JL. Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients [abstract]. Pediatric Pulmonology 2004;38(Suppl 27):286.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nguyen D, Mayor-Hamblett N, Marshall BC, Saiman L, Burns JL.</AU>
<TI>Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2004</YR>
<VL>38</VL>
<NO>Suppl 27</NO>
<PG>286</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-02-03 11:30:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al</AU>
<TI>Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>290</VL>
<NO>13</NO>
<PG>1749-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saiman L, Mayer-Hamblett N, Campbell P, Marshall BC</AU>
<TI>Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2005</YR>
<VL>172</VL>
<NO>8</NO>
<PG>1008-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Saiman L. What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial [abstract]. Pediatric Pulmonology 2003:165-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saiman L</AU>
<TI>What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2003</YR>
<VL>36 Suppl 25</VL>
<PG>165-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Saiman-2010" MODIFIED="2012-09-11 14:34:24 +0100" MODIFIED_BY="[Empty name]" NAME="Saiman 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-02-29 10:10:48 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anstead M, Saiman L, Mayer-Hamblett N, Lands LC, Kloster M, Goss CH, et al</AU>
<TI>Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2010</YR>
<VL>45</VL>
<NO>Suppl 33</NO>
<PG>377, Abstract no: 440</PG>
<IDENTIFIERS MODIFIED="2012-02-29 10:10:08 +0000" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2012-02-29 10:10:08 +0000" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="MA24f"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-07 15:13:02 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ratjen F, Saiman L, Mayer-Hamblett N, Lands LC, Kloster M, Emmett P, et al</AU>
<TI>The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2010</YR>
<VL>45</VL>
<NO>Suppl 33</NO>
<PG>271, Abstract no:149</PG>
<IDENTIFIERS MODIFIED="2012-02-29 10:11:54 +0000" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2012-02-29 10:11:54 +0000" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register " TYPE="OTHER" VALUE="MA24e"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-11 14:34:24 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="OTHER">
<AU>Ratjen F, Saiman L, Mayer-Hamblett N, Lands LC, Kloster M,Thompson V, et al</AU>
<TI>Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with <I>Pseudomonas aeruginosa</I>
</TI>
<SO>Chest</SO>
<YR>2012 May 17 [Epub ahead of print]</YR>
<IDENTIFIERS MODIFIED="2012-09-11 14:26:07 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2012-09-11 14:26:07 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1378/chest.12-0628"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-29 10:09:33 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, et al</AU>
<TI>Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2010</YR>
<VL>303</VL>
<NO>17</NO>
<PG>1707-15</PG>
<IDENTIFIERS MODIFIED="2012-02-29 10:09:33 +0000" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2012-02-29 10:09:33 +0000" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="MA24c"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-29 10:08:33 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, et al</AU>
<TI>Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]</TI>
<SO>JAMA</SO>
<YR>2010</YR>
<VL>303</VL>
<NO>17</NO>
<PG>1707-15 Online</PG>
<IDENTIFIERS MODIFIED="2012-02-29 10:08:33 +0000" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2012-02-29 10:08:33 +0000" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="MA24d"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-29 10:06:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Saiman L, Anstead M, Ratjen F, Lands L</AU>
<TI>Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with <I>P. aeruginosa</I>
</TI>
<SO>www.clinicaltrials.gov (accessed 04 March 2010)</SO>
<YR>2007</YR>
<IDENTIFIERS MODIFIED="2012-02-29 10:06:17 +0000" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2012-02-29 10:06:17 +0000" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="MA24b"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-29 10:06:04 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saiman L</AU>
<TI>Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2009</YR>
<VL>44</VL>
<NO>32</NO>
<PG>185</PG>
<IDENTIFIERS MODIFIED="2012-02-29 10:06:04 +0000" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2012-02-29 10:06:04 +0000" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="MA24a"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Steinkamp-2007" MODIFIED="2011-02-10 09:37:57 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Steinkamp 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-02-10 09:37:57 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Steinkamp G, Schmitt-Grohe S, Doring G, Staab D, Pfrunder D, Beck G, et al</AU>
<TI>Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection</TI>
<SO>Respiratory Medicine</SO>
<YR>2008</YR>
<VL>102</VL>
<NO>11</NO>
<PG>1643-53</PG>
<IDENTIFIERS MODIFIED="2011-02-10 09:37:57 +0000" MODIFIED_BY="Nikki Jahnke"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-04-26 11:05:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steinkamp G, Schmitt-Grohe S, Doring G, Stabb D, Schubert R, Zielen S</AU>
<TI>Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2007</YR>
<VL>42</VL>
<NO>Suppl 30</NO>
<PG>300</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-10-28 15:51:58 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steinkamp G, Schmitt-Grohe S, Doring G, Worlitzsch D, Staab D, Schubert R, et al</AU>
<TI>Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2006</YR>
<VL>5</VL>
<NO>Suppl</NO>
<PG>S25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolter-2002" NAME="Wolter 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bell SC, Seeney S, Walmsley K, Wolter JM, Bowler SD, McCormack JG</AU>
<TI>Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2002</YR>
<VL>34 Suppl 24</VL>
<PG>289-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Pediatric Pulmonology. abstract edition. Suppl 20. 2000:280. (Fourteenth Annual North American Cystic Fibrosis Conference, Baltimore, Maryland, Nov 9-12, 2000).&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bowler SD, Masel PJ, Bell SC, Seeney SL, Wolter JM, McCormack JG</AU>
<TI>A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2000</YR>
<VL>30 Suppl 20</VL>
<PG>280</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Bowler SD//Seeney S//Walmsley K//Wolter JM//Bell SC//McCormack JG. Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis [abstract]. Respirology 2002;(Suppl):A9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bowler SD, Seeney S, Walmsley K, Wolter JM, Bell SC, McCormack JG</AU>
<TI>Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis [abstract]</TI>
<SO>Respirology</SO>
<YR>2002</YR>
<VL>7 Suppl 1</VL>
<PG>A9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bowler SD</AU>
<TI>Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis [abstract]</TI>
<SO>Japanese Journal of Antibiotics</SO>
<YR>2003</YR>
<VL>56</VL>
<NO>Suppl A</NO>
<PG>38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Seeney SL//Bowler SD//Wolter JM//Bell SC//Masel PJ//McCormack JG. A prospective randomised trial of long term azithromycin (AZM) versus placebo in&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seeney SL, Bowler SD, Wolter JM, Bell SC, Masel PJ, McCormack JG</AU>
<TI>A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]</TI>
<SO>Internal Medicine Journal</SO>
<YR>2001</YR>
<VL>31 Suppl</VL>
<PG>A12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J</AU>
<TI>Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial</TI>
<SO>Thorax</SO>
<YR>2002</YR>
<VL>57</VL>
<NO>3</NO>
<PG>212-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-02-10 10:36:32 +0000" MODIFIED_BY="Nikki Jahnke">
<STUDY DATA_SOURCE="PUB" ID="STD-Aaron-2005" MODIFIED="2010-03-16 16:19:58 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Aaron 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-08-12 14:03:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aaron S, Vandemheen K, Ferris W, Tullis E, Haase D, Berthiaume Y, et al</AU>
<TI>Treatment of CF exacerbations based on multiple combination antibiotic susceptibility testing-a randomized, double-blind, controlled clinical trial [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2005</YR>
<VL>40</VL>
<NO>Suppl 28</NO>
<PG>304</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-03-16 16:19:58 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aaron S</AU>
<TI>Clinical evidence for combination antibiotic susceptibility testing (synergy testing) [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2008</YR>
<VL>43</VL>
<NO>Suppl 1</NO>
<PG>157</PG>
<IDENTIFIERS MODIFIED="2010-03-16 16:19:44 +0000" MODIFIED_BY="Nikki Jahnke"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-12-11 15:28:11 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Aaron SD, Vandemheen KL, Ferris W, Fergusson D, Tullis E, Haase D, et al</AU>
<TI>Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>366</VL>
<NO>9484</NO>
<PG>463-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anstead-1999" NAME="Anstead 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;NACFC 1999&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anstead MI, Kuhn RJ, Hartford LH, Craigmyle L, Halsey S, Kanga JF</AU>
<TI>Effect of chronic azithromycin on lung function in cystic fibrosis</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1999</YR>
<VL>28 Suppl 19</VL>
<PG>283-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anstead-2001" MODIFIED="2010-04-28 10:38:57 +0100" MODIFIED_BY="[Empty name]" NAME="Anstead 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-04-28 10:38:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anstead M, Kuhn RJ, Halsey S, Doherty DE, D'Souza N, Kanga JF</AU>
<TI>Effect of azithromycin on lung function, sputum bacteriology, and sputum inflammatory markers in cystic fibrosis [abstract]</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2001</YR>
<VL>163</VL>
<NO>5 Suppl</NO>
<PG>A565</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baumann-2000" NAME="Baumann 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>App EM, Konig A, Duffner K, Baumann U, King M, von der Hardt H</AU>
<TI>The effects of azithromycin therapy on sputum inflammation in CF lung disease [abstract]</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2000</YR>
<VL>161</VL>
<NO>3 Suppl</NO>
<PG>A758</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baumann U, App E, King M, Fischer J, Zimmermann T, Sextro W, et al</AU>
<TI>Low-dose azithromycin therapy reaches sputum drug levels of potential antipseudomonal activity in cystic fibrosis patients [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2002</YR>
<VL>1</VL>
<NO>Suppl 1</NO>
<PG>S130</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Baumann U, App EM, Konig A, Sextro W, Matthys H, von der Hardt H. Sputum DNA under long-term therapy with azithromycin [abstract]. XIIIth International Cystic Fibrosis Congress, 4-8 June 2000, Stockholm, Sweden - Abstract Book. abstract edition2000:164.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Baumann U, App EM, Konig A, Sextro W, Matthys H, von der Hardt H</AU>
<TI>Sputum DNA under long-term therapy with azithromycin [abstract]</TI>
<SO>Proceedings of the 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm</SO>
<YR>2000</YR>
<PG>164</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Baumann U, Fischer JJ, Tummler B et al. Long-term low-dose therapy with azithromycin in CF [abstract]. XIIIth International Cystic Fibrosis Congress, 4-8 June 2000, Stockholm, Sweden - Abstract Book. abstract edition2000:165.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Baumann U, Fischer JJ, Tummler B, Sextro W, App EM, King M et al.</AU>
<TI>Long-term low-dose therapy with azithromycin in CF [abstract]</TI>
<SO>Proceedings of the 13th International Cystic Fibrosis Congress;2000 June 4-8; Stockholm</SO>
<YR>2000</YR>
<PG>165</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beringer-2005" MODIFIED="2010-04-28 10:28:48 +0100" MODIFIED_BY="[Empty name]" NAME="Beringer 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-04-28 10:28:48 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Beringer P, Kriengkauykiat J, Louie S, Gill M, Han E, Woo M, et al. Controlled pharmacokinetic study of azithromycin in adult cystic fibrosis patients [abstract]. Pediatric Pulmonology 2004;38(Suppl 27):285.&lt;/p&gt;" NOTES_MODIFIED="2010-04-28 10:28:48 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beringer P, Huynh KMT, Kriengkauykiat J, Bi L, Hoem N, Louie S et al</AU>
<TI>Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis</TI>
<SO>Antimicrobial agents and chemotherapy</SO>
<YR>2005</YR>
<VL>49</VL>
<NO>12</NO>
<PG>5013-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-04-28 10:28:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beringer P, Kriengkauykiat J, Louie S, Gill M, Han E, Woo M, et al</AU>
<TI>Controlled pharmacokinetic study of azithromycin in adult cystic fibrosis patients [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2004</YR>
<VL>38</VL>
<NO>Suppl 27</NO>
<PG>285</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cipolli-2001" MODIFIED="2010-04-28 15:50:44 +0100" MODIFIED_BY="[Empty name]" NAME="Cipolli 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-04-28 15:50:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cipolli M, Cazzola G, Novelli A, Cassetta MI, Fallani S, Mazzei T</AU>
<TI>Azithromycin concentrations in serum and bronchial secretions of patients with cystic fibrosis</TI>
<SO>Clinical Drug Investigation</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>5</NO>
<PG>353-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dionyssopoulou-2005" MODIFIED="2011-02-03 12:37:34 +0000" MODIFIED_BY="[Empty name]" NAME="Dionyssopoulou 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-04-28 10:50:47 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;28th European cystic fibrosis conference; 2005 June 22-25; Crete, Greece.&lt;/p&gt;" NOTES_MODIFIED="2010-04-28 10:50:47 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dionyssopoulou V, Perpati G, Stefanatou E, Christodoulou E, Kalatzi E, Armeniakou E, et al</AU>
<TI>Laboratory and clinical effect of long-term roxithromycin treatment in adult patients with cystic fibrosis [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2005</YR>
<VL>4</VL>
<NO>Suppl 1</NO>
<PG>S24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dogru-2004" MODIFIED="2011-02-03 12:37:21 +0000" MODIFIED_BY="[Empty name]" NAME="Dogru 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-04-28 11:02:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dogru D, Dalgic F, Kiper N, Ozcelik U, Yalcin E, Aslan AT, et al</AU>
<TI>Effect of clarithromycin on inflammatory markers in bronchoalveolar lavage fluid in cystic fibrosis: a randomised, placebo-controlled crossover trial [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2004</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>S21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Frederiksen-2001" MODIFIED="2011-02-03 11:44:03 +0000" MODIFIED_BY="[Empty name]" NAME="Frederiksen 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-04-28 10:53:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Frederiksen B, Koch C, Hoiby N, Pressler T</AU>
<TI>Clinical efficacy of clarithromycin in CF patients with chronic lung infection [abstract]</TI>
<SO>Abstracts of the 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna</SO>
<YR>2001</YR>
<PG>P208</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jaffe-1998" NAME="Jaffe 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jaffe A, Francis J, Rosenthal M, Bush A</AU>
<TI>Long-term azithromycin may improve lung function in children with cystic fibrosis</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>351</VL>
<NO>9100</NO>
<PG>420</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jensen-2005" NAME="Jensen 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;28th European cystic fibrosis conference; 2005 June 22-25; Crete, Greece.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jensen PØ, Moser C, Pressler T, Koch C, Høiby N</AU>
<TI>Circulating phagocytes during Azithromycin treatment of Cystic Fibrosis patients with chronic Pseudomonas aeruginosa lung infection [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2005</YR>
<VL>4</VL>
<NO>Suppl 1</NO>
<PG>S24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kessaris-2003" MODIFIED="2011-02-03 12:43:14 +0000" MODIFIED_BY="[Empty name]" NAME="Kessaris 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-02-03 12:43:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kessaris A, Souli M, Inglezos I, Kanellakopoulou K, Apostolopoulou F, Giamarellou E</AU>
<TI>Efficacy of low-dose, long-term clarithromycin administration in improving the clinical course in cystic fibrosis patients with chronic P. aeruginosa airway colonization [abstract]</TI>
<SO>European Respiratory Journal</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>Suppl 45</NO>
<PG>514s</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ordonez-2001" NAME="Ordonez 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ordonez CL, Stulbarg M, Grundland H, Liu JT, Boushey HA</AU>
<TI>Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2001</YR>
<VL>32</VL>
<NO>1</NO>
<PG>29-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Pirzada-1999" NAME="Pirzada 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pirzada, OM Taylor, CJ</AU>
<TI>Long term macrolide antibiotics improve pulmonary function in cystic fibrosis [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1999</YR>
<VL>28 Suppl 19</VL>
<PG>263</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pukhalsky-2001" NAME="Pukhalsky 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pukhalsky AL, Shmarina GV, Kaproanov NI, Kashirskaja NJ, Kokarovtseva SN,Shabalova LA et al</AU>
<TI>Increase of the sputum neutrophil elastase activity is a paradoxical effect of the successful lung disease treatment in cystic fibrosis [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2001</YR>
<VL>32 Suppl 22</VL>
<PG>274</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Radionovitch-2005" MODIFIED="2011-02-03 12:38:21 +0000" MODIFIED_BY="[Empty name]" NAME="Radionovitch 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-10-28 15:53:17 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Radionovitch AM, Kashirskaya NJ, Kapranov NI</AU>
<TI>Long-term low-dose therapy with macrolides in bronchopulmonary disease in Cystic Fibrosis (CF) pediatric patients [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2005</YR>
<VL>4</VL>
<NO>Suppl 1</NO>
<PG>S31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rubin-2003" MODIFIED="2011-02-10 10:36:18 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Rubin 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-02-03 12:44:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barker PM, Gillie DJ, Schechter MS, Rubin BK</AU>
<TI>Effect of macrolides on in vivo ion transport across cystic fibrosis nasal epithelium</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2005</YR>
<VL>171</VL>
<NO>8</NO>
<PG>868-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-02-03 12:45:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Rubin BK</AU>
<TI>Macrolide antibiotic therapy for patients with cystic fibrosis</TI>
<SO>www.clinicaltrials.gov (accessed 04 March 2010)</SO>
<YR>2005</YR>
<IDENTIFIERS MODIFIED="2010-11-24 11:59:29 +0000" MODIFIED_BY="Nikki Jahnke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shmarina-2004" MODIFIED="2011-02-10 09:34:11 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Shmarina 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-02-10 09:34:11 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shmarina GV, Pukhalsky AL, Kashirskaja NJ, Research Centre for Medical Genetics MR</AU>
<TI>Anti-inflammatory therapy in cystic fibrosis: a comparative study in the treatment with nimesulide (selective cyclooxygenase-2 inhibitor) and clarithromycin (14-memebered ring macrolide antibiotic) [abstract]</TI>
<SO>European Respiratory Journal</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>Suppl 48</NO>
<PG>P3758</PG>
<IDENTIFIERS MODIFIED="2011-02-10 09:34:11 +0000" MODIFIED_BY="Nikki Jahnke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sriram-2003" MODIFIED="2011-02-03 11:44:10 +0000" MODIFIED_BY="[Empty name]" NAME="Sriram 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-10-28 15:53:33 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sriram S, Young J, Waterhouse JC, Bucknall CE,Stack BHR</AU>
<TI>The antiinflammatory effect of clarithromycin in CF [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2003</YR>
<VL>2</VL>
<NO>Suppl 1</NO>
<PG>S52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-09-11 14:51:22 +0100" MODIFIED_BY="Nikki Jahnke">
<STUDY DATA_SOURCE="PUB" ID="STD-Elmasry-2010" MODIFIED="2011-02-10 09:57:44 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Elmasry 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-02-10 09:57:44 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elmasry S, Mok SS, Braithwaite M, Sofianopoulos S, Clark D, Finlayson F, et al</AU>
<TI>Adherence behaviour of adult cystic fibrosis (CF) patients to prescribed azithromycin [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2010</YR>
<VL>9</VL>
<NO>Suppl 1</NO>
<PG>S24, Abstract no: 92</PG>
<IDENTIFIERS MODIFIED="2011-02-10 09:57:34 +0000" MODIFIED_BY="Nikki Jahnke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pukhalsky-2008" MODIFIED="2012-09-11 14:51:22 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Pukhalsky 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-09-11 14:51:22 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pukhalsky A, Shmarina G, Pukhalskaya D, Perederko L</AU>
<TI>Whether low frequency of hepatobiliary abnormalities in cystic fibrosis patients is associated with anti-inflammatory treatment? [abstract]</TI>
<SO>European Respiratory Society Annual Congress; 2008 Oct 4-8; Berlin, Germany</SO>
<YR>2008</YR>
<PG>216s</PG>
<IDENTIFIERS MODIFIED="2011-02-10 09:39:50 +0000" MODIFIED_BY="Nikki Jahnke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2010-04-29 11:45:36 +0100" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-09-11 14:50:37 +0100" MODIFIED_BY="Nikki Jahnke">
<ADDITIONAL_REFERENCES MODIFIED="2012-09-11 14:38:47 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Anderson-1996" NAME="Anderson 1996" TYPE="JOURNAL_ARTICLE">
<AU>Anderson R, Theron AJ, Feldman C</AU>
<TI>Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils</TI>
<SO>Inflammation</SO>
<YR>1996</YR>
<VL>20</VL>
<NO>6</NO>
<PG>693-705</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ball-1991" NAME="Ball 1991" TYPE="JOURNAL_ARTICLE">
<AU>Ball AP</AU>
<TI>Azithromycin: an interim analysis</TI>
<SO>Journal of International Medical Research</SO>
<YR>1991</YR>
<VL>19</VL>
<NO>6</NO>
<PG>446-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boucher-1999" MODIFIED="2011-02-03 12:45:27 +0000" MODIFIED_BY="[Empty name]" NAME="Boucher 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boucher RC</AU>
<TI>Molecular insights into the physiology of the 'thin film' of airway surface liquid</TI>
<SO>Journal of Physiology</SO>
<YR>1999</YR>
<VL>516</VL>
<NO>Pt 3</NO>
<PG>631-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curtin-2002a" MODIFIED="2008-04-09 14:54:40 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Curtin 2002a" TYPE="JOURNAL_ARTICLE">
<AU>Curtin F, Altman DG, Elbourne E</AU>
<TI>Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>15</NO>
<PG>2131-44</PG>
<IDENTIFIERS MODIFIED="2008-04-09 14:54:40 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2008-04-09 14:54:40 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/sim.1205"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Curtin-2002b" MODIFIED="2008-04-09 14:56:29 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Curtin 2002b" TYPE="JOURNAL_ARTICLE">
<AU>Curtin F, Elbourne D, Altman DG</AU>
<TI>Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>15</NO>
<PG>2145-59</PG>
<IDENTIFIERS MODIFIED="2008-04-09 14:56:29 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2008-04-09 14:56:29 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/sim.1206"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Curtin-2002c" MODIFIED="2008-04-09 14:58:09 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Curtin 2002c" TYPE="JOURNAL_ARTICLE">
<AU>Curtin F, Altman DG, Elbourne E</AU>
<TI>Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carryover</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>15</NO>
<PG>2161-73</PG>
<IDENTIFIERS MODIFIED="2008-04-09 14:58:09 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2008-04-09 14:58:09 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/sim.1207"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Florescu-2009" MODIFIED="2010-10-28 15:08:01 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Florescu 2009" TYPE="JOURNAL_ARTICLE">
<AU>Florescu DF, Murphy PJ, Kalil AC</AU>
<TI>Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis</TI>
<SO>Pulmonary Pharmacology and Therapeutics</SO>
<YR>2009</YR>
<VL>22</VL>
<NO>6</NO>
<PG>467-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hansen-2009" MODIFIED="2010-07-15 16:39:39 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Hansen 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hansen CR, Pressler T, Hoiby N, Johansen HK</AU>
<TI>Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2009</YR>
<VL>8</VL>
<NO>1</NO>
<PG>58-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2010-10-28 10:23:38 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2010-10-28 10:44:40 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Higgins 2009" TYPE="OTHER">
<AU>Higgins JPT, Altman DG on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group (editors)</AU>
<TI>Chapter 8:  Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]</TI>
<SO>The CochraneCollaboration, 2008. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hoiby-1994" NAME="Hoiby 1994" TYPE="JOURNAL_ARTICLE">
<AU>Hoiby N</AU>
<TI>Diffuse panbronchiolitis and cystic fibrosis: East meets West</TI>
<SO>Thorax</SO>
<YR>1994</YR>
<VL>49</VL>
<NO>6</NO>
<PG>531-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hutchison-1999" MODIFIED="2011-02-03 12:45:51 +0000" MODIFIED_BY="[Empty name]" NAME="Hutchison 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hutchison ML, Govan JR</AU>
<TI>Pathogenicity of microbes associated with cystic fibrosis</TI>
<SO>Microbes and Infection</SO>
<YR>1999</YR>
<VL>1</VL>
<NO>12</NO>
<PG>1005-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ichimiya-1996" NAME="Ichimiya 1996" TYPE="JOURNAL_ARTICLE">
<AU>Ichimiya T, Takeoka K, Hiramatsu K, Hirai K, Yamasaki T, Nasu M</AU>
<TI>The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro</TI>
<SO>Chemotherapy</SO>
<YR>1996</YR>
<VL>42</VL>
<NO>3</NO>
<PG>186-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kobayashi-1993" NAME="Kobayashi 1993" TYPE="JOURNAL_ARTICLE">
<AU>Kobayashi H, Ohgaki N, Takeda H</AU>
<TI>Therapeutic possibilities for diffuse panbronchiolitis</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>1993</YR>
<VL>3</VL>
<PG>S81-S86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Labro-1998" NAME="Labro 1998" TYPE="JOURNAL_ARTICLE">
<AU>Labro MT</AU>
<TI>Anti-inflammatory activity of macrolides: a new therapeutic potential?</TI>
<SO>Journal Antimicrobial Chemotherapeutics</SO>
<YR>1998</YR>
<VL>41 Suppl B</VL>
<PG>37-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Matsui-1998" NAME="Matsui 1998" TYPE="JOURNAL_ARTICLE">
<AU>Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, et al</AU>
<TI>Evidence for periciliary liquid layer depletion, not abnormal ion composition in the pathogenesis of cystic fibrosis airways disease</TI>
<SO>Cell</SO>
<YR>1998</YR>
<VL>95</VL>
<NO>7</NO>
<PG>1005-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mizukane-1994" NAME="Mizukane 1994" TYPE="JOURNAL_ARTICLE">
<AU>Mizukane R, Hirakata Y, Kaku M, Ishii Y, Furuya N, Ishida K, et al</AU>
<TI>Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1994</YR>
<VL>38</VL>
<NO>3</NO>
<PG>528-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Molinari-1993" NAME="Molinari 1993" TYPE="JOURNAL_ARTICLE">
<AU>Molinari G, Guzman CA, Pesce A, Schito GC</AU>
<TI>Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1993</YR>
<VL>31</VL>
<NO>5</NO>
<PG>681-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Phaff-2006" MODIFIED="2010-07-15 16:41:15 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Phaff 2006" TYPE="JOURNAL_ARTICLE">
<AU>Phaff SJ, Tiddens HA, Verbrugh HA, Ott A</AU>
<TI>Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>2006</YR>
<VL>57</VL>
<NO>4</NO>
<PG>741-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ratjen-2012" MODIFIED="2012-09-11 14:38:33 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Ratjen 2012" TYPE="OTHER">
<AU>Ratjen F, Saiman L, Mayer-Hamblett N, Lands LC, Kloster M,Thompson V, et al</AU>
<TI>Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with <I>Pseudomonas aeruginosa</I>
</TI>
<SO>Chest</SO>
<YR>2012 May 17 [Epub ahead of print]</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1378/chest.12-0628"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Retsema-1987" NAME="Retsema 1987" TYPE="JOURNAL_ARTICLE">
<AU>Retsema J, Girard A, Schelkly W, Manousos M, Anderson M, Bright G, et al</AU>
<TI>Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1987</YR>
<VL>31</VL>
<NO>12</NO>
<PG>1939-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2008" MODIFIED="2010-10-27 15:30:34 +0100" MODIFIED_BY="Nikki Jahnke" NAME="RevMan 2008" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Riordan-1989" NAME="Riordan 1989" TYPE="JOURNAL_ARTICLE">
<AU>Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, et al</AU>
<TI>Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA</TI>
<SO>Science</SO>
<YR>1989</YR>
<VL>245</VL>
<NO>4922</NO>
<PG>1066-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smyth-2003" MODIFIED="2010-10-28 15:05:21 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Smyth 2003" TYPE="COCHRANE_REVIEW">
<AU>Smyth AR, Walters S</AU>
<TI>Prophylactic anti-staphylococcal antibiotics for cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2010-10-28 15:05:21 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2010-10-28 15:05:21 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.CD001912"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Steinkamp-2010" MODIFIED="2010-10-28 15:54:53 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Steinkamp 2010" TYPE="CORRESPONDENCE">
<AU>Steinkamp G (CF-Centre Hamburg-Altona and Clinical Research Hannover, Germany)</AU>
<SO>Email to KW Southern</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tramper_x002d_Stranders-2007" MODIFIED="2010-07-15 16:32:22 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Tramper-Stranders 2007" TYPE="JOURNAL_ARTICLE">
<AU>Tramper-Stranders GA, Wolfs TF, Fleer A, Kimpen JL, van der Ent CK</AU>
<TI>Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>1</NO>
<PG>8-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yanagihara-1997" MODIFIED="2011-02-03 12:47:33 +0000" MODIFIED_BY="[Empty name]" NAME="Yanagihara 1997" TYPE="JOURNAL_ARTICLE">
<AU>Yanagihara K, Tomono K, Sawai T, Hirakata Y, Kadota J, Koga H et al</AU>
<TI>Effect of clarithromycin on lymphocytes in chronic respiratory Pseudomonas aeruginosa infection</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1997</YR>
<VL>155</VL>
<NO>1</NO>
<PG>337-42</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-09-11 14:50:37 +0100" MODIFIED_BY="Nikki Jahnke">
<REFERENCE ID="REF-Southern-2003" MODIFIED="2011-10-20 11:37:09 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Southern 2003" TYPE="COCHRANE_REVIEW">
<AU>Southern KW, Barker PM, Solis A</AU>
<TI>Macrolide antibiotics for cystic fibrosis (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-10-20 11:37:09 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2011-10-20 11:37:09 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.CD002203"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Southern-2004" MODIFIED="2011-10-20 11:36:27 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Southern 2004" TYPE="COCHRANE_REVIEW">
<AU>Southern KW, Barker PM, Solis A</AU>
<TI>Macrolide antibiotics for cystic fibrosis (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2011-10-20 11:36:27 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2011-10-20 11:36:27 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.CD002203.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Southern-2011" MODIFIED="2012-09-11 14:50:37 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Southern 2011" TYPE="COCHRANE_REVIEW">
<AU>Southern KW, Barker PM, Solis-Moya A, Patel L</AU>
<TI>Macrolide antibiotics for cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2012-09-11 14:50:37 +0100" MODIFIED_BY="Nikki Jahnke">
<IDENTIFIER MODIFIED="2012-09-11 14:50:37 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.CD002203.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2012-02-29 10:10:56 +0000" MODIFIED_BY="Nikki Jahnke"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-02-10 10:36:32 +0000" MODIFIED_BY="Nikki Jahnke">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-02-10 09:37:10 +0000" MODIFIED_BY="Nikki Jahnke" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-10-28 15:21:22 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Clement-2006">
<CHAR_METHODS MODIFIED="2010-10-28 15:21:08 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Randomised, multicentre, double-blind, placebo-controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-28 15:20:52 +0100" MODIFIED_BY="Nikki Jahnke">
<P>82 young people with CF (6-21 years, mean age 11.0 years, SD 3.3 years), 40 in azithromycin group, 42 in placebo group. 35 in treatment group and 37 in placebo group completed trial.</P>
<P>FEV<SUB>1</SUB> &gt;40% predicted.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-28 15:21:01 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Azithromycin 250 mg tablet 3 times per week (&gt;40 kg, 500 mg) versus placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-28 15:21:18 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Relative change in FEV<SUB>1</SUB> &amp; FVC % predicted, number of pulmonary exacerbations, additional antibiotic treatment (oral and IV), lung microbiology and adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-28 15:21:22 +0100" MODIFIED_BY="Nikki Jahnke">
<P>French study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-28 15:23:07 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Equi-2002">
<CHAR_METHODS>
<P>Randomised placebo controlled cross-over trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>41 children (8 to 18 years).<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Azithromycin, 250 mg (500 mg if weight &gt; 40 kg) once a day for 6 months versus placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-28 15:23:07 +0100" MODIFIED_BY="Nikki Jahnke">
<P>% change in FEV<SUB>1</SUB> (average of 4 and 6 month values, also for FVC and MEF), hearing, sputum bacterial densities, inflammatory markers, exercise tolerance, subjective well-being.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-08-03 14:55:52 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment arms not reported individually, these have subsequently been calculated for the first arm from figures provided in the paper and IPD kindly provided by the authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-03 12:24:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kabra-2010">
<CHAR_METHODS MODIFIED="2010-10-28 15:23:48 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Randomised study comparing 2 doses of azithromycin.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-03 12:24:04 +0000" MODIFIED_BY="[Empty name]">
<P>Children with CF (5-18 years). 56/105 children screened were randomised, 47 completed 12 months follow-up.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-28 15:23:58 +0100" MODIFIED_BY="Nikki Jahnke">
<P>High (15 mg/kg/day) versus low (5 mg/kg/day) dose of azithromycin for 12 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-28 15:24:01 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Change in FEV<SUB>1</SUB> (% predicted), pulmonary exacerbation (hospitalisation), microbiology, antibiotic use.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-28 15:24:09 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Children admitted if breathlessness or hypoxia occurred with exacerbation (suggests severe respiratory compromise).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-03 12:25:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McCormack-2007">
<CHAR_METHODS MODIFIED="2011-02-03 12:24:51 +0000" MODIFIED_BY="[Empty name]">
<P>Multicentre parallel RCT comparing 2 dosing regimens (daily versus weekly) of azithromycin.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-28 15:25:00 +0100" MODIFIED_BY="Nikki Jahnke">
<P>208 CF patients (6-58 years).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-28 15:25:02 +0100" MODIFIED_BY="Nikki Jahnke">
<P>250 mg daily versus 1200 mg weekly doses of azithromycin.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-03 12:25:14 +0000" MODIFIED_BY="[Empty name]">
<P>Change in FEV<SUB>1</SUB> (%) at 1,3 and 6 months from baseline. Also time to PEx, adverse effects, days in hospital, QoL, changes in inflammatory markers, acquisition of azithromycin resistant <I>S. aureus</I>.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-28 15:25:33 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Australian study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-03 12:25:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-O_x0027_Connor-2009">
<CHAR_METHODS MODIFIED="2010-10-28 15:26:45 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Single centre randomised double blind cross-over study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-28 15:26:46 +0100" MODIFIED_BY="Nikki Jahnke">
<P>CF patients, aged 6-20 years (mean, 11.7 years).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-02-03 12:25:38 +0000" MODIFIED_BY="[Empty name]">
<P>Azithromycin, 250 mg (or 500 if weight &gt;40 kg) 3 times a week or placebo for 4 months, then following 2-month washout period cross-over to other arm for 4 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-03 12:25:47 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: comparative change in FEV<SUB>1</SUB>. Also QoL and nutritional parameters. Adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-03 12:25:56 +0000" MODIFIED_BY="[Empty name]">
<P>Northern Ireland study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-03 12:27:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rotschild-2005">
<CHAR_METHODS MODIFIED="2010-10-28 15:27:48 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Single centre randomised placebo controlled study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-03 12:26:38 +0000" MODIFIED_BY="[Empty name]">
<P>18 CF patients (5.5-36.3 years, median 15.1). Diagnosis not clear, mean sweat chloride, 74.5 mg/L. One patient had 5T mutation (associated with a milder phenotype).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-28 15:28:10 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Azithromycin (10 patients) 250 mg twice a week for 12 weeks versus placebo (8 patients).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-08-09 11:34:17 +0100" MODIFIED_BY="[Empty name]">
<P>BPI-ANCA levels in the blood (a possible marker of inflammation). Also respiratory function. Also secondary outcomes not fully reported (authors contacted). Overall weight gain in both groups, but wide range and differences not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-03 12:27:04 +0000" MODIFIED_BY="[Empty name]">
<P>Israeli study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-03 12:28:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saiman-2003">
<CHAR_METHODS MODIFIED="2011-02-03 12:27:16 +0000" MODIFIED_BY="[Empty name]">
<P>Multicentre randomised placebo-controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-03 12:27:30 +0000" MODIFIED_BY="[Empty name]">
<P>185 participants: adults and children with CF (&gt; 6 years) with chronic <I>P. aeruginosa</I> chest infection (&gt; 1 year) and an FEV<SUB>1</SUB> &gt;30% predicted.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Azithromycin, 500 mg (250 mg if weight &lt;40 kg) 3 days a week versus placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-03 12:28:02 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: relative change in FEV<SUB>1</SUB> (% predicted).<BR/>Secondary: adverse events, self-reported symptoms, audiology and laboratory tests, respiratory cultures, relative change in FVC (% predicted), body weight, PEx (number and time to), hospitalisation rate, use of non-quinolone antibiotics, inflammatory markers, and QoL.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-28 15:31:21 +0100" MODIFIED_BY="Nikki Jahnke">
<P>First North American Study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-03 12:29:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saiman-2010">
<CHAR_METHODS MODIFIED="2010-10-28 15:31:57 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Multi-centre placebo-controlled parallel design.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-03 12:28:31 +0000" MODIFIED_BY="[Empty name]">
<P>Young CF patients (6-18 years) without chronic <I>P. aeruginosa</I> airway infection (clear (2 or more cultures) for &gt; 12 months)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-02-03 12:28:53 +0000" MODIFIED_BY="[Empty name]">
<P>Azithromycin (250 mg 3 times a week, increased to 500, if weight &gt;36 kg) versus placebo; for 6 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-03 12:29:17 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: relative change in FEV<SUB>1</SUB> from baseline.</P>
<P>Secondary: respiratory exacerbations; treatment requirements; and adverse events. Acquisition of resistant bacteria in respiratory culture. Authors contacted for full data on nutritional outcomes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-28 15:33:11 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Second North American study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-03 12:30:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steinkamp-2007">
<CHAR_METHODS MODIFIED="2010-10-28 15:33:46 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Double-blind placebo-controlled study from 10 German and 1 Swiss centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-03 12:30:35 +0000" MODIFIED_BY="[Empty name]">
<P>38/40 screened patients were randomised. Mean age (SD), 24.8 years (10.0).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-28 15:33:58 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Azithromycin (once a week, dose from 500-1250 mg depending on weight) versus placebo for 8 weeks, following a course of IV antibiotic treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-03 12:30:48 +0000" MODIFIED_BY="[Empty name]">
<P>Change in pulmonary function tests from baseline, adverse events, change in QoL domains, inflammatory markers in sputum.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-26 11:05:33 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-02-03 12:32:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wolter-2002">
<CHAR_METHODS MODIFIED="2010-10-28 15:35:06 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Randomised placebo-controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-03 12:31:19 +0000" MODIFIED_BY="[Empty name]">
<P>60 adult participants. Mean age 27.9 (SD, 6.5).<BR/>The placebo group contained more men (20/30 versus 9/30), was taller, heavier and had better lung function (FEV<SUB>1</SUB> mean (SD), 62.3 (24.8) versus 50.9 (18.3)).<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Azithromycin, 250 mg once a day for 3 months versus placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-28 15:35:28 +0100" MODIFIED_BY="Nikki Jahnke">
<P>% change in FEV<SUB>1</SUB> (FVC), weight, QoL, inflammatory markers, microbiology, respiratory exacerbations.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-03 12:32:21 +0000" MODIFIED_BY="[Empty name]">
<P>Patients recruited from two adult clinics in Brisbane (first Australian study).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AB: antibiotic<BR/>BPI-ANCA: bactericidal or permeability-increasing protein<BR/>CF: cystic fibrosis<BR/>FEV<SUB>1</SUB>: forced expiratory volume at one second<BR/>FVC: forced vital capacity<BR/>IPD: individual patient data<BR/>ITT: intention to treat<BR/>IV: intravenous<BR/>MEF: maximum expiratory flow<BR/>
<I>P. aeruginosa</I>: <I>Pseudomonas aeruginosa</I>
<BR/>PEx: pulmonary exacerbation<BR/>QoL: quality of life<BR/>Relative change in FEV<SUB>1</SUB>: ((Intervention value - Baseline value)*100)/Baseline value<BR/>
<I>S. aureus</I>: <I>Staphylococcal aureus</I>
<BR/>SD: standard deviation<BR/>TDN: therapeutics development network<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-02-10 10:36:32 +0000" MODIFIED_BY="Nikki Jahnke" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-10-28 15:35:58 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Aaron-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-28 15:35:58 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Intervention is not a macrolide antibiotic.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anstead-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial. An open study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-28 15:36:01 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Anstead-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-28 15:36:01 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Small RCT presented in abstract form only. Not able to assess study design, randomisation process or results. Authors contacted for more details (2002).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Baumann-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial. An open prospective study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-28 10:32:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beringer-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-28 10:32:14 +0100" MODIFIED_BY="[Empty name]">
<P>Open label pharmacokinetic study on adults, results suggest considerable intracellular accumulation of azithromycin and no dose adjustment required for CF patients who are pancreatic insufficient.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-28 15:36:17 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Cipolli-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-28 15:36:17 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Randomised but open label short-term (5 days) pharmacokinetic study of 2 dosing regimens (500 versus 1000 mg azithromycin a day) on adult patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-28 10:52:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dionyssopoulou-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-28 10:52:28 +0100" MODIFIED_BY="[Empty name]">
<P>Authors report randomised trial of roxithromycin in CF patients in abstract form. No details of study design, randomisation process or whether placebo used. Authors contacted for further details in 2005.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-28 15:36:38 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Dogru-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-28 15:36:38 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Small randomised cross-over study of clarithromycin versus placebo. Results presented in abstract form; not able to assess study design design, randomisation process or results. Authors contacted for further details (2004 and 2006).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-03 12:36:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frederiksen-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-03 12:36:33 +0000" MODIFIED_BY="[Empty name]">
<P>Authors report a randomised cross-over study of clarithromycin (500 bd) versus placebo in abstract form. Not able to assess study design, randomisation process or results from abstract. Large number of drop outs from study (20/41) and lack of positive findings probably influenced the decision not to submit for publication. Authors contacted and kindly provided protocol, suggesting adequate sequence generation, allocation and blinding, however it was not possible to analyse the data provided as it was not in a manner that permits analysis (2001).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jaffe-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial. Open study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-28 15:37:12 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Jensen-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-28 15:37:12 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-29 14:44:17 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Kessaris-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-29 14:44:17 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Authors present results in abstract form only, describing small (n = 12) RCT of clarithromycin versus placebo for six months. Not able to assess randomisation process or results from the abstract. Authors contacted for further information and results (2006).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ordonez-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not randomised controlled trial. A single-blinded prospective pilot study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pirzada-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective case control study, no randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pukhalsky-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-03 12:38:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Radionovitch-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-03 12:38:11 +0000" MODIFIED_BY="[Empty name]">
<P>Authors confirm not randomised. Treatments allocated in open manner.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-28 10:47:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rubin-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-28 10:47:29 +0100" MODIFIED_BY="[Empty name]">
<P>Study described as an RCT, examining the impact of clarithromycin on airway ion transport. Nasal PD data published, suggesting no impact of clarithromycin on airway ion transport.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-10 09:35:41 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Shmarina-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-10 09:35:41 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Study comparing clarithromycin to nimesulide<B> </B>not to placebo, another antibiotic class, another macrolide or the same macrolide at a different dose.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-02-03 12:38:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sriram-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-02-03 12:38:32 +0000" MODIFIED_BY="[Empty name]">
<P>Study presented in abstract form. Authors approached and have kindly provided protocol which suggests adequate randomisation processes. No aggregate data available, it has not been possible to analyse the limited IPD provided due to format.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>bd: twice daily<BR/>CF: cystic fibrosis<BR/>IPD: individual patient data<BR/>PD: potential difference<BR/>RCT: randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2011-02-10 10:06:57 +0000" MODIFIED_BY="Nikki Jahnke" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2011-02-10 10:06:44 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Elmasry-2010">
<CHAR_METHODS MODIFIED="2011-02-10 10:01:29 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Randomised (no details of method given) parallel study. Duration 24 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-10 10:05:40 +0000" MODIFIED_BY="Nikki Jahnke">
<P>49 participants with CF. Mean (SD) age 33.4 (8) years. Mean (SD) baseline FEV<SUB>1</SUB> % predicted 59.9 (21.5)%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-02-10 10:01:22 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Azithromycin either 1 g weekly (n=22) or 1.5 g 3x per week (n=27).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-10 10:05:35 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Total adherence (total medication taken / total medication prescribed), total number of days adhered (number of days prescribed doses taken / number of days monitored), pill counts, pharmacy pick-up, self-reports using a Morisky and a Beliefs and Behaviour Questionnaire, FEV<SUB>1</SUB> % predicted.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-02-10 10:06:44 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Supported by ARC Linkage grant, Roche Australia Pty. Ltd</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2011-02-10 09:50:56 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Pukhalsky-2008">
<CHAR_METHODS MODIFIED="2011-02-10 09:50:56 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Parallel study, not clear if randomised.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-02-10 09:48:38 +0000" MODIFIED_BY="Nikki Jahnke">
<P>160 participants with CF, 100 healthy controls (children). Of CF participants, 90 received no anti-inflammatory treatment, 70 received anti-inflammatory treatment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-02-10 09:48:35 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Anti-inflammatory treatment (either azithromycin at a dose of 500 mg orally 3x per week (n=48) or alternated course of prednisolone at a dose of 0.3 mg/kg body weight every other day (n=22) versus no treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-02-10 09:50:25 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Plasma cytokines, hepatobiliary abnormalities (portal hypertension, cirrhosis).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES>
<P>ARC: Australian Research Council<BR/>CF: cystic fibrosis<BR/>FEV<SUB>1: </SUB>forced expiratory volume at one second<BR/>SD: standard deviation</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-11-29 14:44:42 +0000" MODIFIED_BY="Nikki Jahnke" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-02-10 09:37:10 +0000" MODIFIED_BY="Nikki Jahnke">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-02-10 09:37:10 +0000" MODIFIED_BY="Nikki Jahnke" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 15:21:34 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Clement-2006">
<DESCRIPTION>
<P>"Centralised secure randomisation department".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 15:23:16 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Equi-2002">
<DESCRIPTION>
<P>Provided by Statistics Dept at Pfizer, USA.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-03 12:24:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kabra-2010">
<DESCRIPTION>
<P>Computer-generated blocks of 4.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 15:26:13 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-McCormack-2007">
<DESCRIPTION>
<P>Microsoft Excel program used by Mater Hospital Pharmacy to generate randomisation schedule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 15:27:24 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-O_x0027_Connor-2009">
<DESCRIPTION>
<P>Computer-generated random numbers in pharmacy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 15:30:25 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Rotschild-2005">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-27 12:21:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saiman-2003">
<DESCRIPTION>
<P>By CF TDN Co-ordinating Centre. Randomisation included a valid allocation strategy to ensure equivalence between placebo and intervention with respect to weight, respiratory function and site of study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 15:33:17 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Saiman-2010">
<DESCRIPTION>
<P>University of South Florida generated assignments via secure centralized randomisation system.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 15:34:12 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Steinkamp-2007">
<DESCRIPTION>
<P>Allocation was undertaken centrally using a computer-generated sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 15:35:39 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Wolter-2002">
<DESCRIPTION>
<P>Hospital pharmacy staff, exact method not stated ("randomised prior to commencement of study").</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-02-10 09:37:10 +0000" MODIFIED_BY="Nikki Jahnke" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 15:21:35 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Clement-2006">
<DESCRIPTION>
<P>Centralised, study number assigned by interactive voice response system, study kits distributed by chief pharmacist in each centre.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 15:23:17 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Equi-2002">
<DESCRIPTION>
<P>Hospital Pharmacy department, described in detail.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-29 14:37:43 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Kabra-2010">
<DESCRIPTION>
<P>Not clear if patients or physicians knew of allocation to high or low dose.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 15:26:15 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-McCormack-2007">
<DESCRIPTION>
<P>By hospital pharmacy staff (code A or B seen by them and then removed prior to allocation).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 15:27:31 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-O_x0027_Connor-2009">
<DESCRIPTION>
<P>Placebo were coloured red and the intervention brown (known by pharmacy but not investigators, CF team or participants, but resulted in speculation).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-25 18:06:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rotschild-2005">
<DESCRIPTION>
<P>By hospital pharmacy staff independent of trial staff</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-03 12:28:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saiman-2003">
<DESCRIPTION>
<P>Centralised secure randomisation system at the co-ordinating centre.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 15:33:19 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Saiman-2010">
<DESCRIPTION>
<P>Data co-ordinating centre distributed blinded study drug kits.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-25 09:44:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Steinkamp-2007">
<DESCRIPTION>
<P>Allocation was organised centrally with support from the Clinical Trials Officer.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 15:35:40 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Wolter-2002">
<DESCRIPTION>
<P>By hospital pharmacy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-02-10 09:37:10 +0000" MODIFIED_BY="Nikki Jahnke" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-28 15:21:36 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Clement-2006">
<DESCRIPTION>
<P>Identically packaged, all participants and investigators blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-28 15:23:19 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Equi-2002">
<DESCRIPTION>
<P>All parties involved, identical packaging for intervention and placebo.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-25 09:40:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kabra-2010">
<DESCRIPTION>
<P>As above.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-28 15:26:16 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-McCormack-2007">
<DESCRIPTION>
<P>Identical capsules, all parties involved were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-28 15:27:32 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-O_x0027_Connor-2009">
<DESCRIPTION>
<P>See above, a concern.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-28 15:30:26 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Rotschild-2005">
<DESCRIPTION>
<P>Tablets identical in colour and shape.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-28 15:31:34 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Saiman-2003">
<DESCRIPTION>
<P>All study personnel and participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-04-27 13:34:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saiman-2010">
<DESCRIPTION>
<P>Identically packaged tablets.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-28 15:34:55 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Steinkamp-2007">
<DESCRIPTION>
<P>Indentical look and taste of tablets.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-28 15:35:41 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Wolter-2002">
<DESCRIPTION>
<P>Identical capsules and number, all parties blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-02-10 09:37:10 +0000" MODIFIED_BY="Nikki Jahnke" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-28 15:21:42 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Clement-2006">
<DESCRIPTION>
<P>A complete ITT analysis undertaken on primary outcome and pulmonary exacerbation data. Some per protocol analysis on other outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-25 09:40:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Equi-2002">
<DESCRIPTION>
<P>Complete ITT analysis undertaken on primary outcome. Not clear from paper whether primary outcome was a <I>post hoc</I> protocol change, but subsequent correspondence has confirmed that this was determined <I>a priori.</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-25 09:41:10 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kabra-2010">
<DESCRIPTION>
<P>Primary outcome assessed on per protocol basis not ITT.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-28 15:26:18 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-McCormack-2007">
<DESCRIPTION>
<P>A clear ITT analysis of the primary outcome and time to first exacerbation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-02-03 12:26:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Connor-2009">
<DESCRIPTION>
<P>21 randomised and completed first arm. 4 dropped out for second arm and not included in comparative analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-04-27 14:40:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rotschild-2005">
<DESCRIPTION>
<P>3 patients dropped out and were not included in analysis. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-28 15:31:35 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Saiman-2003">
<DESCRIPTION>
<P>Clear ITT analysis of primary outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-28 15:33:27 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Saiman-2010">
<DESCRIPTION>
<P>Modified ITT analysis (3 patients in placebo arm did not receive study drug and were removed) of primary outcome and most others.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-28 15:34:56 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Steinkamp-2007">
<DESCRIPTION>
<P>A clear ITT analysis of the primary outcome. Some secondary outcomes analysed per protocol.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-10-28 15:35:51 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Wolter-2002">
<DESCRIPTION>
<P>ITT analysis performed on primary outcome, others reported per protocol.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-02-10 09:37:10 +0000" MODIFIED_BY="Nikki Jahnke" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 15:21:59 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Clement-2006">
<DESCRIPTION>
<P>Some data at intermediate time points not reported (requested from authors, who kindly provided some IPD, although intermediate time points not available).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-27 11:50:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Equi-2002">
<DESCRIPTION>
<P>Not clear if primary outcome calculation (months 4 and 6 averaged for relative change) was an <I>a priori</I> decision.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-03 14:58:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kabra-2010">
<DESCRIPTION>
<P>Only limited time points reported, patients seen monthly. All outcomes measured were reported, but not completely.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-03 12:25:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCormack-2007">
<DESCRIPTION>
<P>Some data requested from authors (QoL, relative change in FEV<SUB>1</SUB> and weight z scores).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 15:27:37 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-O_x0027_Connor-2009">
<DESCRIPTION>
<P>All outcomes measured were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-29 14:39:44 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-Rotschild-2005">
<DESCRIPTION>
<P>Patients seen at 4, 8 and 12 weeks, but data only reported for week 12.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-03 12:28:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saiman-2003">
<DESCRIPTION>
<P>Outcomes clearly reported. Subsequent subgroup analysis published separately.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 15:33:27 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Saiman-2010">
<DESCRIPTION>
<P>All outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 15:34:59 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-Steinkamp-2007">
<DESCRIPTION>
<P>All measured outcomes reported, some provided by authors directly (QoL). Data from outcomes beyond 8 weeks not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 15:35:52 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Wolter-2002">
<DESCRIPTION>
<P>All outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-02-10 09:37:10 +0000" MODIFIED_BY="Nikki Jahnke" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-24 14:38:46 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Clement-2006">
<DESCRIPTION>
<P>None identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-03 12:23:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Equi-2002">
<DESCRIPTION>
<P>Adequate washout, authors have provided IPD.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-03 12:24:44 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kabra-2010">
<DESCRIPTION>
<P>More boys in the high-dose group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-24 14:41:18 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-McCormack-2007">
<DESCRIPTION>
<P>None identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-24 14:41:22 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-O_x0027_Connor-2009">
<DESCRIPTION>
<P>None identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 15:30:31 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-Rotschild-2005">
<DESCRIPTION>
<P>Visual analogue scale not validated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-24 14:42:02 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Saiman-2003">
<DESCRIPTION>
<P>None identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 15:33:29 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Saiman-2010">
<DESCRIPTION>
<P>Very clearly reported study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 15:35:02 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-Steinkamp-2007">
<DESCRIPTION>
<P>Duration of study was shortened after commencement of study and data only reported for 8 weeks (correspondence with Prof Steinkamp).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-28 15:35:53 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Wolter-2002">
<DESCRIPTION>
<P>Baseline characteristics significantly different between interventions, see above "Participants".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2011-01-25 18:10:00 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2011-01-25 18:10:00 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-04-28 16:08:42 +0100" MODIFIED_BY="[Empty name]">Summary of included studies</TITLE>
<TABLE COLS="11" ROWS="11">
<TR>
<TH>
<P>Study Name</P>
</TH>
<TH>
<P>Design</P>
</TH>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Duration</P>
</TH>
<TH>
<P>Dosing Regimen</P>
</TH>
<TH>
<P>Number</P>
</TH>
<TH>
<P>Age</P>
</TH>
<TH>
<P>PA infection</P>
</TH>
<TH>
<P>Risk of bias</P>
</TH>
<TH>
<P>Primary Outcome</P>
</TH>
<TH>
<P>Main results</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Equi-2002" TYPE="STUDY">Equi 2002</LINK>
</P>
</TD>
<TD>
<P>RCT X-over</P>
</TD>
<TD>
<P>azithromycin versus placebo</P>
</TD>
<TD>
<P>6 months each arm (2 month washout)</P>
</TD>
<TD>
<P>250 mg/day (500 mg if weight &gt;40 kg)</P>
</TD>
<TD>
<P>41</P>
</TD>
<TD>
<P>8-18 years</P>
</TD>
<TD>
<P>+/-</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>comparative change in FEV<SUB>1</SUB>
</P>
</TD>
<TD>
<P>mean relative difference of 5.4% in favour of azithromycin</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Wolter-2002" TYPE="STUDY">Wolter 2002</LINK>
</P>
</TD>
<TD>
<P>RCT Parallel</P>
</TD>
<TD>
<P>azithromycin versus placebo</P>
</TD>
<TD>
<P>3 months</P>
</TD>
<TD>
<P>250 mg/day</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>adults</P>
</TD>
<TD>
<P>+/-</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>relative change in FEV<SUB>1</SUB>
</P>
</TD>
<TD>
<P>mean difference 3.6% in favour of azithromycin</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Saiman-2003" TYPE="STUDY">Saiman 2003</LINK>
</P>
</TD>
<TD>
<P>RCT Parallel</P>
</TD>
<TD>
<P>Azithromycin versus placebo</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>250 mg 3 times a week (500 if weight &gt;40kg)</P>
</TD>
<TD>
<P>185</P>
</TD>
<TD>
<P>6-adults</P>
</TD>
<TD>
<P>+</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>relative change in FEV<SUB>1</SUB>
</P>
</TD>
<TD>
<P>mean difference, 6.2% in favour of azithromycin</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Rotschild-2005" TYPE="STUDY">Rotschild 2005</LINK>
</P>
</TD>
<TD>
<P>RCT Parallel</P>
</TD>
<TD>
<P>azithromycin versus placebo</P>
</TD>
<TD>
<P>3 months</P>
</TD>
<TD>
<P>250 mg twice a week</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>5-36 years</P>
</TD>
<TD>
<P>+/-</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>BPI-ANCA levels</P>
</TD>
<TD>
<P>no difference</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Clement-2006" TYPE="STUDY">Clement 2006</LINK>
</P>
</TD>
<TD>
<P>RCT Parallel</P>
</TD>
<TD>
<P>azithromycin versus placebo</P>
</TD>
<TD>
<P>12 months</P>
</TD>
<TD>
<P>250 mg 3 times a week (500 if weight &gt;40 kg)</P>
</TD>
<TD>
<P>82</P>
</TD>
<TD>
<P>6-adults</P>
</TD>
<TD>
<P>+/-</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>relative change in FEV<SUB>1</SUB>
</P>
</TD>
<TD>
<P>no difference</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-McCormack-2007" TYPE="STUDY">McCormack 2007</LINK>
</P>
</TD>
<TD>
<P>RCT Parallel</P>
</TD>
<TD>
<P>weekly versus daily azithromycin</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>250 mg daily versus 1200 mg weekly</P>
</TD>
<TD>
<P>208</P>
</TD>
<TD>
<P>6-adults</P>
</TD>
<TD>
<P>+/-</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>relative change in FEV<SUB>1</SUB>
</P>
</TD>
<TD>
<P>equivalence</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Steinkamp-2007" TYPE="STUDY">Steinkamp 2007</LINK>
</P>
</TD>
<TD>
<P>RCT Parallel</P>
</TD>
<TD>
<P>azithromycin versus placebo</P>
</TD>
<TD>
<P>2 months</P>
</TD>
<TD>
<P>500-1250 mg weekly based on weight</P>
</TD>
<TD>
<P>38</P>
</TD>
<TD>
<P>8-adults</P>
</TD>
<TD>
<P>+/-</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>absolute change in FEV<SUB>1</SUB>
</P>
</TD>
<TD>
<P>no difference</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-O_x0027_Connor-2009" TYPE="STUDY">O'Connor 2009</LINK>
</P>
</TD>
<TD>
<P>RCT X-over</P>
</TD>
<TD>
<P>azithromycin versus placebo</P>
</TD>
<TD>
<P>4 months each arm (2 month washout)</P>
</TD>
<TD>
<P>250 mg 3 times a week (500 if weight &gt;40 kg)</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>6-18 years</P>
</TD>
<TD>
<P>+/-</P>
</TD>
<TD>
<P>High</P>
</TD>
<TD>
<P>comparative change in FEV<SUB>1</SUB>
</P>
</TD>
<TD>
<P>no difference</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kabra-2010" TYPE="STUDY">Kabra 2010</LINK>
</P>
</TD>
<TD>
<P>RCT Parallel</P>
</TD>
<TD>
<P>azithromycin, low versus high dose</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>5 versus 15 mg/kg/day</P>
</TD>
<TD>
<P>47</P>
</TD>
<TD>
<P>children</P>
</TD>
<TD>
<P>+/-</P>
</TD>
<TD>
<P>High</P>
</TD>
<TD>
<P>change in FEV<SUB>1</SUB> from baseline</P>
</TD>
<TD>
<P>no difference</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Saiman-2010" TYPE="STUDY">Saiman 2010</LINK>
</P>
</TD>
<TD>
<P>RCT Parallel</P>
</TD>
<TD>
<P>azithromycin versus placebo</P>
</TD>
<TD>
<P>6 months</P>
</TD>
<TD>
<P>250 mg 3 times a week (500 if weight &gt;36 kg)</P>
</TD>
<TD>
<P>260</P>
</TD>
<TD>
<P>6-18 years</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Low</P>
</TD>
<TD>
<P>relative change in FEV<SUB>1</SUB>
</P>
</TD>
<TD>
<P>no difference</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>BPI-ANCA: bactericidal or permeability-increasing protein<BR/>FEV<SUB>1</SUB>: forced expiratory volume at one second<BR/>PA: <I>Pseudomonas aeruginosa</I>
<BR/>RCT: randomised controlled trial<BR/>X-over: cross-over</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-02-03 13:50:10 +0000" MODIFIED_BY="Nikki Jahnke">
<COMPARISON ID="CMP-001" MODIFIED="2011-02-03 13:50:10 +0000" MODIFIED_BY="Nikki Jahnke" NO="1">
<NAME>Azithromycin versus placebo</NAME>
<CONT_OUTCOME CHI2="8.840964406785337" CI_END="4.4586999212192095" CI_START="2.0328788832359512" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="MD" EFFECT_SIZE="3.2457894022275804" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2010-10-28 15:57:12 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.9198180150273496" P_Q="0.6399913293990116" P_Z="1.5634197988892414E-7" Q="5.163720685637708" RANDOM="NO" SCALE="16.11" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="772" TOTAL_2="802" UNITS="" WEIGHT="800.0" Z="5.244929638384771">
<NAME>Relative change in FEV<SUB>1</SUB> (% predicted)</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azithromycin</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.027054952922390747" CI_END="6.50699602906356" CI_START="1.466003901807245" DF="1" EFFECT_SIZE="3.9864999654354025" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" MODIFIED="2010-10-28 15:56:37 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.8693502456075795" P_Z="0.0019355731011927602" STUDIES="2" TAU2="0.0" TOTAL_1="109" TOTAL_2="120" WEIGHT="100.0" Z="3.0999438838148694">
<NAME>at 1 month</NAME>
<CONT_DATA CI_END="7.092700337926974" CI_START="0.5272996620730246" EFFECT_SIZE="3.8099999999999996" ESTIMABLE="YES" MEAN_1="4.01" MEAN_2="0.2" ORDER="1" SD_1="13.03" SD_2="9.1" SE="1.6748778874614514" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="97" WEIGHT="58.9534964103716"/>
<CONT_DATA CI_END="8.174123045264006" CI_START="0.3058769547359943" EFFECT_SIZE="4.24" ESTIMABLE="YES" MEAN_1="2.92" MEAN_2="-1.32" ORDER="2" SD_1="7.72" SD_2="5.51" SE="2.007242518891095" STUDY_ID="STD-Wolter-2002" TOTAL_1="22" TOTAL_2="23" WEIGHT="41.04650358962841"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.10240366302228776" CI_END="5.25805812505347" CI_START="-0.8165783516079208" DF="3" EFFECT_SIZE="2.220739886722775" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" MODIFIED="2010-10-28 15:56:43 +0100" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.9915474232652753" P_Z="0.15184907201661427" STUDIES="4" TAU2="0.0" TOTAL_1="105" TOTAL_2="97" WEIGHT="99.99999999999999" Z="1.4330306722815989">
<NAME>at 2 months</NAME>
<CONT_DATA CI_END="8.820650348536182" CI_START="-4.6206503485361825" EFFECT_SIZE="2.1" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="-1.3" MODIFIED="2010-04-26 11:26:31 +0100" MODIFIED_BY="[Empty name]" ORDER="42" SD_1="16.6" SD_2="14.3" SE="3.4289662471085256" STUDY_ID="STD-Clement-2006" TOTAL_1="40" TOTAL_2="42" WEIGHT="20.42480851064858"/>
<CONT_DATA CI_END="9.332121007420987" CI_START="-5.252121007420987" EFFECT_SIZE="2.04" ESTIMABLE="YES" MEAN_1="5.29" MEAN_2="3.25" ORDER="3" SD_1="9.69" SD_2="13.86" SE="3.7205382675091516" STUDY_ID="STD-Equi-2002" TOTAL_1="20" TOTAL_2="21" WEIGHT="17.348936693333982"/>
<CONT_DATA CI_END="8.743715519739062" CI_START="-6.143715519739062" EFFECT_SIZE="1.2999999999999998" ESTIMABLE="YES" MEAN_1="-3.7" MEAN_2="-5.0" MODIFIED="2010-05-05 09:50:18 +0100" MODIFIED_BY="[Empty name]" ORDER="111" SD_1="13.3" SD_2="10.1" SE="3.7978838276897635" STUDY_ID="STD-Steinkamp-2007" TOTAL_1="21" TOTAL_2="17" WEIGHT="16.64949486073377"/>
<CONT_DATA CI_END="7.1790267364999005" CI_START="-1.819026736499901" EFFECT_SIZE="2.6799999999999997" ESTIMABLE="YES" MEAN_1="1.51" MEAN_2="-1.17" ORDER="4" SD_1="8.84" SD_2="5.85" SE="2.2954639840260582" STUDY_ID="STD-Wolter-2002" TOTAL_1="24" TOTAL_2="17" WEIGHT="45.57675993528366"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.3857109341609166" CI_END="5.520010396593772" CI_START="-0.12369751122893957" DF="1" EFFECT_SIZE="2.6981564426824165" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.03" MODIFIED="2010-10-28 15:56:48 +0100" MODIFIED_BY="Nikki Jahnke" NO="3" P_CHI2="0.5345629231205321" P_Z="0.06092382450122302" STUDIES="2" TAU2="0.0" TOTAL_1="109" TOTAL_2="116" WEIGHT="100.0" Z="1.87404789145171">
<NAME>at 3 months</NAME>
<CONT_DATA CI_END="5.570791709304038" CI_START="-1.550791709304038" EFFECT_SIZE="2.0100000000000002" ESTIMABLE="YES" MEAN_1="2.33" MEAN_2="0.32" ORDER="5" SD_1="12.47" SD_2="11.99" SE="1.8167638473926606" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="95" WEIGHT="62.8023544495991"/>
<CONT_DATA CI_END="8.486758239372431" CI_START="-0.7667582393724297" EFFECT_SIZE="3.8600000000000003" ESTIMABLE="YES" MEAN_1="2.95" MEAN_2="-0.91" ORDER="6" SD_1="9.22" SD_2="5.99" SE="2.3606343156648326" STUDY_ID="STD-Wolter-2002" TOTAL_1="22" TOTAL_2="21" WEIGHT="37.19764555040091"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0016870219476869254" CI_END="10.680778276496397" CI_START="-0.30835325273917924" DF="1" EFFECT_SIZE="5.186212511878609" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.04" MODIFIED="2010-10-28 15:56:54 +0100" MODIFIED_BY="Nikki Jahnke" NO="4" P_CHI2="0.9672374083794328" P_Z="0.06431766605500887" STUDIES="2" TAU2="0.0" TOTAL_1="60" TOTAL_2="63" WEIGHT="100.0" Z="1.8499714399469314">
<NAME>at 4 months</NAME>
<CONT_DATA CI_END="11.964019283872345" CI_START="-1.7640192838723454" EFFECT_SIZE="5.1" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="-2.1" MODIFIED="2010-04-26 11:27:35 +0100" MODIFIED_BY="[Empty name]" ORDER="43" SD_1="17.2" SD_2="14.3" SE="3.502115007221996" STUDY_ID="STD-Clement-2006" TOTAL_1="40" TOTAL_2="42" WEIGHT="64.07812005057941"/>
<CONT_DATA CI_END="14.507561820723184" CI_START="-3.8275618207231847" EFFECT_SIZE="5.34" ESTIMABLE="YES" MEAN_1="8.07" MEAN_2="2.73" ORDER="7" SD_1="14.58" SD_2="15.37" SE="4.67741340812165" STUDY_ID="STD-Equi-2002" TOTAL_1="20" TOTAL_2="21" WEIGHT="35.92187994942058"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.1603871490943503" CI_END="6.191764546405761" CI_START="1.743772056686681" DF="3" EFFECT_SIZE="3.967768301546221" ESTIMABLE="YES" I2="5.0749209361995815" ID="CMP-001.01.05" MODIFIED="2010-10-28 15:56:59 +0100" MODIFIED_BY="Nikki Jahnke" NO="5" P_CHI2="0.367551875113456" P_Z="4.7102321965411466E-4" STUDIES="4" TAU2="0.0" TOTAL_1="269" TOTAL_2="280" WEIGHT="100.0" Z="3.496715872612188">
<NAME>at 6 months</NAME>
<CONT_DATA CI_END="13.57774562757282" CI_START="-1.977745627572821" EFFECT_SIZE="5.8" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="-3.0" MODIFIED="2010-04-26 11:28:10 +0100" MODIFIED_BY="[Empty name]" ORDER="44" SD_1="18.3" SD_2="17.6" SE="3.9683104837245406" STUDY_ID="STD-Clement-2006" TOTAL_1="40" TOTAL_2="42" WEIGHT="8.176371739791703"/>
<CONT_DATA CI_END="12.586537661873454" CI_START="-6.0065376618734545" EFFECT_SIZE="3.29" ESTIMABLE="YES" MEAN_1="6.74" MEAN_2="3.45" ORDER="8" SD_1="13.74" SD_2="16.56" SE="4.743218617894694" STUDY_ID="STD-Equi-2002" TOTAL_1="20" TOTAL_2="21" WEIGHT="5.723024869771851"/>
<CONT_DATA CI_END="9.836618199692918" CI_START="2.5833818003070843" EFFECT_SIZE="6.210000000000001" ESTIMABLE="YES" MEAN_1="4.44" MEAN_2="-1.77" ORDER="9" SD_1="13.6" SD_2="10.66" SE="1.8503494086111878" STUDY_ID="STD-Saiman-2003" TOTAL_1="84" TOTAL_2="93" WEIGHT="37.606630750928225"/>
<CONT_DATA CI_END="5.193670951115877" CI_START="-1.1936709511158763" EFFECT_SIZE="2.0000000000000004" ESTIMABLE="YES" MEAN_1="5.4" MEAN_2="3.4" MODIFIED="2010-04-29 12:24:01 +0100" MODIFIED_BY="[Empty name]" ORDER="48" SD_1="13.3" SD_2="12.4" SE="1.6294538962486789" STUDY_ID="STD-Saiman-2010" TOTAL_1="125" TOTAL_2="124" WEIGHT="48.49397263950822"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="12.047475284744898" CI_START="-3.2474752847448984" DF="0" EFFECT_SIZE="4.4" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.06" MODIFIED="2010-10-28 15:57:06 +0100" MODIFIED_BY="Nikki Jahnke" NO="6" P_CHI2="1.0" P_Z="0.2594586079348261" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="42" WEIGHT="100.0" Z="1.127671710058218">
<NAME>at 8 months</NAME>
<CONT_DATA CI_END="12.047475284744898" CI_START="-3.2474752847448984" EFFECT_SIZE="4.4" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="-3.3" MODIFIED="2010-04-26 11:29:33 +0100" MODIFIED_BY="[Empty name]" ORDER="45" SD_1="18.7" SD_2="16.5" SE="3.901844801775547" STUDY_ID="STD-Clement-2006" TOTAL_1="40" TOTAL_2="42" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.89454823164262" CI_START="-7.49454823164262" DF="0" EFFECT_SIZE="0.19999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.07" MODIFIED="2010-10-28 15:57:12 +0100" MODIFIED_BY="Nikki Jahnke" NO="7" P_CHI2="1.0" P_Z="0.9593699647309379" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="42" WEIGHT="100.00000000000001" Z="0.05094422506782166">
<NAME>at 10 months</NAME>
<CONT_DATA CI_END="7.89454823164262" CI_START="-7.49454823164262" EFFECT_SIZE="0.19999999999999996" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="-1.2" MODIFIED="2010-04-26 11:30:28 +0100" MODIFIED_BY="[Empty name]" ORDER="46" SD_1="18.9" SD_2="16.5" SE="3.9258620527398636" STUDY_ID="STD-Clement-2006" TOTAL_1="40" TOTAL_2="42" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.4430989909465755" CI_START="-10.043098990946575" DF="0" EFFECT_SIZE="-2.8" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.08" MODIFIED="2010-04-26 11:31:03 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.4486468871727892" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="42" WEIGHT="100.0" Z="0.7576728087758686">
<NAME>at 12 months</NAME>
<CONT_DATA CI_END="4.4430989909465755" CI_START="-10.043098990946575" EFFECT_SIZE="-2.8" ESTIMABLE="YES" MEAN_1="-4.3" MEAN_2="-1.5" MODIFIED="2010-04-26 11:31:03 +0100" MODIFIED_BY="[Empty name]" ORDER="47" SD_1="17.9" SD_2="15.4" SE="3.6955265750183246" STUDY_ID="STD-Clement-2006" TOTAL_1="40" TOTAL_2="42" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2010-10-28 15:57:41 +0100" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="11.349049418113076" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="21" TOTAL_2="17" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Absolute change in FEV<SUB>1</SUB> (% predicted)</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azithromycin</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.01" MODIFIED="2010-04-26 11:19:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>At 2 months</NAME>
<CONT_DATA CI_END="8.743715519739062" CI_START="-6.143715519739062" EFFECT_SIZE="1.2999999999999998" ESTIMABLE="YES" MEAN_1="-3.7" MEAN_2="-5.0" MODIFIED="2010-04-26 11:19:33 +0100" MODIFIED_BY="[Empty name]" ORDER="41" SD_1="13.3" SD_2="10.1" SE="3.7978838276897635" STUDY_ID="STD-Steinkamp-2007" TOTAL_1="21" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="10.921560612661725" CI_END="4.191580735982547" CI_START="1.6575350449011053" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="MD" EFFECT_SIZE="2.924557890441826" ESTIMABLE="YES" I2="17.594194463692272" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2010-10-28 15:58:21 +0100" MODIFIED_BY="Nikki Jahnke" NO="3" P_CHI2="0.2811240887807388" P_Q="0.4726836410250361" P_Z="6.067792438967712E-6" Q="4.554056632971254" RANDOM="NO" SCALE="20.091968071162913" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="416" TOTAL_2="446" UNITS="" WEIGHT="600.0" Z="4.524013245808672">
<NAME>Percentage change in FVC</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azithromycin</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.306615313533557" CI_END="4.194082946453786" CI_START="-0.41993526733339026" DF="1" EFFECT_SIZE="1.8870738395601983" ESTIMABLE="YES" I2="76.77990887977629" ID="CMP-001.03.01" MODIFIED="2010-10-28 15:58:00 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.037964610392033915" P_Z="0.10889052830297664" STUDIES="2" TAU2="0.0" TOTAL_1="106" TOTAL_2="119" WEIGHT="99.99999999999999" Z="1.60319989663409">
<NAME>at 1 month</NAME>
<CONT_DATA CI_END="3.1583581655483695" CI_START="-2.13835816554837" EFFECT_SIZE="0.51" ESTIMABLE="YES" MEAN_1="1.21" MEAN_2="0.7" ORDER="10" SD_1="10.0" SD_2="8.1" SE="1.3512279748190685" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="97" WEIGHT="75.88312014780738"/>
<CONT_DATA CI_END="10.91773753656069" CI_START="1.5222624634393096" EFFECT_SIZE="6.22" ESTIMABLE="YES" MEAN_1="2.96" MEAN_2="-3.26" ORDER="11" SD_1="8.19" SD_2="6.98" SE="2.3968489082533373" STUDY_ID="STD-Wolter-2002" TOTAL_1="19" TOTAL_2="22" WEIGHT="24.116879852192614"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.42344419980457054" CI_END="9.047602959451105" CI_START="1.7856758831412356" DF="1" EFFECT_SIZE="5.41663942129617" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.02" MODIFIED="2010-10-28 15:58:04 +0100" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.5152234579990351" P_Z="0.0034572352300146826" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="36" WEIGHT="100.0" Z="2.9238570069406653">
<NAME>at 2 months</NAME>
<CONT_DATA CI_END="10.652920085143606" CI_START="-4.072920085143606" EFFECT_SIZE="3.29" ESTIMABLE="YES" MEAN_1="4.05" MEAN_2="0.76" ORDER="12" SD_1="7.45" SD_2="15.43" SE="3.756660909701086" STUDY_ID="STD-Equi-2002" TOTAL_1="20" TOTAL_2="21" WEIGHT="24.318881804406754"/>
<CONT_DATA CI_END="10.273766199640336" CI_START="1.9262338003596646" EFFECT_SIZE="6.1000000000000005" ESTIMABLE="YES" MEAN_1="4.28" MEAN_2="-1.82" ORDER="13" SD_1="6.46" SD_2="6.06" SE="2.129511681113771" STUDY_ID="STD-Wolter-2002" TOTAL_1="20" TOTAL_2="15" WEIGHT="75.68111819559324"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.2624642063317055" CI_END="4.259133881554862" CI_START="-0.35112003258635904" DF="1" EFFECT_SIZE="1.9540069244842517" ESTIMABLE="YES" I2="20.789833487187554" ID="CMP-001.03.03" MODIFIED="2010-10-28 15:58:09 +0100" MODIFIED_BY="Nikki Jahnke" NO="3" P_CHI2="0.2611852604870434" P_Z="0.09662919615556022" STUDIES="2" TAU2="0.0" TOTAL_1="106" TOTAL_2="114" WEIGHT="100.0" Z="1.6614196392887424">
<NAME>at 3 months</NAME>
<CONT_DATA CI_END="3.8539663312532975" CI_START="-1.453966331253297" EFFECT_SIZE="1.2000000000000002" ESTIMABLE="YES" MEAN_1="1.09" MEAN_2="-0.11" ORDER="14" SD_1="9.3" SD_2="8.93" SE="1.3540893364303859" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="95" WEIGHT="75.43951386044783"/>
<CONT_DATA CI_END="8.921321619183576" CI_START="-0.3813216191835762" EFFECT_SIZE="4.2700000000000005" ESTIMABLE="YES" MEAN_1="3.81" MEAN_2="-0.46" ORDER="15" SD_1="6.76" SD_2="7.83" SE="2.3731668825920313" STUDY_ID="STD-Wolter-2002" TOTAL_1="19" TOTAL_2="19" WEIGHT="24.560486139552165"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.4683998070697" CI_START="-5.368399807069698" DF="0" EFFECT_SIZE="2.5500000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.04" MODIFIED="2010-10-28 15:58:15 +0100" MODIFIED_BY="Nikki Jahnke" NO="4" P_CHI2="1.0" P_Z="0.5279251058607657" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0" Z="0.6311765359605751">
<NAME>at 4 months</NAME>
<CONT_DATA CI_END="10.4683998070697" CI_START="-5.368399807069698" EFFECT_SIZE="2.5500000000000003" ESTIMABLE="YES" MEAN_1="5.69" MEAN_2="3.14" ORDER="16" SD_1="11.44" SD_2="14.33" SE="4.040074138876544" STUDY_ID="STD-Equi-2002" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.3749802600206391" CI_END="7.417668070948583" CI_START="1.7135241457500618" DF="1" EFFECT_SIZE="4.565596108349323" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.05" MODIFIED="2010-10-28 15:58:21 +0100" MODIFIED_BY="Nikki Jahnke" NO="5" P_CHI2="0.5403023335568993" P_Z="0.0017038953570874585" STUDIES="2" TAU2="0.0" TOTAL_1="104" TOTAL_2="114" WEIGHT="100.0" Z="3.1375098727052095">
<NAME>at 6 months</NAME>
<CONT_DATA CI_END="9.700284116208701" CI_START="-4.700284116208703" EFFECT_SIZE="2.4999999999999996" ESTIMABLE="YES" MEAN_1="4.85" MEAN_2="2.35" ORDER="17" SD_1="9.71" SD_2="13.58" SE="3.673681849770518" STUDY_ID="STD-Equi-2002" TOTAL_1="20" TOTAL_2="21" WEIGHT="15.689954761252121"/>
<CONT_DATA CI_END="8.05613851072864" CI_START="1.843861489271359" EFFECT_SIZE="4.95" ESTIMABLE="YES" MEAN_1="3.7" MEAN_2="-1.25" ORDER="18" SD_1="11.76" SD_2="8.97" SE="1.5847936672456562" STUDY_ID="STD-Saiman-2003" TOTAL_1="84" TOTAL_2="93" WEIGHT="84.31004523874788"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.281581147776933" CI_START="-2.8815811477769318" DF="0" EFFECT_SIZE="2.7" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.06" MODIFIED="2010-05-04 15:40:20 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.3430780425652421" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="42" WEIGHT="100.0" Z="0.9481010162086132">
<NAME>at 12 months</NAME>
<CONT_DATA CI_END="8.281581147776933" CI_START="-2.8815811477769318" EFFECT_SIZE="2.7" ESTIMABLE="YES" MEAN_1="-1.8" MEAN_2="-4.5" MODIFIED="2010-05-04 15:40:20 +0100" MODIFIED_BY="[Empty name]" ORDER="82" SD_1="13.6" SD_2="12.1" SE="2.847797812512746" STUDY_ID="STD-Clement-2006" TOTAL_1="40" TOTAL_2="42" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="15.718265879666008" CI_END="4.082331680754576" CI_START="1.7201281033803808" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="OR" EFFECT_SIZE="2.649930838981654" ESTIMABLE="YES" EVENTS_1="358" EVENTS_2="281" I2="55.46582521513665" I2_Q="51.67253479213244" ID="CMP-001.04" LOG_CI_END="0.6109082873152665" LOG_CI_START="0.23556079139564143" LOG_EFFECT_SIZE="0.42323453935545396" METHOD="MH" MODIFIED="2011-01-25 15:54:46 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.02781876420066054" P_Q="0.10193331092310076" P_Z="9.868511241456395E-6" Q="6.207650219386242" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.22507108038467794" TOTALS="SUB" TOTAL_1="523" TOTAL_2="556" WEIGHT="400.0" Z="4.420034571525263">
<NAME>Free of pulmonary exacerbation</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azithromycin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="17.22867249292295" CI_START="1.8588379302299962" DF="0" EFFECT_SIZE="5.659090909090908" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="77" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="1.2362518153929447" LOG_CI_START="0.269241525826153" LOG_EFFECT_SIZE="0.7527466706095488" MODIFIED="2010-10-28 15:59:28 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="1.0" P_Z="0.0022779453759605153" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="98" WEIGHT="100.0" Z="3.0513767636083626">
<NAME>at 1 month</NAME>
<DICH_DATA CI_END="17.22867249292295" CI_START="1.8588379302299962" EFFECT_SIZE="5.659090909090909" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="77" LOG_CI_END="1.2362518153929447" LOG_CI_START="0.269241525826153" LOG_EFFECT_SIZE="0.7527466706095489" MODIFIED="2010-05-04 13:40:37 +0100" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="0.568026630869667" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="98" VAR="0.32265425337714493" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4805729006078294" CI_END="7.9747910367450485" CI_START="0.5873215431044206" DF="1" EFFECT_SIZE="2.164201140752958" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="57" I2="32.45857737977891" ID="CMP-001.04.02" LOG_CI_END="0.901719312070596" LOG_CI_START="-0.23112406883220096" LOG_EFFECT_SIZE="0.3352976216191975" MODIFIED="2010-10-28 15:59:34 +0100" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.2236852445034503" P_Z="0.24596107069811868" STUDIES="2" TAU2="0.4496867299340244" TOTAL_1="97" TOTAL_2="106" WEIGHT="100.0" Z="1.16021556651873">
<NAME>at 3 months</NAME>
<DICH_DATA CI_END="7.739737646939633" CI_START="0.0421888476250886" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.8887262396987212" LOG_CI_START="-1.37480233707131" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2010-05-04 15:35:02 +0100" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="1.3296078906418776" STUDY_ID="STD-Rotschild-2005" TOTAL_1="10" TOTAL_2="8" VAR="1.7678571428571428" WEIGHT="19.968375096806852"/>
<DICH_DATA CI_END="5.669919248284875" CI_START="1.6055168727776556" EFFECT_SIZE="3.0171428571428573" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="50" LOG_CI_END="0.7535768736593937" LOG_CI_START="0.20561487403564213" LOG_EFFECT_SIZE="0.47959587384751784" MODIFIED="2010-05-04 13:40:53 +0100" MODIFIED_BY="[Empty name]" ORDER="70" O_E="0.0" SE="0.32187559103463576" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="98" VAR="0.1036038961038961" WEIGHT="80.03162490319315"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.604742522726964" CI_END="3.334858726811707" CI_START="1.1537171377333502" DF="3" EFFECT_SIZE="1.9615003607040928" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="145" I2="54.578093094818165" ID="CMP-001.04.03" LOG_CI_END="0.5230774408115908" LOG_CI_START="0.062099343846036915" LOG_EFFECT_SIZE="0.2925883923288138" MODIFIED="2010-10-28 15:59:40 +0100" MODIFIED_BY="Nikki Jahnke" NO="3" P_CHI2="0.085622184702834" P_Z="0.012845439511842693" STUDIES="4" TAU2="0.15671583982384954" TOTAL_1="299" TOTAL_2="310" WEIGHT="100.0" Z="2.4880258521341503">
<NAME>at 6 months</NAME>
<DICH_DATA CI_END="12.019659870011207" CI_START="1.8354532967521524" EFFECT_SIZE="4.696969696969697" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="11" LOG_CI_END="1.0798921782601258" LOG_CI_START="0.2637433383246824" LOG_EFFECT_SIZE="0.671817758292404" MODIFIED="2010-05-04 16:03:27 +0100" MODIFIED_BY="[Empty name]" ORDER="88" O_E="0.0" SE="0.47940986857999346" STUDY_ID="STD-Clement-2006" TOTAL_1="40" TOTAL_2="42" VAR="0.2298338220918866" WEIGHT="18.968390754685853"/>
<DICH_DATA CI_END="2.6516893118926173" CI_START="0.46035338482023785" EFFECT_SIZE="1.104859335038363" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" LOG_CI_END="0.4235226381207674" LOG_CI_START="-0.33690865928267694" LOG_EFFECT_SIZE="0.043306989419045254" MODIFIED="2010-05-04 13:33:22 +0100" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.4466811082904135" STUDY_ID="STD-Equi-2002" TOTAL_1="41" TOTAL_2="41" VAR="0.19952401250355215" WEIGHT="20.58227058372661"/>
<DICH_DATA CI_END="2.5334640251347365" CI_START="0.7606810094267886" EFFECT_SIZE="1.3882211538461537" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="32" LOG_CI_END="0.40371474174435407" LOG_CI_START="-0.11879742586947584" LOG_EFFECT_SIZE="0.14245865793743914" MODIFIED="2010-05-04 13:41:29 +0100" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="0.3069262337333076" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="98" VAR="0.09420371295371295" WEIGHT="29.221417590399305"/>
<DICH_DATA CI_END="4.025997921520129" CI_START="1.3463893462259304" EFFECT_SIZE="2.3282097649186255" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="79" LOG_CI_END="0.6048735463418627" LOG_CI_START="0.12917066647519784" LOG_EFFECT_SIZE="0.36702210640853034" MODIFIED="2010-04-29 12:45:23 +0100" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.2794302264009115" STUDY_ID="STD-Saiman-2010" TOTAL_1="131" TOTAL_2="129" VAR="0.07808125142646465" WEIGHT="31.22792107118823"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="51.33599730790361" CI_START="2.25916194177241" DF="0" EFFECT_SIZE="10.76923076923077" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" I2="0.0" ID="CMP-001.04.04" LOG_CI_END="1.7104220035084217" LOG_CI_START="0.35394736323438086" LOG_EFFECT_SIZE="1.0321846833714012" MODIFIED="2010-05-04 16:05:10 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.002856266000850217" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="42" WEIGHT="100.0" Z="2.9827978271574938">
<NAME>at 12 months</NAME>
<DICH_DATA CI_END="51.33599730790361" CI_START="2.25916194177241" EFFECT_SIZE="10.76923076923077" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" LOG_CI_END="1.7104220035084217" LOG_CI_START="0.35394736323438086" LOG_EFFECT_SIZE="1.0321846833714012" MODIFIED="2010-05-04 16:05:10 +0100" MODIFIED_BY="[Empty name]" ORDER="89" O_E="0.0" SE="0.7967999183547335" STUDY_ID="STD-Clement-2006" TOTAL_1="40" TOTAL_2="42" VAR="0.63489010989011" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="74.55057260200691" CI_END="0.9698062119110286" CI_START="0.773749420062862" CI_STUDY="95" CI_TOTAL="95" DF="42" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8662488060825939" ESTIMABLE="YES" EVENTS_1="826" EVENTS_2="964" I2="43.662404547554935" I2_Q="42.83803378698973" ID="CMP-001.05" LOG_CI_END="-0.013315038420080284" LOG_CI_START="-0.11139966348212388" LOG_EFFECT_SIZE="-0.06235735095110207" METHOD="MH" MODIFIED="2011-02-03 11:37:43 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0014602488400372593" P_Q="0.014456841146660127" P_Z="0.012699162715319887" Q="40.236544548331366" RANDOM="NO" SCALE="228.61" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3962" TOTAL_2="4175" WEIGHT="2400.0" Z="2.492096227276706">
<NAME>Mild adverse effects of antibiotic treatment</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.4939421258910226" CI_END="2.8673055293277865" CI_START="0.9923705770772687" DF="1" EFFECT_SIZE="1.686840135518437" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="28" I2="71.37903365399961" ID="CMP-001.05.01" LOG_CI_END="0.4574739722040386" LOG_CI_START="-0.003326120661832962" LOG_EFFECT_SIZE="0.22707392577110283" MODIFIED="2011-02-01 16:06:55 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.06159387338982836" P_Z="0.05340032563218528" STUDIES="2" TAU2="0.0" TOTAL_1="218" TOTAL_2="227" WEIGHT="100.0" Z="1.9316693864861225">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="5.1441393093841725" CI_START="1.276482975105527" EFFECT_SIZE="2.5625" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="16" LOG_CI_END="0.7113127212842825" LOG_CI_START="0.106015026843339" LOG_EFFECT_SIZE="0.4086638740638107" ORDER="23" O_E="0.0" SE="0.355554861986521" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="98" VAR="0.126419259882254" WEIGHT="47.526000630318315"/>
<DICH_DATA CI_END="2.105430229384231" CI_START="0.3793946963199154" EFFECT_SIZE="0.89375" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.3233408541649823" LOG_CI_START="-0.42090874454670824" LOG_EFFECT_SIZE="-0.04878394519086295" MODIFIED="2010-04-29 12:39:53 +0100" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="0.43717589837817694" STUDY_ID="STD-Saiman-2010" TOTAL_1="131" TOTAL_2="129" VAR="0.1911227661227661" WEIGHT="52.47399936968169"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.015438191385634" CI_END="2.4543568541004777" CI_START="0.782239159040206" DF="2" EFFECT_SIZE="1.3856024110603025" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="23" I2="75.04815142671248" ID="CMP-001.05.02" LOG_CI_END="0.38993770773874553" LOG_CI_START="-0.10666044697581432" LOG_EFFECT_SIZE="0.1416386303814656" MODIFIED="2011-02-01 16:07:23 +0000" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.018174856107703752" P_Z="0.26355282819604453" STUDIES="3" TAU2="0.0" TOTAL_1="258" TOTAL_2="269" WEIGHT="100.0" Z="1.1180332094742442">
<NAME>Diarrhoea</NAME>
<DICH_DATA CI_END="3.679881020680782" CI_START="0.16123246537804398" EFFECT_SIZE="0.7702702702702703" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.565833777125385" LOG_CI_START="-0.7925475052423544" LOG_EFFECT_SIZE="-0.11335686405848479" MODIFIED="2010-05-04 16:08:55 +0100" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.7979198893586026" STUDY_ID="STD-Clement-2006" TOTAL_1="40" TOTAL_2="42" VAR="0.6366761498340445" WEIGHT="18.065695607189635"/>
<DICH_DATA CI_END="8.086521334427283" CI_START="1.3946129516697288" EFFECT_SIZE="3.3582089552238807" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="8" LOG_CI_END="0.9077617366719662" LOG_CI_START="0.1444536941491059" LOG_EFFECT_SIZE="0.526107715410536" ORDER="30" O_E="0.0" SE="0.4483709226136765" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="98" VAR="0.20103648424543946" WEIGHT="29.000126125902074"/>
<DICH_DATA CI_END="1.4365905642023367" CI_START="0.1845559747554376" EFFECT_SIZE="0.5149090909090909" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.15733300957861424" LOG_CI_START="-0.7338718905316394" LOG_EFFECT_SIZE="-0.2882694404765125" MODIFIED="2010-04-29 12:40:34 +0100" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="0.5234981698601667" STUDY_ID="STD-Saiman-2010" TOTAL_1="131" TOTAL_2="129" VAR="0.274050333846944" WEIGHT="52.9341782669083"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.937611625931785" CI_END="4.249707342526814" CI_START="1.067525529844832" DF="1" EFFECT_SIZE="2.1299462628236445" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="13" I2="74.60389456861778" ID="CMP-001.05.03" LOG_CI_END="0.6283590232498487" LOG_CI_START="0.028378269962312127" LOG_EFFECT_SIZE="0.3283686466060804" MODIFIED="2011-02-01 16:08:01 +0000" MODIFIED_BY="Nikki Jahnke" NO="3" P_CHI2="0.04721783593865081" P_Z="0.03192317810304665" STUDIES="2" TAU2="0.0" TOTAL_1="218" TOTAL_2="227" WEIGHT="99.99999999999999" Z="2.1453712222386643">
<NAME>Wheezing</NAME>
<DICH_DATA CI_END="15.382565719355135" CI_START="1.5582045586594515" EFFECT_SIZE="4.895833333333333" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="1.1870287792121919" LOG_CI_START="0.1926244705801063" LOG_EFFECT_SIZE="0.689826624896149" ORDER="33" O_E="0.0" SE="0.5841180132712019" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="98" VAR="0.341193853427896" WEIGHT="27.096564077511804"/>
<DICH_DATA CI_END="2.8076113667103626" CI_START="0.4324836967354037" EFFECT_SIZE="1.1019283746556474" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.44833699199975496" LOG_CI_START="-0.3640302594160552" LOG_EFFECT_SIZE="0.04215336629184988" MODIFIED="2010-04-29 12:41:15 +0100" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.4771885447643958" STUDY_ID="STD-Saiman-2010" TOTAL_1="131" TOTAL_2="129" VAR="0.2277089072543618" WEIGHT="72.90343592248819"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1880850244805936" CI_END="0.6898424334654548" CI_START="0.3032524757886542" DF="1" EFFECT_SIZE="0.45737995786049607" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="171" I2="15.830939756421937" ID="CMP-001.05.04" LOG_CI_END="-0.16125009490180517" LOG_CI_START="-0.5181956448160085" LOG_EFFECT_SIZE="-0.3397228698589068" MODIFIED="2011-02-01 16:08:01 +0000" MODIFIED_BY="Nikki Jahnke" NO="4" P_CHI2="0.2757162290928079" P_Z="1.9087966583439784E-4" STUDIES="2" TAU2="0.0" TOTAL_1="218" TOTAL_2="227" WEIGHT="99.99999999999999" Z="3.730790815619302">
<NAME>Cough</NAME>
<DICH_DATA CI_END="1.2594109497759498" CI_START="0.3112446157438829" EFFECT_SIZE="0.6260869565217392" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="80" LOG_CI_END="0.10016746489632858" LOG_CI_START="-0.506898152741015" LOG_EFFECT_SIZE="-0.20336534392234318" ORDER="19" O_E="0.0" SE="0.35659334882344734" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="98" VAR="0.12715881642512078" WEIGHT="29.473009770943452"/>
<DICH_DATA CI_END="0.6446888362780282" CI_START="0.23216541906344246" EFFECT_SIZE="0.38687782805429866" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="91" LOG_CI_END="-0.1906498501624442" LOG_CI_START="-0.634202467751432" LOG_EFFECT_SIZE="-0.412426158956938" MODIFIED="2010-04-29 12:28:50 +0100" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.26054500319263896" STUDY_ID="STD-Saiman-2010" TOTAL_1="131" TOTAL_2="129" VAR="0.06788369868865224" WEIGHT="70.52699022905654"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7908477140205562" CI_START="0.1653074819251137" DF="0" EFFECT_SIZE="0.3615702479338843" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="24" I2="0.0" ID="CMP-001.05.05" LOG_CI_END="-0.10190713638578226" LOG_CI_START="-0.7817074895304538" LOG_EFFECT_SIZE="-0.44180731295811804" MODIFIED="2011-02-01 16:11:08 +0000" MODIFIED_BY="Nikki Jahnke" NO="5" P_CHI2="1.0" P_Z="0.010846975021062365" STUDIES="1" TAU2="0.0" TOTAL_1="131" TOTAL_2="129" WEIGHT="99.99999999999999" Z="2.547590384437608">
<NAME>Productive cough</NAME>
<DICH_DATA CI_END="0.7908477140205561" CI_START="0.1653074819251137" EFFECT_SIZE="0.3615702479338843" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="24" LOG_CI_END="-0.10190713638578232" LOG_CI_START="-0.7817074895304538" LOG_EFFECT_SIZE="-0.44180731295811804" MODIFIED="2010-04-29 12:36:02 +0100" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.39931809250319916" STUDY_ID="STD-Saiman-2010" TOTAL_1="131" TOTAL_2="129" VAR="0.15945493900039354" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.294265085739397" CI_END="1.259036099338846" CI_START="0.5679214925879051" DF="1" EFFECT_SIZE="0.845596630053935" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="79" I2="76.71312832268208" ID="CMP-001.05.06" LOG_CI_END="0.10003818246600504" LOG_CI_START="-0.2457116954375034" LOG_EFFECT_SIZE="-0.07283675648574918" MODIFIED="2011-02-01 16:11:08 +0000" MODIFIED_BY="Nikki Jahnke" NO="6" P_CHI2="0.038241299156523634" P_Z="0.40892643999840994" STUDIES="2" TAU2="0.0" TOTAL_1="218" TOTAL_2="227" WEIGHT="100.0" Z="0.8257843521357552">
<NAME>Sore throat</NAME>
<DICH_DATA CI_END="2.409519523711418" CI_START="0.7403259302544711" EFFECT_SIZE="1.3356009070294785" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="36" LOG_CI_END="0.38193044962696926" LOG_CI_START="-0.13057703898844297" LOG_EFFECT_SIZE="0.12567670531926314" ORDER="20" O_E="0.0" SE="0.3010494357656772" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="98" VAR="0.09063076277483262" WEIGHT="36.11196409590174"/>
<DICH_DATA CI_END="0.987034659348816" CI_START="0.32758442162687174" EFFECT_SIZE="0.5686274509803921" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="43" LOG_CI_END="-0.0056675969761028795" LOG_CI_START="-0.48467675942185773" LOG_EFFECT_SIZE="-0.2451721781989803" MODIFIED="2010-04-29 12:30:29 +0100" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="0.28137235315423165" STUDY_ID="STD-Saiman-2010" TOTAL_1="131" TOTAL_2="129" VAR="0.07917040111954965" WEIGHT="63.88803590409827"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1995844683771266" CI_START="0.37224836140100237" DF="0" EFFECT_SIZE="0.6682389937106918" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="48" I2="0.0" ID="CMP-001.05.07" LOG_CI_END="0.07903083409501195" LOG_CI_START="-0.4291672052912167" LOG_EFFECT_SIZE="-0.17506818559810233" MODIFIED="2011-02-01 16:11:03 +0000" MODIFIED_BY="Nikki Jahnke" NO="7" P_CHI2="1.0" P_Z="0.17689777628634834" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="98" WEIGHT="100.0" Z="1.3503686044340635">
<NAME>Increased sputum</NAME>
<DICH_DATA CI_END="1.1995844683771266" CI_START="0.3722483614010025" EFFECT_SIZE="0.6682389937106918" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="48" LOG_CI_END="0.07903083409501195" LOG_CI_START="-0.4291672052912166" LOG_EFFECT_SIZE="-0.17506818559810233" ORDER="21" O_E="0.0" SE="0.298518043956337" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="98" VAR="0.08911302256751757" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.9492909247967773" CI_END="1.3830991840086897" CI_START="0.5927299906836884" DF="1" EFFECT_SIZE="0.9054304868139175" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="61" I2="74.6789988622715" ID="CMP-001.05.08" LOG_CI_END="0.14085332510073711" LOG_CI_START="-0.2271430979694893" LOG_EFFECT_SIZE="-0.04314488643437612" MODIFIED="2011-02-01 16:07:51 +0000" MODIFIED_BY="Nikki Jahnke" NO="8" P_CHI2="0.04689119018314669" P_Z="0.6458156686509431" STUDIES="2" TAU2="0.0" TOTAL_1="218" TOTAL_2="227" WEIGHT="100.00000000000001" Z="0.4595828558491751">
<NAME>Rhinorrhea</NAME>
<DICH_DATA CI_END="2.7588519765790496" CI_START="0.7726402206772846" EFFECT_SIZE="1.46" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="25" LOG_CI_END="0.4407283994717646" LOG_CI_START="-0.11202268790289055" LOG_EFFECT_SIZE="0.1643528557844371" ORDER="24" O_E="0.0" SE="0.32468872488588324" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="98" VAR="0.10542276806802078" WEIGHT="34.81199674964911"/>
<DICH_DATA CI_END="1.0896091336987566" CI_START="0.34068926342687333" EFFECT_SIZE="0.6092767295597484" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="36" LOG_CI_END="0.03727073507746885" LOG_CI_START="-0.4676415526896383" LOG_EFFECT_SIZE="-0.21518540880608478" MODIFIED="2010-04-29 12:33:26 +0100" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="0.2965879771905323" STUDY_ID="STD-Saiman-2010" TOTAL_1="131" TOTAL_2="129" VAR="0.08796442821397173" WEIGHT="65.1880032503509"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.573794661018206" CI_END="1.2652053553167786" CI_START="0.5641949462421438" DF="2" EFFECT_SIZE="0.8448801497420935" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="71" I2="22.293723338100712" ID="CMP-001.05.09" LOG_CI_END="0.10216102151400101" LOG_CI_START="-0.24857080834190703" LOG_EFFECT_SIZE="-0.07320489341395303" MODIFIED="2011-02-01 16:07:48 +0000" MODIFIED_BY="Nikki Jahnke" NO="9" P_CHI2="0.27612630776625" P_Z="0.41326070357649447" STUDIES="3" TAU2="0.0" TOTAL_1="258" TOTAL_2="269" WEIGHT="100.0" Z="0.8181689961951111">
<NAME>Headache</NAME>
<DICH_DATA CI_END="118.60536621773129" CI_START="0.256857393357726" EFFECT_SIZE="5.51948051948052" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0741043388261127" LOG_CI_START="-0.5903079290704532" LOG_EFFECT_SIZE="0.7418982048778296" MODIFIED="2010-05-04 16:11:11 +0100" MODIFIED_BY="[Empty name]" ORDER="94" O_E="0.0" SE="1.565088955215879" STUDY_ID="STD-Clement-2006" TOTAL_1="40" TOTAL_2="42" VAR="2.449503437738732" WEIGHT="0.893293997557328"/>
<DICH_DATA CI_END="1.9054016074638593" CI_START="0.552143202475438" EFFECT_SIZE="1.025697102241662" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="31" LOG_CI_END="0.2799865272678378" LOG_CI_START="-0.25794827013458016" LOG_EFFECT_SIZE="0.011019128566628783" ORDER="25" O_E="0.0" SE="0.31598556281437284" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="98" VAR="0.09984687590711598" WEIGHT="38.5376248813528"/>
<DICH_DATA CI_END="1.1483853406851279" CI_START="0.38034013165213415" EFFECT_SIZE="0.6608910891089109" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="40" LOG_CI_END="0.060087640024231816" LOG_CI_START="-0.4198278475162912" LOG_EFFECT_SIZE="-0.1798701037460297" MODIFIED="2010-04-29 12:31:51 +0100" MODIFIED_BY="[Empty name]" ORDER="53" O_E="0.0" SE="0.28190473300128005" STUDY_ID="STD-Saiman-2010" TOTAL_1="131" TOTAL_2="129" VAR="0.079470278488523" WEIGHT="60.56908112108988"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2058765885059976" CI_END="1.3774667945185715" CI_START="0.5942596094902906" DF="2" EFFECT_SIZE="0.9047501751292721" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="62" I2="0.0" ID="CMP-001.05.10" LOG_CI_END="0.1390811384630828" LOG_CI_START="-0.2260237867729175" LOG_EFFECT_SIZE="-0.043471324154917355" MODIFIED="2011-02-01 16:07:46 +0000" MODIFIED_BY="Nikki Jahnke" NO="10" P_CHI2="0.9021827300264873" P_Z="0.6406949508081282" STUDIES="3" TAU2="0.0" TOTAL_1="258" TOTAL_2="269" WEIGHT="100.00000000000001" Z="0.4667273641889668">
<NAME>Abdominal pain</NAME>
<DICH_DATA CI_END="2.8401162567398672" CI_START="0.4023382051137602" EFFECT_SIZE="1.0689655172413792" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.4533361177326812" LOG_CI_START="-0.39540872586204806" LOG_EFFECT_SIZE="0.028963695935316558" MODIFIED="2010-05-04 16:08:29 +0100" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.49855692248227834" STUDY_ID="STD-Clement-2006" TOTAL_1="40" TOTAL_2="42" VAR="0.2485590049550005" WEIGHT="17.001999609518787"/>
<DICH_DATA CI_END="1.7228988710479203" CI_START="0.4925535542019579" EFFECT_SIZE="0.9212057112638815" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="31" LOG_CI_END="0.23625978642376744" LOG_CI_START="-0.3075465427705581" LOG_EFFECT_SIZE="-0.03564337817339533" ORDER="26" O_E="0.0" SE="0.31943452965349045" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="98" VAR="0.10203841873494668" WEIGHT="44.672779182431626"/>
<DICH_DATA CI_END="1.6330846348762327" CI_START="0.4044570891397199" EFFECT_SIZE="0.8127192982456141" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="20" LOG_CI_END="0.21300869270191813" LOG_CI_START="-0.3931275480650306" LOG_EFFECT_SIZE="-0.09005942768155621" MODIFIED="2010-04-29 12:34:48 +0100" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="0.35604742824928765" STUDY_ID="STD-Saiman-2010" TOTAL_1="131" TOTAL_2="129" VAR="0.12676977116293162" WEIGHT="38.32522120804959"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.00819470395772556" CI_END="0.9687993157027783" CI_START="0.43264307295237836" DF="2" EFFECT_SIZE="0.6474135564071943" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="80" I2="0.0" ID="CMP-001.05.11" LOG_CI_END="-0.01376617662244875" LOG_CI_START="-0.36387024538161095" LOG_EFFECT_SIZE="-0.18881821100202983" MODIFIED="2011-02-01 16:07:43 +0000" MODIFIED_BY="Nikki Jahnke" NO="11" P_CHI2="0.9959110307266047" P_Z="0.034507026078382456" STUDIES="3" TAU2="0.0" TOTAL_1="258" TOTAL_2="269" WEIGHT="99.99999999999999" Z="2.114096499940081">
<NAME>Fever</NAME>
<DICH_DATA CI_END="4.325975738612095" CI_START="0.1082169833138095" EFFECT_SIZE="0.6842105263157895" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6360840794543355" LOG_CI_START="-0.9657045767463198" LOG_EFFECT_SIZE="-0.16481024864599217" MODIFIED="2010-05-04 16:10:05 +0100" MODIFIED_BY="[Empty name]" ORDER="92" O_E="0.0" SE="0.9408985856339902" STUDY_ID="STD-Clement-2006" TOTAL_1="40" TOTAL_2="42" VAR="0.8852901484480432" WEIGHT="4.700481663501095"/>
<DICH_DATA CI_END="1.2248227422512987" CI_START="0.35143622101475147" EFFECT_SIZE="0.656084656084656" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="36" LOG_CI_END="0.0880732416537489" LOG_CI_START="-0.4541534796757671" LOG_EFFECT_SIZE="-0.18304011901100908" ORDER="27" O_E="0.0" SE="0.31850666017451634" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="98" VAR="0.10144649257552484" WEIGHT="41.44982351120339"/>
<DICH_DATA CI_END="1.1059297196331555" CI_START="0.36751059483712767" EFFECT_SIZE="0.6375271673508814" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="41" LOG_CI_END="0.04372752900727401" LOG_CI_START="-0.434730136272368" LOG_EFFECT_SIZE="-0.195501303632547" MODIFIED="2010-04-29 12:32:34 +0100" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="0.28104840098890194" STUDY_ID="STD-Saiman-2010" TOTAL_1="131" TOTAL_2="129" VAR="0.07898820369841862" WEIGHT="53.84969482529551"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.576574553371078E-5" CI_END="1.0943518563432415" CI_START="0.39420218321930967" DF="1" EFFECT_SIZE="0.6568073469295316" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="49" I2="0.0" ID="CMP-001.05.12" LOG_CI_END="0.03915697894441189" LOG_CI_START="-0.40428097478647573" LOG_EFFECT_SIZE="-0.18256199792103198" MODIFIED="2011-02-01 16:07:40 +0000" MODIFIED_BY="Nikki Jahnke" NO="12" P_CHI2="0.9952283221686321" P_Z="0.10656606251347665" STUDIES="2" TAU2="0.0" TOTAL_1="218" TOTAL_2="227" WEIGHT="100.0" Z="1.6138219016230109">
<NAME>Fatigue</NAME>
<DICH_DATA CI_END="1.2248227422512987" CI_START="0.35143622101475147" EFFECT_SIZE="0.656084656084656" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="36" LOG_CI_END="0.0880732416537489" LOG_CI_START="-0.4541534796757671" LOG_EFFECT_SIZE="-0.18304011901100908" ORDER="28" O_E="0.0" SE="0.31850666017451634" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="98" VAR="0.10144649257552484" WEIGHT="66.7746209333137"/>
<DICH_DATA CI_END="1.5982903762398948" CI_START="0.27110588614545766" EFFECT_SIZE="0.6582597730138714" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.20365568445374896" LOG_CI_START="-0.5668610530844321" LOG_EFFECT_SIZE="-0.18160268431534163" MODIFIED="2010-04-29 12:37:06 +0100" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.4526053457492917" STUDY_ID="STD-Saiman-2010" TOTAL_1="131" TOTAL_2="129" VAR="0.20485159900083585" WEIGHT="33.225379066686294"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1494340306714506" CI_START="0.5712320411464872" DF="0" EFFECT_SIZE="1.1080729166666667" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="24" I2="0.0" ID="CMP-001.05.13" LOG_CI_END="0.3323241205137297" LOG_CI_START="-0.2431874404075779" LOG_EFFECT_SIZE="0.0445683400530759" MODIFIED="2011-02-01 16:07:38 +0000" MODIFIED_BY="Nikki Jahnke" NO="13" P_CHI2="1.0" P_Z="0.7614599614752808" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="98" WEIGHT="100.0" Z="0.3035641585198558">
<NAME>Dyspnea</NAME>
<DICH_DATA CI_END="2.1494340306714506" CI_START="0.5712320411464872" EFFECT_SIZE="1.1080729166666667" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="24" LOG_CI_END="0.3323241205137297" LOG_CI_START="-0.2431874404075779" LOG_EFFECT_SIZE="0.0445683400530759" ORDER="29" O_E="0.0" SE="0.338058339713348" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="98" VAR="0.11428344104974539" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.005344788989140431" CI_END="1.5810071071151133" CI_START="0.7246417449138903" DF="1" EFFECT_SIZE="1.0703568324727775" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="78" I2="0.0" ID="CMP-001.05.14" LOG_CI_END="0.19893382222439018" LOG_CI_START="-0.13987665089278947" LOG_EFFECT_SIZE="0.02952858566580031" MODIFIED="2011-02-01 16:07:36 +0000" MODIFIED_BY="Nikki Jahnke" NO="14" P_CHI2="0.9417201249512075" P_Z="0.7326246775929102" STUDIES="2" TAU2="0.0" TOTAL_1="218" TOTAL_2="227" WEIGHT="100.00000000000001" Z="0.34163621854368065">
<NAME>Nasal congestion</NAME>
<DICH_DATA CI_END="1.9116640463323806" CI_START="0.5794382563934052" EFFECT_SIZE="1.0524691358024691" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="36" LOG_CI_END="0.28141157222686497" LOG_CI_START="-0.23699283465509374" LOG_EFFECT_SIZE="0.022209368785885586" ORDER="22" O_E="0.0" SE="0.30451331474566284" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="98" VAR="0.09272835885739111" WEIGHT="43.06528296099382"/>
<DICH_DATA CI_END="1.8147867642353321" CI_START="0.6473549099796329" EFFECT_SIZE="1.0838870431893688" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="42" LOG_CI_END="0.25882560317028463" LOG_CI_START="-0.18885755366529655" LOG_EFFECT_SIZE="0.03498402475249403" MODIFIED="2010-04-29 12:31:02 +0100" MODIFIED_BY="[Empty name]" ORDER="52" O_E="0.0" SE="0.262971302392587" STUDY_ID="STD-Saiman-2010" TOTAL_1="131" TOTAL_2="129" VAR="0.06915390588205343" WEIGHT="56.934717039006195"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6260197703700132" CI_END="1.2781409859675872" CI_START="0.3321861488195974" DF="1" EFFECT_SIZE="0.6515985971263718" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="27" I2="0.0" ID="CMP-001.05.15" LOG_CI_END="0.10657876153024812" LOG_CI_START="-0.4786184803031344" LOG_EFFECT_SIZE="-0.1860198593864432" MODIFIED="2011-02-01 16:07:34 +0000" MODIFIED_BY="Nikki Jahnke" NO="15" P_CHI2="0.4288192726157244" P_Z="0.21274642332549742" STUDIES="2" TAU2="0.0" TOTAL_1="127" TOTAL_2="140" WEIGHT="100.00000000000001" Z="1.2460490198634278">
<NAME>Hemoptysis</NAME>
<DICH_DATA CI_END="4.2973754739176915" CI_START="0.009308006768962665" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.633203300885803" LOG_CI_START="-2.0311433095578404" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2010-05-04 16:12:11 +0100" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="1.565050387703023" STUDY_ID="STD-Clement-2006" TOTAL_1="40" TOTAL_2="42" VAR="2.449382716049383" WEIGHT="11.302183504921372"/>
<DICH_DATA CI_END="1.425106745506039" CI_START="0.3528743326929987" EFFECT_SIZE="0.7091428571428572" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="25" LOG_CI_END="0.15384739574661457" LOG_CI_START="-0.45237993012174377" LOG_EFFECT_SIZE="-0.14926626718756458" ORDER="32" O_E="0.0" SE="0.3561009320887342" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="98" VAR="0.1268078738344653" WEIGHT="88.69781649507864"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.630942472808593" CI_START="0.7766689792657796" DF="0" EFFECT_SIZE="1.8964992389649924" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" I2="0.0" ID="CMP-001.05.16" LOG_CI_END="0.6656693860690467" LOG_CI_START="-0.10976404054230655" LOG_EFFECT_SIZE="0.27795267276337005" NO="16" P_CHI2="1.0" P_Z="0.15999424793930556" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="98" WEIGHT="100.0" Z="1.405090906136278">
<NAME>Dizziness (except vertigo)</NAME>
<DICH_DATA CI_END="4.630942472808592" CI_START="0.7766689792657797" EFFECT_SIZE="1.8964992389649924" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.6656693860690466" LOG_CI_START="-0.1097640405423065" LOG_EFFECT_SIZE="0.27795267276337005" ORDER="34" O_E="0.0" SE="0.45549343324887637" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="98" VAR="0.2074742677328486" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.5436741855082197" CI_END="1.3239212497955104" CI_START="0.5169839757229988" DF="2" EFFECT_SIZE="0.8273125595948876" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="46" I2="21.373577976520405" ID="CMP-001.05.17" LOG_CI_END="0.12186215293116368" LOG_CI_START="-0.2865229179562131" LOG_EFFECT_SIZE="-0.08233038251252471" MODIFIED="2010-05-04 16:11:43 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.280316292161633" P_Z="0.42937768893543105" STUDIES="3" TAU2="0.0" TOTAL_1="258" TOTAL_2="269" WEIGHT="100.0" Z="0.7902570199607291">
<NAME>Vomiting</NAME>
<DICH_DATA CI_END="118.60536621773129" CI_START="0.256857393357726" EFFECT_SIZE="5.51948051948052" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0741043388261127" LOG_CI_START="-0.5903079290704532" LOG_EFFECT_SIZE="0.7418982048778296" MODIFIED="2010-05-04 16:11:43 +0100" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="1.565088955215879" STUDY_ID="STD-Clement-2006" TOTAL_1="40" TOTAL_2="42" VAR="2.449503437738732" WEIGHT="1.197052865347729"/>
<DICH_DATA CI_END="2.3460449875768483" CI_START="0.480007122804083" EFFECT_SIZE="1.0611872146118722" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.37033633585668435" LOG_CI_START="-0.31875231810033483" LOG_EFFECT_SIZE="0.025792008878174788" ORDER="35" O_E="0.0" SE="0.4047740863782028" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="98" VAR="0.16384206100330875" WEIGHT="30.917493170848473"/>
<DICH_DATA CI_END="1.1751413493693321" CI_START="0.34644238644349873" EFFECT_SIZE="0.6380585972181119" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="31" LOG_CI_END="0.07009010793461139" LOG_CI_START="-0.46036897845500185" LOG_EFFECT_SIZE="-0.19513943526019523" MODIFIED="2010-04-29 12:34:10 +0100" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.0" SE="0.3115942931600851" STUDY_ID="STD-Saiman-2010" TOTAL_1="131" TOTAL_2="129" VAR="0.09709100352993305" WEIGHT="67.8854539638038"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.731581223111622" CI_END="1.7633996433104537" CI_START="0.5139537346643779" DF="1" EFFECT_SIZE="0.9520009623867193" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" I2="82.55280766208685" ID="CMP-001.05.18" LOG_CI_END="0.24635074860987002" LOG_CI_START="-0.2890759737757315" LOG_EFFECT_SIZE="-0.02136261258293072" MODIFIED="2010-04-29 12:37:47 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.01666250077689302" P_Z="0.8757189690901461" STUDIES="2" TAU2="0.0" TOTAL_1="218" TOTAL_2="227" WEIGHT="100.0" Z="0.1563984370883628">
<NAME>Decreased lung function</NAME>
<DICH_DATA CI_END="6.016737627751373" CI_START="0.8668598655552513" EFFECT_SIZE="2.2837837837837838" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.7793610735983219" LOG_CI_START="-0.06205110383292718" LOG_EFFECT_SIZE="0.35865498488269737" ORDER="36" O_E="0.0" SE="0.49424967808056713" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="98" VAR="0.24428274428274427" WEIGHT="27.002967359050448"/>
<DICH_DATA CI_END="1.1144273937822313" CI_START="0.18933673940728016" EFFECT_SIZE="0.45934959349593496" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="0.0470517789563238" LOG_CI_START="-0.7227651061962426" LOG_EFFECT_SIZE="-0.3378566636199594" MODIFIED="2010-04-29 12:37:47 +0100" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.4521942489936564" STUDY_ID="STD-Saiman-2010" TOTAL_1="131" TOTAL_2="129" VAR="0.2044796388229369" WEIGHT="72.99703264094956"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.176611179321093" CI_START="0.43412627954857" DF="0" EFFECT_SIZE="0.972072072072072" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" I2="0.0" ID="CMP-001.05.19" LOG_CI_END="0.3377808554274697" LOG_CI_START="-0.36238392363496336" LOG_EFFECT_SIZE="-0.012301534103746783" NO="19" P_CHI2="1.0" P_Z="0.9450922124162074" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="98" WEIGHT="100.0" Z="0.0688711129692086">
<NAME>Decreased appetite</NAME>
<DICH_DATA CI_END="2.1766111793210934" CI_START="0.43412627954856997" EFFECT_SIZE="0.972072072072072" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.33778085542746983" LOG_CI_START="-0.3623839236349634" LOG_EFFECT_SIZE="-0.012301534103746783" ORDER="37" O_E="0.0" SE="0.4112802570928265" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="98" VAR="0.16915144987434147" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8669337101033683E-32" CI_END="18.307874868949405" CI_START="0.06948781097176104" DF="0" EFFECT_SIZE="1.1279069767441863" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="100.00000000000001" ID="CMP-001.05.20" LOG_CI_END="1.2626379354402901" LOG_CI_START="-1.1580913693949355" LOG_EFFECT_SIZE="0.05227328302267722" NO="20" P_CHI2="0.0" P_Z="0.9325420224521981" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="98" WEIGHT="100.0" Z="0.08464701267793362">
<NAME>Hearing impairment</NAME>
<DICH_DATA CI_END="18.307874868949398" CI_START="0.06948781097176102" EFFECT_SIZE="1.127906976744186" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.26263793544029" LOG_CI_START="-1.1580913693949357" LOG_EFFECT_SIZE="0.052273283022677135" ORDER="38" O_E="0.0" SE="1.4219483764635268" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="98" VAR="2.0219371853272596" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8669337101033683E-32" CI_END="18.307874868949405" CI_START="0.06948781097176104" DF="0" EFFECT_SIZE="1.1279069767441863" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="100.00000000000001" ID="CMP-001.05.21" LOG_CI_END="1.2626379354402901" LOG_CI_START="-1.1580913693949355" LOG_EFFECT_SIZE="0.05227328302267722" NO="21" P_CHI2="0.0" P_Z="0.9325420224521981" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="98" WEIGHT="100.0" Z="0.08464701267793362">
<NAME>Tinnitus</NAME>
<DICH_DATA CI_END="18.307874868949398" CI_START="0.06948781097176102" EFFECT_SIZE="1.127906976744186" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.26263793544029" LOG_CI_START="-1.1580913693949357" LOG_EFFECT_SIZE="0.052273283022677135" ORDER="39" O_E="0.0" SE="1.4219483764635268" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="98" VAR="2.0219371853272596" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.230692617254146" CI_START="0.5274169458010391" DF="0" EFFECT_SIZE="1.0846681922196797" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" I2="0.0" ID="CMP-001.05.22" LOG_CI_END="0.34843972993085076" LOG_CI_START="-0.27784592052352425" LOG_EFFECT_SIZE="0.03529690470366324" MODIFIED="2010-04-29 12:36:29 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="1.0" P_Z="0.8251518674041698" STUDIES="1" TAU2="0.0" TOTAL_1="87" TOTAL_2="98" WEIGHT="100.0" Z="0.22092366936630684">
<NAME>Pulmonary congestion</NAME>
<DICH_DATA CI_END="2.230692617254146" CI_START="0.5274169458010391" EFFECT_SIZE="1.0846681922196797" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.34843972993085076" LOG_CI_START="-0.27784592052352425" LOG_EFFECT_SIZE="0.03529690470366324" ORDER="31" O_E="0.0" SE="0.36788329124086844" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="98" VAR="0.13533811597421364" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.2973754739176915" CI_START="0.009308006768962665" DF="0" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.05.23" LOG_CI_END="0.633203300885803" LOG_CI_START="-2.0311433095578404" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2010-05-04 16:10:40 +0100" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="1.0" P_Z="0.30377972148875876" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="42" WEIGHT="100.0" Z="1.0283617224594432">
<NAME>Rash</NAME>
<DICH_DATA CI_END="4.2973754739176915" CI_START="0.009308006768962665" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.633203300885803" LOG_CI_START="-2.0311433095578404" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2010-05-04 16:10:40 +0100" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="1.565050387703023" STUDY_ID="STD-Clement-2006" TOTAL_1="40" TOTAL_2="42" VAR="2.449382716049383" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.2037165030360715" CI_START="0.3078005496006915" DF="0" EFFECT_SIZE="1.1375" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" I2="0.0" ID="CMP-001.05.24" LOG_CI_END="0.623633419697166" LOG_CI_START="-0.5117306090388661" LOG_EFFECT_SIZE="0.055951405329149995" MODIFIED="2010-05-05 10:10:52 +0100" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="1.0" P_Z="0.8468208601752402" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="17" WEIGHT="100.0" Z="0.19317634970630662">
<NAME>Total</NAME>
<DICH_DATA CI_END="4.203716503036072" CI_START="0.3078005496006914" EFFECT_SIZE="1.1375" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.6236334196971661" LOG_CI_START="-0.5117306090388661" LOG_EFFECT_SIZE="0.055951405329149995" MODIFIED="2010-05-05 10:10:52 +0100" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="0.6669184506221281" STUDY_ID="STD-Steinkamp-2007" TOTAL_1="21" TOTAL_2="17" VAR="0.4447802197802198" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.481069591778775" CI_END="1.0392817178219451" CI_START="0.35571710054872446" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6080216108962904" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="42" I2="32.48122805634049" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.01673328760678162" LOG_CI_START="-0.4488952562777205" LOG_EFFECT_SIZE="-0.21608098433546943" METHOD="MH" MODIFIED="2010-10-28 16:18:49 +0100" MODIFIED_BY="Nikki Jahnke" NO="6" P_CHI2="0.22360758689893834" P_Q="1.0" P_Z="0.06889715461642751" Q="0.0" RANDOM="NO" SCALE="7.14" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="218" TOTAL_2="227" WEIGHT="100.0" Z="1.8190935783633335">
<NAME>Admission to hospital</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.481069591778775" CI_END="1.0392817178219451" CI_START="0.35571710054872446" DF="1" EFFECT_SIZE="0.6080216108962904" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="42" I2="32.48122805634049" ID="CMP-001.06.01" LOG_CI_END="0.01673328760678162" LOG_CI_START="-0.4488952562777205" LOG_EFFECT_SIZE="-0.21608098433546943" MODIFIED="2010-10-28 15:59:51 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.22360758689893834" P_Z="0.06889715461642751" STUDIES="2" TAU2="0.0" TOTAL_1="218" TOTAL_2="227" WEIGHT="100.0" Z="1.8190935783633335">
<NAME>After 6 months</NAME>
<DICH_DATA CI_END="0.935333720506005" CI_START="0.22261065374470768" EFFECT_SIZE="0.45630609352857815" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="29" LOG_CI_END="-0.02903340825513309" LOG_CI_START="-0.6524540549527044" LOG_EFFECT_SIZE="-0.3407437316039187" MODIFIED="2010-05-04 13:43:09 +0100" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="0.36620037385212456" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="98" VAR="0.13410271380943578" WEIGHT="65.79131380623106"/>
<DICH_DATA CI_END="2.0537362156850816" CI_START="0.39423318765128" EFFECT_SIZE="0.8998060762766645" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.31254466154500693" LOG_CI_START="-0.4042468183946555" LOG_EFFECT_SIZE="-0.045851078424824214" MODIFIED="2010-04-29 13:24:49 +0100" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="0.42104686349160764" STUDY_ID="STD-Saiman-2010" TOTAL_1="131" TOTAL_2="129" VAR="0.1772804612561205" WEIGHT="34.20868619376893"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.7832787342296257" CI_START="0.14921561281941118" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6444444444444445" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="100.0" ID="CMP-001.07" LOG_CI_END="0.4445567013668018" LOG_CI_START="-0.826185733119577" LOG_EFFECT_SIZE="-0.19081451587638756" METHOD="MH" MODIFIED="2010-10-28 16:10:13 +0100" MODIFIED_BY="Nikki Jahnke" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.556118991632255" Q="5.530573886755034E-33" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="124" TOTAL_2="134" WEIGHT="100.00000000000001" Z="0.5886158653328182">
<NAME>Acquisition of <I>Pseudomonas aeruginosa</I>
</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7832787342296257" CI_START="0.14921561281941118" DF="0" EFFECT_SIZE="0.6444444444444445" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="0.4445567013668018" LOG_CI_START="-0.826185733119577" LOG_EFFECT_SIZE="-0.19081451587638756" MODIFIED="2010-10-28 16:01:11 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="1.0" P_Z="0.556118991632255" STUDIES="1" TAU2="0.0" TOTAL_1="84" TOTAL_2="92" WEIGHT="100.00000000000001" Z="0.5886158653328182">
<NAME>after 6 months</NAME>
<DICH_DATA CI_END="2.7832787342296257" CI_START="0.14921561281941118" EFFECT_SIZE="0.6444444444444445" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.4445567013668018" LOG_CI_START="-0.826185733119577" LOG_EFFECT_SIZE="-0.19081451587638756" MODIFIED="2010-05-04 13:46:50 +0100" MODIFIED_BY="[Empty name]" ORDER="73" O_E="0.0" SE="0.746440396293798" STUDY_ID="STD-Saiman-2003" TOTAL_1="84" TOTAL_2="92" VAR="0.5571732652192422" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-05-04 16:13:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>after 12 months</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-04 16:13:31 +0100" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="0.0" STUDY_ID="STD-Clement-2006" TOTAL_1="40" TOTAL_2="42" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.9109437392572213" CI_END="0.5128121604451366" CI_START="0.11802536007992818" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.24601796659980577" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-0.290041684831668" LOG_CI_START="-0.9280246659190561" LOG_EFFECT_SIZE="-0.6090331753753621" METHOD="MH" MODIFIED="2010-10-28 16:11:05 +0100" MODIFIED_BY="Nikki Jahnke" NO="8" P_CHI2="0.40556083055637715" P_Q="0.4882989290724463" P_Z="1.8252295017251444E-4" Q="1.4336552987182951" RANDOM="NO" SCALE="888.27" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="174" TOTAL_2="179" WEIGHT="100.00000000000003" Z="3.7420530782537313">
<NAME>Acquisition of <I>Staphylococcal aureus</I>
</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.412814208204605E-32" CI_END="0.9921003385091317" CI_START="0.0024548793068558472" DF="0" EFFECT_SIZE="0.04935064935064936" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" I2="100.00000000000001" ID="CMP-001.08.01" LOG_CI_END="-0.0034444021833639794" LOG_CI_START="-2.609969854927979" LOG_EFFECT_SIZE="-1.3067071285556717" MODIFIED="2010-10-28 16:01:42 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.04939757475462805" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="14" WEIGHT="17.91977113551721" Z="1.96514398707604">
<NAME>after 2 months</NAME>
<DICH_DATA CI_END="0.9921003385091313" CI_START="0.002454879306855845" EFFECT_SIZE="0.04935064935064935" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="-0.0034444021833641737" LOG_CI_START="-2.6099698549279795" LOG_EFFECT_SIZE="-1.3067071285556717" MODIFIED="2010-05-05 11:10:41 +0100" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="1.531085953451267" STUDY_ID="STD-Steinkamp-2007" TOTAL_1="17" TOTAL_2="14" VAR="2.3442241968557753" WEIGHT="17.91977113551721"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2787497544146016" CI_END="0.7095984801899464" CI_START="0.1358120986433988" DF="1" EFFECT_SIZE="0.31043849437330234" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="27" I2="21.79861645738578" ID="CMP-001.08.02" LOG_CI_END="-0.1489873233423766" LOG_CI_START="-0.8670615397755456" LOG_EFFECT_SIZE="-0.508024431558961" MODIFIED="2010-10-28 16:01:47 +0100" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.25813173261505795" P_Z="0.0055494749292186035" STUDIES="2" TAU2="0.0" TOTAL_1="117" TOTAL_2="123" WEIGHT="67.46968375747575" Z="2.7732776538556245">
<NAME>after 6 months</NAME>
<DICH_DATA CI_END="0.749651348517022" CI_START="0.03526878039429206" EFFECT_SIZE="0.16260162601626016" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.12514067343587332" LOG_CI_START="-1.4526095581149598" LOG_EFFECT_SIZE="-0.7888751157754167" MODIFIED="2010-05-04 13:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="74" O_E="0.0" SE="0.7797617939374517" STUDY_ID="STD-Saiman-2003" TOTAL_1="84" TOTAL_2="92" VAR="0.6080284552845528" WEIGHT="34.35010674808234"/>
<DICH_DATA CI_END="1.2905037841429183" CI_START="0.16666426554282762" EFFECT_SIZE="0.463768115942029" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" LOG_CI_END="0.1107592823630172" LOG_CI_START="-0.7781575071977159" LOG_EFFECT_SIZE="-0.33369911241734934" MODIFIED="2010-05-05 11:08:50 +0100" MODIFIED_BY="[Empty name]" ORDER="123" O_E="0.0" SE="0.5221541223970485" STUDY_ID="STD-Saiman-2010" TOTAL_1="33" TOTAL_2="31" VAR="0.2726449275362319" WEIGHT="33.11957700939341"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.701588228959014" CI_START="0.021158250413385343" DF="0" EFFECT_SIZE="0.18974358974358974" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-001.08.03" LOG_CI_END="0.2308544725952906" LOG_CI_START="-1.6745202471863367" LOG_EFFECT_SIZE="-0.7218328872955231" MODIFIED="2010-05-05 11:09:01 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.13753666918485666" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="42" WEIGHT="14.610545107007061" Z="1.485027010453807">
<NAME>after 12 months</NAME>
<DICH_DATA CI_END="1.7015882289590132" CI_START="0.02115825041338535" EFFECT_SIZE="0.18974358974358974" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.23085447259529038" LOG_CI_START="-1.6745202471863365" LOG_EFFECT_SIZE="-0.7218328872955231" MODIFIED="2010-05-04 16:14:19 +0100" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="1.119226542156704" STUDY_ID="STD-Clement-2006" TOTAL_1="40" TOTAL_2="42" VAR="1.2526680526680525" WEIGHT="14.610545107007061"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6976404766572084" CI_END="4.10315047497999" CI_START="0.9215127837870256" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.9445065226159226" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="12" I2="41.09471270565597" I2_Q="39.407392739027046" ID="CMP-001.09" LOG_CI_END="0.613117444155594" LOG_CI_START="-0.03549863560534905" LOG_EFFECT_SIZE="0.2888094042751225" METHOD="MH" MODIFIED="2010-10-28 16:11:36 +0100" MODIFIED_BY="Nikki Jahnke" NO="9" P_CHI2="0.1925969271252269" P_Q="0.19890914399851956" P_Z="0.08091055760043879" Q="1.650366348642154" RANDOM="NO" SCALE="420.8015162240457" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="111" TOTAL_2="109" WEIGHT="100.0" Z="1.7454270667613936">
<NAME>Eradication of <I>Staphylococcal aureus</I> present at baseline</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azithromycin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.463520304427681" CI_START="0.7033682995966878" DF="0" EFFECT_SIZE="1.5608108108108107" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="12" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.5395177379740277" LOG_CI_START="-0.15281720897965384" LOG_EFFECT_SIZE="0.1933502644971869" MODIFIED="2010-10-28 16:02:06 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="1.0" P_Z="0.2736354186563038" STUDIES="1" TAU2="0.0" TOTAL_1="92" TOTAL_2="89" WEIGHT="96.29007623493318" Z="1.0947289501511555">
<NAME>after 6 months</NAME>
<DICH_DATA CI_END="3.463520304427681" CI_START="0.7033682995966878" EFFECT_SIZE="1.5608108108108107" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="12" LOG_CI_END="0.5395177379740277" LOG_CI_START="-0.15281720897965384" LOG_EFFECT_SIZE="0.1933502644971869" MODIFIED="2010-05-05 11:35:40 +0100" MODIFIED_BY="[Empty name]" ORDER="128" O_E="0.0" SE="0.40668097495385175" STUDY_ID="STD-Saiman-2010" TOTAL_1="92" TOTAL_2="89" VAR="0.16538941538941537" WEIGHT="96.29007623493318"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="237.96072986684004" CI_START="0.5954208691436684" DF="0" EFFECT_SIZE="11.903225806451612" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="2.3765052923114878" LOG_CI_START="-0.22517594766191273" LOG_EFFECT_SIZE="1.0756646723247876" MODIFIED="2010-05-05 11:40:02 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.10508337517104101" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="20" WEIGHT="3.7099237650668133" Z="1.6206935613835747">
<NAME>after 12 months</NAME>
<DICH_DATA CI_END="237.96072986684004" CI_START="0.5954208691436684" EFFECT_SIZE="11.903225806451612" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.3765052923114878" LOG_CI_START="-0.22517594766191273" LOG_EFFECT_SIZE="1.0756646723247876" MODIFIED="2010-05-05 11:40:02 +0100" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="1.5282404388902155" STUDY_ID="STD-Clement-2006" TOTAL_1="19" TOTAL_2="20" VAR="2.3355188390593584" WEIGHT="3.7099237650668133"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="33" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-10-28 16:19:50 +0100" MODIFIED_BY="Nikki Jahnke" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="20.03" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="89" TOTAL_2="76" WEIGHT="0.0" Z="0.0">
<NAME>Acquisition of macrolide-resistant <I>Staphylococcal aureus</I>
</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="33" EVENTS_2="8" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-10-28 16:02:38 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="89" TOTAL_2="76" WEIGHT="0.0" Z="0.0">
<NAME>after 6 months</NAME>
<DICH_DATA CI_END="11.713469011275418" CI_START="2.1419244298612456" EFFECT_SIZE="5.008928571428571" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="8" LOG_CI_END="1.0686855329325249" LOG_CI_START="0.3308041442394346" LOG_EFFECT_SIZE="0.6997448385859798" MODIFIED="2010-05-05 11:12:54 +0100" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="0.43343518029010325" STUDY_ID="STD-Saiman-2010" TOTAL_1="89" TOTAL_2="76" VAR="0.18786605551311433" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9107200857809448" CI_END="2.9823173235402414" CI_START="0.5959711714093217" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3331823389261466" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.4745538512331859" LOG_CI_START="-0.2247747476434242" LOG_EFFECT_SIZE="0.12488955179488088" METHOD="MH" MODIFIED="2010-10-28 16:12:41 +0100" MODIFIED_BY="Nikki Jahnke" NO="11" P_CHI2="0.6342196112037506" P_Q="0.7522316318376918" P_Z="0.48390228050660844" Q="0.09966534224467452" RANDOM="NO" SCALE="19.55" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="242" TOTAL_2="235" WEIGHT="100.00000000000003" Z="0.7000400783166174">
<NAME>Acquisition of MRSA</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8190043405722844" CI_END="3.604544923637186" CI_START="0.5687330940088203" DF="1" EFFECT_SIZE="1.4317904828968393" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="0.5568504425287889" LOG_CI_START="-0.24509149985185108" LOG_EFFECT_SIZE="0.15587947133846897" MODIFIED="2010-10-28 16:02:48 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.3654714955390723" P_Z="0.44609235613725384" STUDIES="2" TAU2="0.0" TOTAL_1="202" TOTAL_2="193" WEIGHT="73.89498696941047" Z="0.7619458058162751">
<NAME>after 6 months</NAME>
<DICH_DATA CI_END="3.75193303929523" CI_START="0.17695496574384853" EFFECT_SIZE="0.8148148148148148" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5742550789276863" LOG_CI_START="-0.7521372456012485" LOG_EFFECT_SIZE="-0.0889410833367811" MODIFIED="2010-05-05 11:46:30 +0100" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="0.7791294171761938" STUDY_ID="STD-Saiman-2003" TOTAL_1="84" TOTAL_2="92" VAR="0.6070426487093153" WEIGHT="35.50153491997867"/>
<DICH_DATA CI_END="6.708942292606604" CI_START="0.597587428475091" EFFECT_SIZE="2.0022935779816513" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.8266540562803554" LOG_CI_START="-0.22359854740638813" LOG_EFFECT_SIZE="0.3015277544369837" MODIFIED="2010-05-05 11:22:17 +0100" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="0.6169235782398271" STUDY_ID="STD-Saiman-2010" TOTAL_1="118" TOTAL_2="101" VAR="0.3805947013882321" WEIGHT="38.3934520494318"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.556452134530332" CI_START="0.1999531215185566" DF="0" EFFECT_SIZE="1.054054054054054" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="0.7447975775159722" LOG_CI_START="-0.6990718115969639" LOG_EFFECT_SIZE="0.022862882959504165" MODIFIED="2010-05-05 11:23:02 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9505071528687874" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="42" WEIGHT="26.105013030589554" Z="0.062069917848888934">
<NAME>after 12 months</NAME>
<DICH_DATA CI_END="5.556452134530332" CI_START="0.1999531215185566" EFFECT_SIZE="1.054054054054054" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7447975775159722" LOG_CI_START="-0.6990718115969639" LOG_EFFECT_SIZE="0.022862882959504165" MODIFIED="2010-05-04 16:16:30 +0100" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="0.8481360264336844" STUDY_ID="STD-Clement-2006" TOTAL_1="40" TOTAL_2="42" VAR="0.7193347193347194" WEIGHT="26.105013030589554"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.016630304435757106" CI_END="2.8794859291097574" CI_START="0.43875810811831695" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1240096968485243" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.45931496064855454" LOG_CI_START="-0.35777484482012045" LOG_EFFECT_SIZE="0.05077005791421707" METHOD="MH" MODIFIED="2010-10-28 16:13:07 +0100" MODIFIED_BY="Nikki Jahnke" NO="12" P_CHI2="0.8973904614365594" P_Q="0.8973908937179879" P_Z="0.8075672722236202" Q="0.016630163533797062" RANDOM="NO" SCALE="92.17494088964807" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="162" TOTAL_2="158" WEIGHT="100.00000000000001" Z="0.24356560157497412">
<NAME>Acquisition of <I>Haemophilus influenzae</I>
</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.570116542304617" CI_START="0.31329760341071244" DF="0" EFFECT_SIZE="1.1965811965811965" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="0.659927275132093" LOG_CI_START="-0.5040429272679402" LOG_EFFECT_SIZE="0.07794217393207636" MODIFIED="2010-10-28 16:03:02 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="1.0" P_Z="0.7929455690741216" STUDIES="1" TAU2="0.0" TOTAL_1="122" TOTAL_2="116" WEIGHT="47.95441481518507" Z="0.26248756792680245">
<NAME>after 6 months</NAME>
<DICH_DATA CI_END="4.570116542304617" CI_START="0.31329760341071244" EFFECT_SIZE="1.1965811965811965" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.659927275132093" LOG_CI_START="-0.5040429272679402" LOG_EFFECT_SIZE="0.07794217393207636" MODIFIED="2010-05-05 11:23:55 +0100" MODIFIED_BY="[Empty name]" ORDER="126" O_E="0.0" SE="0.6837218586352056" STUDY_ID="STD-Saiman-2010" TOTAL_1="122" TOTAL_2="116" VAR="0.46747557997558004" WEIGHT="47.95441481518507"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.9689715365246228" CI_START="0.2815719412759337" DF="0" EFFECT_SIZE="1.0571428571428572" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="0.5986779843758917" LOG_CI_START="-0.5504106249424529" LOG_EFFECT_SIZE="0.02413367971671937" MODIFIED="2010-05-05 11:24:53 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9343858068024281" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="42" WEIGHT="52.045585184814946" Z="0.08232810363903004">
<NAME>after 12 months</NAME>
<DICH_DATA CI_END="3.9689715365246228" CI_START="0.2815719412759337" EFFECT_SIZE="1.0571428571428572" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5986779843758917" LOG_CI_START="-0.5504106249424529" LOG_EFFECT_SIZE="0.02413367971671937" MODIFIED="2010-05-04 16:18:32 +0100" MODIFIED_BY="[Empty name]" ORDER="100" O_E="0.0" SE="0.6749803371939479" STUDY_ID="STD-Clement-2006" TOTAL_1="40" TOTAL_2="42" VAR="0.45559845559845563" WEIGHT="52.045585184814946"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-02-01 16:21:29 +0000" MODIFIED_BY="Nikki Jahnke" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="339.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="124" TOTAL_2="116" WEIGHT="0.0" Z="0.0">
<NAME>Acquisition of macrolide-resistant <I>Haemophilus influenzae</I>
</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="1" I2="0.0" ID="CMP-001.13.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-10-28 16:03:44 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="124" TOTAL_2="116" WEIGHT="0.0" Z="0.0">
<NAME>after 6 months</NAME>
<DICH_DATA CI_END="80.09419261761715" CI_START="1.270530076082119" EFFECT_SIZE="10.087719298245615" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.9036010278750453" LOG_CI_START="0.10398495015923308" LOG_EFFECT_SIZE="1.003792989017139" MODIFIED="2010-05-05 11:27:06 +0100" MODIFIED_BY="[Empty name]" ORDER="127" O_E="0.0" SE="1.0571033922935231" STUDY_ID="STD-Saiman-2010" TOTAL_1="124" TOTAL_2="116" VAR="1.1174675819984743" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-10-28 16:21:02 +0100" MODIFIED_BY="Nikki Jahnke" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="84" TOTAL_2="92" WEIGHT="0.0" Z="0.0">
<NAME>Acquisition of non-tuberculous mycobacterium</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-001.14.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-10-28 16:03:51 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="84" TOTAL_2="92" WEIGHT="0.0" Z="0.0">
<NAME>After 6 months</NAME>
<DICH_DATA CI_END="2.4204028556131987" CI_START="0.029026957713623174" EFFECT_SIZE="0.26506024096385544" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.38388765664525354" LOG_CI_START="-1.537198479752989" LOG_EFFECT_SIZE="-0.5766554115538677" MODIFIED="2010-08-11 09:01:45 +0100" MODIFIED_BY="[Empty name]" ORDER="133" O_E="0.0" SE="1.1284555060500705" STUDY_ID="STD-Saiman-2003" TOTAL_1="84" TOTAL_2="92" VAR="1.2734118291347207" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8933671115284132" CI_END="0.41833340187790496" CI_START="0.18646935506999332" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.2792961862475198" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="217" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="-0.3784774577427805" LOG_CI_START="-0.7293925312416445" LOG_EFFECT_SIZE="-0.5539349944922125" METHOD="MH" MODIFIED="2010-10-28 16:21:22 +0100" MODIFIED_BY="Nikki Jahnke" NO="15" P_CHI2="0.38802582528514196" P_Q="1.0" P_Z="6.101739800247226E-10" Q="0.0" RANDOM="NO" SCALE="18.64" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="259" TOTAL_2="268" WEIGHT="100.0" Z="6.187780012730883">
<NAME>Need for additional oral antibiotics</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.8933671115284132" CI_END="0.41833340187790496" CI_START="0.18646935506999332" DF="2" EFFECT_SIZE="0.2792961862475198" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="217" I2="0.0" ID="CMP-001.15.01" LOG_CI_END="-0.3784774577427805" LOG_CI_START="-0.7293925312416445" LOG_EFFECT_SIZE="-0.5539349944922125" MODIFIED="2010-10-28 16:00:00 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.38802582528514196" P_Z="6.101739800247226E-10" STUDIES="3" TAU2="0.0" TOTAL_1="259" TOTAL_2="268" WEIGHT="100.0" Z="6.187780012730883">
<NAME>After 6 months</NAME>
<DICH_DATA CI_END="0.9909441071021268" CI_START="0.1661761610613851" EFFECT_SIZE="0.4057971014492754" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="27" LOG_CI_END="-0.003950840632466264" LOG_CI_START="-0.7794312781576059" LOG_EFFECT_SIZE="-0.39169105939503607" MODIFIED="2010-05-04 13:34:42 +0100" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.45552104769234236" STUDY_ID="STD-Equi-2002" TOTAL_1="41" TOTAL_2="41" VAR="0.20749942489072923" WEIGHT="16.468777353681993"/>
<DICH_DATA CI_END="0.4174759579018446" CI_START="0.06999335288171277" EFFECT_SIZE="0.17094017094017094" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="91" LOG_CI_END="-0.3793685301233992" LOG_CI_START="-1.1549432020409616" LOG_EFFECT_SIZE="-0.7671558660821804" MODIFIED="2010-05-04 13:50:05 +0100" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="0.4555764014409192" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="98" VAR="0.20754985754985755" WEIGHT="28.881320003096366"/>
<DICH_DATA CI_END="0.5085821761023522" CI_START="0.1751256768152426" EFFECT_SIZE="0.29843893480257117" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="99" LOG_CI_END="-0.2936388642862167" LOG_CI_START="-0.7566501732675843" LOG_EFFECT_SIZE="-0.5251445187769006" MODIFIED="2010-04-29 13:26:36 +0100" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.27197513483859875" STUDY_ID="STD-Saiman-2010" TOTAL_1="131" TOTAL_2="129" VAR="0.07397047397047397" WEIGHT="54.64990264322165"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.16" MODIFIED="2010-10-28 16:21:39 +0100" MODIFIED_BY="Nikki Jahnke" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.2274982072076304" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="42" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Number of courses of oral antibiotics</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.16.01" MODIFIED="2010-05-04 15:46:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>after 12 months</NAME>
<CONT_DATA CI_END="-1.5044708165095755" CI_START="-1.895529183490424" EFFECT_SIZE="-1.6999999999999997" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="3.8" MODIFIED="2010-05-04 15:46:33 +0100" MODIFIED_BY="[Empty name]" ORDER="83" SD_1="0.4" SD_2="0.5" SE="0.09976162063830435" STUDY_ID="STD-Clement-2006" TOTAL_1="40" TOTAL_2="42" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.17" MODIFIED="2011-02-01 16:24:16 +0000" MODIFIED_BY="Nikki Jahnke" NO="17" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="27.05" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="42" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Number of days of additional oral antibiotics</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.17.01" MODIFIED="2010-05-04 15:49:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>after 12 months</NAME>
<CONT_DATA CI_END="-6.370838241313027" CI_START="-17.629161758686973" EFFECT_SIZE="-12.0" ESTIMABLE="YES" MEAN_1="62.0" MEAN_2="74.0" MODIFIED="2010-05-04 15:49:21 +0100" MODIFIED_BY="[Empty name]" ORDER="84" SD_1="13.0" SD_2="13.0" SE="2.8720740804877445" STUDY_ID="STD-Clement-2006" TOTAL_1="40" TOTAL_2="42" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.18887767800008" CI_END="1.2276831966863164" CI_START="0.4934738124413736" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7783505042967528" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="54" I2="8.6289736470177" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="0.08908631168995292" LOG_CI_START="-0.30673588942590174" LOG_EFFECT_SIZE="-0.10882478886797438" METHOD="MH" MODIFIED="2010-10-28 16:22:05 +0100" MODIFIED_BY="Nikki Jahnke" NO="18" P_CHI2="0.33472764251986764" P_Q="1.0" P_Z="0.2811589372877703" Q="0.0" RANDOM="NO" SCALE="6.277844460436688" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="259" TOTAL_2="268" WEIGHT="100.0" Z="1.077719573106895">
<NAME>Need for intravenous antibiotics</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.18887767800008" CI_END="1.2276831966863164" CI_START="0.4934738124413736" DF="2" EFFECT_SIZE="0.7783505042967528" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="54" I2="8.6289736470177" ID="CMP-001.18.01" LOG_CI_END="0.08908631168995292" LOG_CI_START="-0.30673588942590174" LOG_EFFECT_SIZE="-0.10882478886797438" MODIFIED="2010-10-28 16:00:14 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.33472764251986764" P_Z="0.2811589372877703" STUDIES="3" TAU2="0.0" TOTAL_1="259" TOTAL_2="268" WEIGHT="100.0" Z="1.077719573106895">
<NAME>After 6 months</NAME>
<DICH_DATA CI_END="3.796473364552975" CI_START="0.5456493878473074" EFFECT_SIZE="1.4392857142857143" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.5793803572843308" LOG_CI_START="-0.2630863276865504" LOG_EFFECT_SIZE="0.15814701479889023" MODIFIED="2010-05-04 13:35:39 +0100" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.4948691010292436" STUDY_ID="STD-Equi-2002" TOTAL_1="41" TOTAL_2="41" VAR="0.2448954271534917" WEIGHT="16.209710420528125"/>
<DICH_DATA CI_END="1.159623012790533" CI_START="0.301512498373634" EFFECT_SIZE="0.591304347826087" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="30" LOG_CI_END="0.06431682536937926" LOG_CI_START="-0.5206946806641299" LOG_EFFECT_SIZE="-0.22818892764737533" MODIFIED="2010-05-04 13:51:14 +0100" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="0.34363865449774195" STUDY_ID="STD-Saiman-2003" TOTAL_1="87" TOTAL_2="98" VAR="0.11808752486501847" WEIGHT="53.116529860626336"/>
<DICH_DATA CI_END="1.7269492150282097" CI_START="0.32830910051676" EFFECT_SIZE="0.7529761904761905" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.23727956631250358" LOG_CI_START="-0.48371707874055586" LOG_EFFECT_SIZE="-0.12321875621402613" MODIFIED="2010-04-29 13:28:30 +0100" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.4235169982951201" STUDY_ID="STD-Saiman-2010" TOTAL_1="131" TOTAL_2="129" VAR="0.17936664784490872" WEIGHT="30.67375971884553"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.19" MODIFIED="2010-10-28 16:22:28 +0100" MODIFIED_BY="Nikki Jahnke" NO="19" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.65" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="42" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Number of courses of intravenous antibiotics</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.19.01" MODIFIED="2010-05-04 15:51:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>After 12 months</NAME>
<CONT_DATA CI_END="-0.66407506607898" CI_START="-0.93592493392102" EFFECT_SIZE="-0.8" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.6" MODIFIED="2010-05-04 15:51:02 +0100" MODIFIED_BY="[Empty name]" ORDER="85" SD_1="0.2" SD_2="0.4" SE="0.06935073041809878" STUDY_ID="STD-Clement-2006" TOTAL_1="40" TOTAL_2="42" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.20" MODIFIED="2010-10-28 16:22:39 +0100" MODIFIED_BY="Nikki Jahnke" NO="20" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="17.6" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="42" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Number of days of intravenous antibiotics</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.20.01" MODIFIED="2010-05-04 15:55:22 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>after 12 months</NAME>
<CONT_DATA CI_END="-10.044708165095757" CI_START="-13.955291834904243" EFFECT_SIZE="-12.0" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="24.0" MODIFIED="2010-05-04 15:55:22 +0100" MODIFIED_BY="[Empty name]" ORDER="86" SD_1="4.0" SD_2="5.0" SE="0.9976162063830435" STUDY_ID="STD-Clement-2006" TOTAL_1="40" TOTAL_2="42" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.21" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-10-28 16:22:52 +0100" MODIFIED_BY="Nikki Jahnke" NO="21" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>Development of allergic bronchopulmonary aspergillosis</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.21.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-05-04 16:20:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>after 12 months</NAME>
<DICH_DATA CI_END="8.632485336897998" CI_START="0.013514742899545901" EFFECT_SIZE="0.34156378600823045" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9361358493314026" LOG_CI_START="-1.8691922117758788" LOG_EFFECT_SIZE="-0.46652818122223827" MODIFIED="2010-05-04 16:20:26 +0100" MODIFIED_BY="[Empty name]" ORDER="101" O_E="0.0" SE="1.64786358969228" STUDY_ID="STD-Clement-2006" TOTAL_1="40" TOTAL_2="42" VAR="2.7154544102335265" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.22" MODIFIED="2010-11-24 14:33:24 +0000" MODIFIED_BY="Nikki Jahnke" NO="22" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.49" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="42" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in BMI z score</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azithromycin</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.22.01" MODIFIED="2010-05-04 15:59:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>at 12 months</NAME>
<CONT_DATA CI_END="0.3318601967998257" CI_START="-0.03186019679982571" EFFECT_SIZE="0.15" ESTIMABLE="YES" MEAN_1="0.03" MEAN_2="-0.12" MODIFIED="2010-05-04 15:59:10 +0100" MODIFIED_BY="[Empty name]" ORDER="87" SD_1="0.4" SD_2="0.44" SE="0.09278751968623696" STUDY_ID="STD-Clement-2006" TOTAL_1="40" TOTAL_2="42" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.09154481881754609" CI_END="0.9756965711732644" CI_START="0.2581495826728894" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.6169230769230769" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.23" LOG_CI_END="-0.010685221220100067" LOG_CI_START="-0.5881285727008483" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.20976898402267327" MODIFIED="2011-02-03 13:50:10 +0000" MODIFIED_BY="Nikki Jahnke" NO="23" P_CHI2="0.7622223659002271" P_Q="1.0" P_Z="7.51071248351045E-4" Q="0.0" RANDOM="NO" SCALE="4.01" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="3.3702239194896495">
<NAME>Change in weight</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azithromycin</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="1.346788114898218" CI_START="0.053211885101781986" EFFECT_SIZE="0.7" ESTIMABLE="YES" ESTIMATE="0.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-03 13:50:10 +0000" MODIFIED_BY="Nikki Jahnke" ORDER="135" SE="0.33" STUDY_ID="STD-Saiman-2003" TOTAL_1="0" TOTAL_2="0" WEIGHT="30.769230769230766"/>
<IV_DATA CI_END="1.0111920765988118" CI_START="0.14880792340118804" EFFECT_SIZE="0.58" ESTIMABLE="YES" ESTIMATE="0.58" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-03 10:36:35 +0000" MODIFIED_BY="[Empty name]" ORDER="136" SE="0.22" STUDY_ID="STD-Saiman-2010" TOTAL_1="0" TOTAL_2="0" WEIGHT="69.23076923076924"/>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.24" MODIFIED="2011-02-03 10:35:08 +0000" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.56" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="85" TOTAL_2="92" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in total quality of life score (CFQ-R)</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azithromycin</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.24.01" MODIFIED="2010-10-28 16:04:00 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="92" WEIGHT="0.0" Z="0.0">
<NAME>at 6 months</NAME>
<CONT_DATA CI_END="3.811528859317197" CI_START="-0.6115288593171975" EFFECT_SIZE="1.5999999999999999" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="0.1" MODIFIED="2010-05-04 13:57:44 +0100" MODIFIED_BY="[Empty name]" ORDER="77" SD_1="7.5" SD_2="7.5" SE="1.128351784400864" STUDY_ID="STD-Saiman-2003" TOTAL_1="85" TOTAL_2="92" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.4393147851443254" CI_END="5.41543731242629" CI_START="0.25795852648482187" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="2.8366979194555557" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.25" MODIFIED="2011-02-03 10:35:05 +0000" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.5074533881736195" P_Q="0.5074533881736195" P_Z="0.031081738599977947" Q="0.4393147851443254" RANDOM="NO" SCALE="26.813017137216058" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="102" TOTAL_2="103" UNITS="" WEIGHT="99.99999999999999" Z="2.156024673260068">
<NAME>Change in physical domain of CFQ-R QoL score</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azithromycin</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="25.051905213985265" CI_START="-8.251905213985266" DF="0" EFFECT_SIZE="8.4" ESTIMABLE="YES" I2="0.0" ID="CMP-001.25.01" MODIFIED="2010-10-28 16:04:16 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="1.0" P_Z="0.3228111671431584" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="11" WEIGHT="2.3982091132553687" Z="0.9886975249119997">
<NAME>at 2 months</NAME>
<CONT_DATA CI_END="25.051905213985265" CI_START="-8.251905213985266" EFFECT_SIZE="8.4" ESTIMABLE="YES" MEAN_1="8.8" MEAN_2="0.4" MODIFIED="2010-05-05 09:53:14 +0100" MODIFIED_BY="[Empty name]" ORDER="112" SD_1="19.7" SD_2="23.3" SE="8.496026123609091" STUDY_ID="STD-Steinkamp-2007" TOTAL_1="17" TOTAL_2="11" WEIGHT="2.3982091132553687"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.310228704900622" CI_START="0.08977129509937809" DF="0" EFFECT_SIZE="2.7" ESTIMABLE="YES" I2="0.0" ID="CMP-001.25.02" MODIFIED="2010-10-28 16:04:22 +0100" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="1.0" P_Z="0.04262445493202118" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="92" WEIGHT="97.60179088674462" Z="2.027371298278487">
<NAME>at 6 months</NAME>
<CONT_DATA CI_END="5.310228704900622" CI_START="0.08977129509937809" EFFECT_SIZE="2.7" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="-1.9" MODIFIED="2010-05-04 14:00:12 +0100" MODIFIED_BY="[Empty name]" ORDER="78" SD_1="8.9" SD_2="8.8" SE="1.3317738108913086" STUDY_ID="STD-Saiman-2003" TOTAL_1="85" TOTAL_2="92" WEIGHT="97.60179088674462"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.32859848647558315" CI_END="3.303039715978422" CI_START="-3.1419801029426853" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.08052980651786845" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.26" MODIFIED="2011-02-03 10:35:00 +0000" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.566485664427423" P_Q="0.566485664427423" P_Z="0.960935980080431" Q="0.32859848647558315" RANDOM="NO" SCALE="22.324359326958746" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="103" UNITS="" WEIGHT="100.0" Z="0.04897906442231008">
<NAME>Change in psychosocial domain of CFQ-R QoL score</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azithromycin</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.338294576961836" CI_START="-12.738294576961835" DF="0" EFFECT_SIZE="-2.6999999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-001.26.01" MODIFIED="2010-10-28 16:04:32 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="1.0" P_Z="0.5980745038778627" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="11" WEIGHT="10.30549011232683" Z="0.527171494887509">
<NAME>at 2 months</NAME>
<CONT_DATA CI_END="7.338294576961836" CI_START="-12.738294576961835" EFFECT_SIZE="-2.6999999999999997" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="4.8" MODIFIED="2010-05-05 09:55:51 +0100" MODIFIED_BY="[Empty name]" ORDER="113" SD_1="14.5" SD_2="12.0" SE="5.1216729777397045" STUDY_ID="STD-Steinkamp-2007" TOTAL_1="16" TOTAL_2="11" WEIGHT="10.30549011232683"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.0224309520761376E-33" CI_END="3.8026033946952564" CI_START="-3.0026033946952566" DF="0" EFFECT_SIZE="0.4000000000000001" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-001.26.02" MODIFIED="2010-10-28 16:04:40 +0100" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Z="0.8177750763698628" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="92" WEIGHT="89.69450988767318" Z="0.2304075741058376">
<NAME>at 6 months</NAME>
<CONT_DATA CI_END="3.8026033946952564" CI_START="-3.0026033946952566" EFFECT_SIZE="0.40000000000000013" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="1.2" MODIFIED="2010-05-04 14:01:57 +0100" MODIFIED_BY="[Empty name]" ORDER="79" SD_1="12.1" SD_2="10.9" SE="1.7360540405510294" STUDY_ID="STD-Saiman-2003" TOTAL_1="85" TOTAL_2="92" WEIGHT="89.69450988767318"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.7547767797249512" CI_END="6.0125631089283775" CI_START="-0.5439402817304062" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="2.7343114135989857" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.27" MODIFIED="2011-02-03 10:34:56 +0000" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.38496810958295047" P_Q="0.38496810958295047" P_Z="0.10209955126963945" Q="0.7547767797249512" RANDOM="NO" SCALE="22.32" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="102" TOTAL_2="103" UNITS="" WEIGHT="100.0" Z="1.634759131157054">
<NAME>Change in body image domain of CFQ-R QoL score</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azithromycin</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.941860292546775" CI_START="-12.541860292546776" DF="0" EFFECT_SIZE="-1.7999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-001.27.01" MODIFIED="2010-10-28 16:04:53 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="1.0" P_Z="0.742587549213862" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="11" WEIGHT="9.313771728020285" Z="0.3284286963422854">
<NAME>at 2 months</NAME>
<CONT_DATA CI_END="8.941860292546775" CI_START="-12.541860292546776" EFFECT_SIZE="-1.7999999999999998" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="5.1" MODIFIED="2010-05-05 09:57:42 +0100" MODIFIED_BY="[Empty name]" ORDER="114" SD_1="17.5" SD_2="11.5" SE="5.480641673661964" STUDY_ID="STD-Steinkamp-2007" TOTAL_1="17" TOTAL_2="11" WEIGHT="9.313771728020285"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.6424815767156815" CI_START="-0.2424815767156816" DF="0" EFFECT_SIZE="3.2" ESTIMABLE="YES" I2="0.0" ID="CMP-001.27.02" MODIFIED="2010-10-28 16:05:00 +0100" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="1.0" P_Z="0.06846894510275384" STUDIES="1" TAU2="0.0" TOTAL_1="85" TOTAL_2="92" WEIGHT="90.68622827197972" Z="1.8219080075693244">
<NAME>at 6 months</NAME>
<CONT_DATA CI_END="6.6424815767156815" CI_START="-0.2424815767156816" EFFECT_SIZE="3.2" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="-0.1" MODIFIED="2010-05-04 14:03:35 +0100" MODIFIED_BY="[Empty name]" ORDER="80" SD_1="14.5" SD_2="7.5" SE="1.7564004256555412" STUDY_ID="STD-Saiman-2003" TOTAL_1="85" TOTAL_2="92" WEIGHT="90.68622827197972"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.28" MODIFIED="2011-02-03 10:34:52 +0000" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="36.91" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="15" TOTAL_2="11" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in respiratory symptom domain of CFQ-R QoL score</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azithromycin</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.28.01" MODIFIED="2010-10-28 16:05:06 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>at 2 months</NAME>
<CONT_DATA CI_END="28.643166284361953" CI_START="2.1568337156380473" EFFECT_SIZE="15.4" ESTIMABLE="YES" MEAN_1="8.9" MEAN_2="-6.5" MODIFIED="2010-05-05 10:00:59 +0100" MODIFIED_BY="[Empty name]" ORDER="115" SD_1="18.9" SD_2="15.5" SE="6.756841650572336" STUDY_ID="STD-Steinkamp-2007" TOTAL_1="15" TOTAL_2="11" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.29" MODIFIED="2011-02-03 10:34:48 +0000" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="31.61" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="16" TOTAL_2="11" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in eating disorder domain of CFQ-R QoL score</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azithromycin</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.29.01" MODIFIED="2010-10-28 16:05:12 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>at 2 months</NAME>
<CONT_DATA CI_END="26.610901399042312" CI_START="0.7890986009576864" EFFECT_SIZE="13.7" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="-10.6" MODIFIED="2010-05-05 10:05:37 +0100" MODIFIED_BY="[Empty name]" ORDER="116" SD_1="16.4" SD_2="17.1" SE="6.5873156348187285" STUDY_ID="STD-Steinkamp-2007" TOTAL_1="16" TOTAL_2="11" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.30" MODIFIED="2011-02-03 10:34:44 +0000" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="61.99" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="15" TOTAL_2="11" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in problems with body weight domain of the CFQ-R QoL score</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours azithromycin</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.30.01" MODIFIED="2010-10-28 16:05:18 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>at 2 months</NAME>
<CONT_DATA CI_END="55.57774812645591" CI_START="14.822251873544097" EFFECT_SIZE="35.2" ESTIMABLE="YES" MEAN_1="20.0" MEAN_2="-15.2" MODIFIED="2010-05-05 10:08:04 +0100" MODIFIED_BY="[Empty name]" ORDER="117" SD_1="24.6" SD_2="27.3" SE="10.397001315938956" STUDY_ID="STD-Steinkamp-2007" TOTAL_1="15" TOTAL_2="11" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.31" MODIFIED="2011-02-03 10:34:39 +0000" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="56.97" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="21" TOTAL_2="16" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in CRP</NAME>
<GROUP_LABEL_1>Azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours azithromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.31.01" MODIFIED="2010-08-12 08:50:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>After 2 months</NAME>
<CONT_DATA CI_END="9.029771422939834" CI_START="-50.42977142293984" EFFECT_SIZE="-20.700000000000003" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="21.6" MODIFIED="2010-08-12 08:50:31 +0100" MODIFIED_BY="[Empty name]" ORDER="134" SD_1="6.6" SD_2="60.4" SE="15.168529451277921" STUDY_ID="STD-Steinkamp-2007" TOTAL_1="21" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2011-02-01 16:04:34 +0000" MODIFIED_BY="Nikki Jahnke" NO="2">
<NAME>Weekly versus daily azithromycin</NAME>
<CONT_OUTCOME CHI2="29.916147038082947" CI_END="-0.6493975445958965" CI_START="-0.8985157261259248" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7739566353609106" ESTIMABLE="YES" I2="93.31464711196257" I2_Q="93.31464711196257" ID="CMP-002.01" MODIFIED="2011-01-25 16:50:08 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="3.1900315122790346E-7" P_Q="3.1900315122790346E-7" P_Z="4.052836497546083E-34" Q="29.916147038082947" RANDOM="NO" SCALE="2.3445969892399563" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="315" TOTAL_2="309" UNITS="" WEIGHT="100.0" Z="12.178373505992669">
<NAME>Relative change in FEV<SUB>1</SUB> (% predicted)</NAME>
<GROUP_LABEL_1>Weekly azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Daily azithromycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours daily</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours weekly</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.1958199144602743" CI_START="-0.6041800855397255" DF="0" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" MODIFIED="2010-05-04 16:26:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.2319624635238676E-4" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="103" WEIGHT="37.21552036827891" Z="3.8396770759677636">
<NAME>at 1 month</NAME>
<CONT_DATA CI_END="-0.1958199144602743" CI_START="-0.6041800855397255" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="2.8" MODIFIED="2010-05-04 16:26:49 +0100" MODIFIED_BY="[Empty name]" ORDER="102" SD_1="0.8" SD_2="0.7" SE="0.10417542727839495" STUDY_ID="STD-McCormack-2007" TOTAL_1="105" TOTAL_2="103" WEIGHT="37.21552036827891"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.995559136859586" CI_START="-1.4044408631404144" DF="0" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.02" MODIFIED="2010-10-28 16:06:14 +0100" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="1.0" P_Z="1.2544827053913768E-30" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="103" WEIGHT="37.120639293149445" Z="11.504337955336712">
<NAME>at 3 months</NAME>
<CONT_DATA CI_END="-0.995559136859586" CI_START="-1.4044408631404144" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="3.5" MODIFIED="2010-05-04 16:32:09 +0100" MODIFIED_BY="[Empty name]" ORDER="103" SD_1="0.7" SD_2="0.8" SE="0.10430847951953079" STUDY_ID="STD-McCormack-2007" TOTAL_1="105" TOTAL_2="103" WEIGHT="37.120639293149445"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.45412486747631353" CI_START="-0.9458751325236868" DF="0" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.03" MODIFIED="2010-10-28 16:06:21 +0100" MODIFIED_BY="Nikki Jahnke" NO="3" P_CHI2="1.0" P_Z="2.405661133129525E-8" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="103" WEIGHT="25.66384033857165" Z="5.579965631725151">
<NAME>at 6 months</NAME>
<CONT_DATA CI_END="-0.45412486747631353" CI_START="-0.9458751325236868" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="3.1" MODIFIED="2010-05-04 16:33:15 +0100" MODIFIED_BY="[Empty name]" ORDER="104" SD_1="1.0" SD_2="0.8" SE="0.12544880133671757" STUDY_ID="STD-McCormack-2007" TOTAL_1="105" TOTAL_2="103" WEIGHT="25.66384033857165"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2011-02-01 16:04:34 +0000" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="51.03" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="105" TOTAL_2="103" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Days to first pulmonary exacerbation</NAME>
<GROUP_LABEL_1>Weekly azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Daily azithromycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours daily</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours weekly</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.02.01" MODIFIED="2010-10-28 16:06:31 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="103" WEIGHT="0.0" Z="0.0">
<NAME>After 6 months</NAME>
<CONT_DATA CI_END="30.281740659627836" CI_START="4.3182593403721565" EFFECT_SIZE="17.299999999999997" ESTIMABLE="YES" MEAN_1="87.3" MEAN_2="70.0" MODIFIED="2010-05-04 16:36:24 +0100" MODIFIED_BY="[Empty name]" ORDER="105" SD_1="50.6" SD_2="44.8" SE="6.6234587788480574" STUDY_ID="STD-McCormack-2007" TOTAL_1="105" TOTAL_2="103" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="74" EVENTS_2="42" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-10-28 16:17:21 +0100" MODIFIED_BY="Nikki Jahnke" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="43.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="420" TOTAL_2="412" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Weekly azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Daily azithromycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours weekly</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours daily</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="27" EVENTS_2="9" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-07-29 15:25:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="103" WEIGHT="0.0" Z="0.0">
<NAME>Gastrointestinal</NAME>
<DICH_DATA CI_END="8.142705878474356" CI_START="1.6052410724687496" EFFECT_SIZE="3.6153846153846154" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="9" LOG_CI_END="0.9107687479866817" LOG_CI_START="0.2055402632710798" LOG_EFFECT_SIZE="0.5581545056288807" MODIFIED="2010-07-29 15:25:56 +0100" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="0.41425470285924504" STUDY_ID="STD-McCormack-2007" TOTAL_1="105" TOTAL_2="103" VAR="0.17160695884100138" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-05-04 16:56:04 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="103" WEIGHT="0.0" Z="0.0">
<NAME>Abnormal liver transaminases</NAME>
<DICH_DATA CI_END="2.1661582150064658" CI_START="0.026145295450406225" EFFECT_SIZE="0.23798076923076922" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3356901740782496" LOG_CI_START="-1.5826064461366354" LOG_EFFECT_SIZE="-0.6234581360291929" MODIFIED="2010-05-04 16:56:04 +0100" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="1.1268169304356386" STUDY_ID="STD-McCormack-2007" TOTAL_1="105" TOTAL_2="103" VAR="1.2697163947163947" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="34" EVENTS_2="24" I2="0.0" ID="CMP-002.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-07-29 15:27:02 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="103" WEIGHT="0.0" Z="0.0">
<NAME>Total adverse events</NAME>
<DICH_DATA CI_END="2.90978840244506" CI_START="0.8539086781044538" EFFECT_SIZE="1.5762910798122065" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="24" LOG_CI_END="0.4638614085763871" LOG_CI_START="-0.06858857277235667" LOG_EFFECT_SIZE="0.19763641790201522" MODIFIED="2010-07-29 15:27:02 +0100" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="0.3127637547141673" STUDY_ID="STD-McCormack-2007" TOTAL_1="105" TOTAL_2="103" VAR="0.09782116626290381" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="5" I2="0.0" ID="CMP-002.03.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-07-29 15:34:30 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="103" WEIGHT="0.0" Z="0.0">
<NAME>Study withdrawal</NAME>
<DICH_DATA CI_END="7.455871100763673" CI_START="0.8578480067440796" EFFECT_SIZE="2.529032258064516" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.872498391203361" LOG_CI_START="-0.06658965350302963" LOG_EFFECT_SIZE="0.4029543688501657" MODIFIED="2010-07-29 15:34:30 +0100" MODIFIED_BY="[Empty name]" ORDER="132" O_E="0.0" SE="0.5516249660213263" STUDY_ID="STD-McCormack-2007" TOTAL_1="105" TOTAL_2="103" VAR="0.3042901031380294" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2010-10-28 16:25:11 +0100" MODIFIED_BY="Nikki Jahnke" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="6.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="105" TOTAL_2="103" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Days in hospital</NAME>
<GROUP_LABEL_1>Weekly azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Daily azithromycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours daily</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours weekly</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.01" MODIFIED="2010-10-28 16:06:49 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="103" WEIGHT="0.0" Z="0.0">
<NAME>after 6 months</NAME>
<CONT_DATA CI_END="2.971896560750039" CI_START="-2.971896560750039" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="6.5" MEAN_2="6.5" MODIFIED="2010-05-04 16:38:40 +0100" MODIFIED_BY="[Empty name]" ORDER="106" SD_1="9.6" SD_2="12.1" SE="1.516301617882767" STUDY_ID="STD-McCormack-2007" TOTAL_1="105" TOTAL_2="103" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2010-10-28 16:25:21 +0100" MODIFIED_BY="Nikki Jahnke" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.46" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="105" TOTAL_2="103" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Number of hospital admissions</NAME>
<GROUP_LABEL_1>Weekly azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Daily azithromycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours daily</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours weekly</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.05.01" MODIFIED="2010-10-28 16:07:02 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="103" WEIGHT="0.0" Z="0.0">
<NAME>After 6 months</NAME>
<CONT_DATA CI_END="0.24639464858424068" CI_START="-0.24639464858424068" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="0.6" MODIFIED="2010-05-04 16:40:53 +0100" MODIFIED_BY="[Empty name]" ORDER="107" SD_1="0.8" SD_2="1.0" SE="0.12571386542190072" STUDY_ID="STD-McCormack-2007" TOTAL_1="105" TOTAL_2="103" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-10-28 16:25:30 +0100" MODIFIED_BY="Nikki Jahnke" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="52.07" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="105" TOTAL_2="103" WEIGHT="0.0" Z="0.0">
<NAME>Acquisition of azithromycin-resistant <I>Staphylococcal aureus</I>
</NAME>
<GROUP_LABEL_1>Weekly azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Daily azithromycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours weekly</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours daily</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-10-28 16:07:59 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="103" WEIGHT="0.0" Z="0.0">
<NAME>After 6 months</NAME>
<DICH_DATA CI_END="3.9558846258046407" CI_START="0.10590084261755875" EFFECT_SIZE="0.6472491909385113" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5972436168212305" LOG_CI_START="-0.9751005843429374" LOG_EFFECT_SIZE="-0.18892848376085347" MODIFIED="2010-05-04 16:57:42 +0100" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="0.9236027669931544" STUDY_ID="STD-McCormack-2007" TOTAL_1="105" TOTAL_2="103" VAR="0.8530420711974109" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.07" MODIFIED="2011-01-31 14:52:31 +0000" MODIFIED_BY="Nikki Jahnke" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="7.04" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="315" TOTAL_2="309" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Change in CRP</NAME>
<GROUP_LABEL_1>Weekly azithromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Daily azithromycin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours weekly</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours daily</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.07.01" MODIFIED="2010-10-28 16:08:03 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="103" WEIGHT="0.0" Z="0.0">
<NAME>at 1 month</NAME>
<CONT_DATA CI_END="2.500583930164869" CI_START="1.6994160698351313" EFFECT_SIZE="2.1" ESTIMABLE="YES" MEAN_1="-2.6" MEAN_2="-4.7" MODIFIED="2010-05-05 10:44:44 +0100" MODIFIED_BY="[Empty name]" ORDER="120" SD_1="1.2" SD_2="1.7" SE="0.20438331179788183" STUDY_ID="STD-McCormack-2007" TOTAL_1="105" TOTAL_2="103" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.07.02" MODIFIED="2010-10-28 16:08:11 +0100" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="103" WEIGHT="0.0" Z="0.0">
<NAME>at 3 months</NAME>
<CONT_DATA CI_END="5.691750265047373" CI_START="4.708249734952627" EFFECT_SIZE="5.2" ESTIMABLE="YES" MEAN_1="-1.3" MEAN_2="-6.5" MODIFIED="2010-05-05 10:46:46 +0100" MODIFIED_BY="[Empty name]" ORDER="121" SD_1="2.0" SD_2="1.6" SE="0.25089760267343514" STUDY_ID="STD-McCormack-2007" TOTAL_1="105" TOTAL_2="103" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.07.03" MODIFIED="2010-10-28 16:08:17 +0100" MODIFIED_BY="Nikki Jahnke" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="103" WEIGHT="0.0" Z="0.0">
<NAME>at 6 months</NAME>
<CONT_DATA CI_END="5.496618493163003" CI_START="4.703381506836997" EFFECT_SIZE="5.1" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-5.8" MODIFIED="2010-05-05 10:47:40 +0100" MODIFIED_BY="[Empty name]" ORDER="122" SD_1="1.3" SD_2="1.6" SE="0.20236009247694303" STUDY_ID="STD-McCormack-2007" TOTAL_1="105" TOTAL_2="103" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-10-20 11:37:51 +0100" MODIFIED_BY="Nikki Jahnke">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2011-02-10 09:37:11 +0000" MODIFIED_BY="Nikki Jahnke" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2011-02-10 09:37:12 +0000" MODIFIED_BY="Nikki Jahnke" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2010-11-24 14:34:19 +0000" MODIFIED_BY="Nikki Jahnke" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_CI_LINES:YES;SHOW_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Azithromycin versus placebo, outcome: 1.1 Relative change in FEV<SUB>1</SUB> (% predicted).</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2011-10-20 11:37:51 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Azithromycin versus placebo, outcome: 1.1 Relative change in FEV<SUB>1</SUB> (% predicted).</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2011-10-20 11:37:51 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.04" SETTINGS="SHOW_CI_LINES:YES;SHOW_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Azithromycin versus placebo, outcome: 1.5 Free of pulmonary exacerbation.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2011-02-03 12:22:20 +0000" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2008-12-15 10:09:01 +0000" MODIFIED_BY="Nikki Jahnke"/>
<EXTENSIONS/>
</COCHRANE_REVIEW>